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behorende bij het proefschrift:
 1) Primair hyperaldosteronisme: wat niet weet, wat wél deert. (dit proefschrift)
 2) De prevalentie van primair hyperaldosteronisme bij patiënten met nieuw 
ontdekte hypertensie in de huisartspraktijk is 1,4% tot 4,9%. (dit proefschrift)
 3) Ook bij patiënten met hypertensie en een normaal kalium moet aan primair 
hyperaldosteronisme worden gedacht. (dit proefschrift)
 4) Bij patiënten met nieuw ontdekte hypertensie op basis van primair 
hyperaldosteronisme komt linker ventrikel hypertrofie waarschijnlijk vaker voor 
dan bij patiënten met nieuw ontdekte hypertensie zonder primair 
hyperaldosteronisme. (dit proefschrift)
 5) De aldosteron-renine ratio heeft geen toegevoegde waarde voor de keuze  
van het soort antihypertensivum bij de behandeling van essentiële hypertensie. 
(dit proefschrift)
 6) Het verdient aanbeveling om het advies uit de richtlijn ‘Primair 
hyperaldosteronisme’ van de Endocrine Society (2016), namelijk om specifieke 
groepen patiënten te screenen op primair hyperaldosteronisme, op te nemen in 
de richtlijn ‘Cardiovasculair risicomanagement’ van Nederlandse huisartsen. 
(dit proefschrift)
 7) Wat gij graag wilt dat u geschiedt, misgun dat ook een ander niet.
 8) Het geven van passende leefstijladviezen is onmisbaar bij de behandeling van 
hypertensie: dit hoort een vast onderdeel te zijn van elk consult.
 9) Natriumchloride is om te strooien, kaliumchloride is om te eten.
 10) Het onterecht en ongedocumenteerd niet stellen van de diagnose hypertensie 
kan niet beschouwd worden als het beredeneerd afwijken van de richtlijn.
 11) Vanuit het perspectief van de volksgezondheid is de publieke en politieke ophef 
over fipronil-eieren op zijn minst merkwaardig te noemen, in ogenschouw 
nemend dat de verkoop van sigaretten ongehinderd kan doorgaan.




Primary Aldosteronism in General practice:
Organ Damage, Epidemiology, and treatment

524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 1
Sabine Käyser
Primary Aldosteronism in General practice:
Organ Damage, Epidemiology, and treatment
- PAGODE study -
524305-L-bw-Kayser





Promotie In Zicht, Arnhem
Print
Ipskamp Printing, Enschede
The work presented in this thesis was carried out within the Radboud Institute  
for Health Sciences.
© S.C. Käyser, 2018
All rights are reserved. No part of this book may be reproduced, distributed, stored in a retrieval system,  
or transmitted in any form or by any means, without prior written permission of the author.
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 3
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken,
volgens besluit van het college van decanen
in het openbaar te verdedigen op dinsdag 6 november 2018
om 14.30 uur precies
door
Sabine Christina Käyser
geboren op 12 januari 1979
te Nijmegen
Primary Aldosteronism in General practice:
Organ Damage, Epidemiology, and treatment
- PAGODE study -
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 4
Promotor




Dr. T.R.J. Schermer 
Manuscriptcommissie 
Prof. dr. M.E.T.C. van den Muijsenbergh (voorzitter)
Prof. dr. J.F.M. Wetzels
Dr. M.N. Kerstens (UMCG)
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 5
CONTENTS
Chapter 1 General introduction 7
Chapter 2 Study heterogeneity and estimation of prevalence  
of primary aldosteronism: a systematic review and  
meta-regression analysis
27
Chapter 3 Prevalence of primary aldosteronism in primary care:  
a cross-sectional study
79
Chapter 4 Do patients with primary aldosteronism have cardiovascular 
damage at time of diagnosing hypertension in primary care?
103
Chapter 5 Is the plasma aldosterone-to-renin ratio associated with blood 
pressure response to treatment in general practice?
123
Chapter 6 General discussion and summary 143








Processed on: 24-9-2018 PDF page: 6
524305-L-bw-Kayser




Processed on: 24-9-2018 PDF page: 8
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 9
9
General introduction
This thesis addresses the question whether screening for primary aldosteronism 
(PA) should be implemented for all patients with newly diagnosed hypertension in 
primary care. As hypertension is the principle clinical clue to initiate a search for PA, 
this introductory chapter starts with a concise overview of hypertension in primary 
care. Subsequently, the background of PA is described, including the rationale and 
practice of diagnosing and treating PA. Special attention will be paid to the criteria 
that need to be fulfilled to accept screening for PA in the primary care setting. This 
information is put into the perspective of the main question of this thesis. Finally, the 
objectives and outline of this thesis are described.
HYPERTENSION
Persistently elevated blood pressure, also called hypertension, is worldwide the leading 
risk factor for disease burden in both men and women, and attributes to 9.4 million 
deaths per year.1,2 Globally, the prevalence of hypertension in the general population 
is estimated to be 30% to 45%, with a higher prevalence with increasing age.3,4 
Although hypertension is a problem of both developed and developing countries, 
the prevalence differs between countries and ethnic groups within countries.5,6 
For example, the prevalence of hypertension in the Netherlands is 50.6% in Dutch- 
African men, and 32% in white-Dutch men. In woman the prevalence of hypertension 
is 41.9%, and 18.1%, respectively.7
 In the majority of patients (approximately 85% to 90%) who are diagnosed with 
hypertension, hypertension is called primary or essential hypertension, and even 
after a comprehensive diagnostic analysis no specific cause of the high blood 
pressure can be established. In the other 10% to 15% of the patients an identifiable 
underlying cause of the elevated blood pressure can be detected, which is referred 
to as secondary hypertension. Examples of secondary hypertension are endocrine 
disease (PA, pheochromocytoma), renal disease, or substance abuse (licorice, 
cocaine). Secondary hypertension is thought to be relatively rare in the primary care 
setting, and is therefore usually not considered by general practitioners (GPs). 
However, given the potential for curative treatment in these patients, diagnosing 
underlying causes could be worthwhile. This may be particularly true for PA, for which a 
diagnosis is even more important since cardiovascular damage is disproportionally 
high when compared to essential hypertension (for further details see paragraph 
‘Primary aldosteronism’ in this chapter). 
 Hypertension results in premature atherosclerosis of the arterial blood vessels 
and hypertrophy of the heart muscle. This ultimately becomes clinically manifest as 
cardiovascular disease such as stroke, cerebral hemorrhage, heart failure, acute 
coronary syndrome, (ruptured) aortic aneurysm, renal failure, and occlusive 
peripheral arterial disease. Moreover, hypertension is associated with other diseases 
such as diabetes and dementia.8,9
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Chapter 1
Most people are not aware that they have hypertension, as an elevated blood pressure is 
generally not associated with specific symptoms. Therefore, elevated blood pressure 
may be discovered during a (periodic) visit to a healthcare worker, a jobsite screening, 
or when hypertension has caused a complication (e.g. stroke). Rarely, hypertension 
is discovered when a patient presents with symptoms related to an underlying cause 
for secondary hypertension (e.g. central obesity in Cushing’s syndrome).
 Treatment of hypertension focuses on primary or secondary prevention of 
cardiovascular disease. The majority of patients has multiple cardiovascular risk 
factors in addition to hypertension, such as hypercholesterolemia and/or an unhealthy 
lifestyle (e.g. smoking). Because multiple risk factors potentiate each other, treatment 
is aimed at blood pressure reduction as well as management of other risk factors for 
cardiovascular disease.
 In the Netherlands treatment of hypertension in the context of primary prevention 
of cardiovascular disease is usually started in primary care. In this setting an adapted 
SCORE (=Systematic COronary Risk Evaluation) table is used to guide therapy. 
The SCORE cardiovascular risk assessment model provides an estimated 10-year 
absolute risk for fatal and non-fatal cardiovascular disease, taking into account gender, 
age, smoking, systolic blood pressure, total cholesterol to high-density lipoprotein 
cholesterol ratio, and comorbidity.10 According to the guidelines, all hypertensive patients 
should receive lifestyle advice, and periodic follow-up encounters should be planned 
to evaluate treatment. If blood pressure remains elevated, the cardiovascular risk 
score (SCORE) guides whether medical treatment should be started, or intensified, 
according to the guideline.11
 Treatment of hypertension in the context of secondary prevention is usually 
started in referral centres where the patient is admitted for specialized investigations, 
or when a cardiovascular event has occurred. After return to primary care, the GP 
becomes in charge of monitoring antihypertensive treatment.
Diagnosis of hypertension in primary care
The Dutch primary care guideline concerning hypertension is called the ‘Dutch 
guideline for Cardiovascular Risk Management’ (Dutch CVRM guideline). According 
to this guideline hypertension is diagnosed when an elevated blood pressure is found 
at two or more different encounters. An elevated blood pressure is defined as 
repeated office systolic blood pressure levels of >140 mmHg (150-160 mmHg in 
patients ≥80 years), measured over a prolonged period of time.11 For out-of-office 
blood pressure measurements different cut-offs for the diagnosis of hypertension 
should be used: when measured with an electronic home blood pressure device the 
cut-off for systolic blood pressure is >135 mmHg, and when using 24-hour ambulatory 
blood pressure monitoring (ABPM) the cut-off is >130 mmHg for the average 24-hour 
blood pressure. In this guideline the diastolic blood pressure is not taken into account, 
and the number of repeated measurements as well as the period over which the 
elevated office blood pressures should be measured are not specified.
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General introduction
In this thesis ‘hypertension’ is defined according to the guideline of the European 
Society of Hypertension: an elevated blood pressure is a systolic blood pressure of 
≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg, measured by an 
auscultatory or semiautomatic sphygmomanometer in the doctor’s office.3 For out-of 
office blood pressure measurements different cut-offs are used: ≥135 and/or 85 
mmHg for an electronic home blood pressure measuring device, and ≥130 and/or 80 
mmHg for the average 24-hour blood pressure using ABPM. It has to be noted that 
the definition of elevated blood pressure varies across international guidelines. Table 1, 
second column, shows examples of different definitions for hypertension.
 Lower cut-offs for out-of-office blood pressures are used because the blood 
pressure in the doctor’s office can be higher than normal due to awareness of the 
patient being at the doctor’s office. If this ‘awareness associated elevated blood 
pressure’ is observed at multiple visits, and out-of-office blood pressure is normal, 
this phenomenon is referred to as ‘white-coat’ hypertension. White-coat hypertension 
is present in approximately 13% of the general population.3 Possibly, patients with 
white-coat hypertension have an intermediate risk for cardiovascular disease, 
new-onset diabetes, and sustained hypertension compared to patients with normal 
blood pressure.12-16 Conversely, a normal blood pressure in the doctor’s office with 
an elevated blood pressure in the usual home environment is termed ‘masked 
hypertension.’ Masked hypertension is present in about 13% of all hypertensive 
patients. It has a similar or even higher incidence of cardiovascular events compared 
to patients with hypertension,17 and an increased risk of diabetes compared to 
normotensive patients.18-20 Despite the risk of not detecting white-coat hypertension 
or of missing masked hypertension, out-of-office blood pressure measurements are 
not required to confirm or refute the diagnosis of hypertension according to the 
current Dutch CVRM guideline. 
PRIMARY ALDOSTERONISM
PA is a group of disorders in which aldosterone production has become autonomous, 
i.e. independent from the physiological regulation by the renin-angiotensin-
aldosterone system (RAAS), and potassium. Under normal conditions the RAAS, 
plasma potassium, and adrenocorticotropic hormone (ACTH) are the major 
controllers of aldosterone secretion. In conditions of decreasing blood pressure and 
circulating volume, renin secretion by the renal juxtaglomerular cells stimulates 
the conversion of angiotensinogen to angiotensin I. Angiotensin converting enzyme 
(ACE) from vascular endothelium converts angiotensin I into angiotensin II. This latter 
compound is not only a strong vasoconstrictor, thus increasing blood pressure, 
but stimulates adrenal aldosterone secretion as well. The hormone aldosterone 
specifically interacts with renal tubular mineralocorticoid receptors. Through complex 
activation of several tubular ion channel transporters, the final effect is an increased 
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Chapter 1
Table 1  Summary of guidelines concerning the definition of hypertension  
and diagnosing secondary hypertension
Guideline 
(country, year)
Criteria for the diagnosis of HT
In which patients should screening  
for secondary hypertension be considered?
Patients in primary care  
specifically addressed?
Dutch guideline for Cardiovascular  
Risk Management
(Netherlands, 2012)11
Office systolic BP >140mmHg  
(150-160 mmHg in patients ≥80 years).
HBPM systolic >135mmHg.
ABPM systolic >130mmHg.
- serum potassium ≤3.5 mmol/L
- suspicion of chronic kidney damage
- therapy resistant HT, defined as a systolic BP 
>140 mmHg despite the use of three different 
classes of antihypertensive agents in adequate 
dosage
Yes (primary care guideline): refer if one or more of 
the conditions in the previous column is met.
NICE-guideline, Hypertension in adults:  
diagnosis and management
(United Kingdom, 2016)21
If office BP is ≥140/90 mmHg offer ABPM to confirm 
the diagnosis of HT. If a person is unable to tolerate 
ABPM, HBPM is a suitable alternative to confirm the 
diagnosis of HT. 
Stage 1 HT: office BP ≥140/90mmHg and 
subsequent mean daytime ABPM or mean HBPM 
≥135/85 mmHg.
Stage 2 HT: office BP ≥160/100mmHg and 
subsequent mean daytime ABPM or mean HBPM 
≥150/95 mmHg or higher.
Severe hypertension: office systolic BP ≥180 mmHg 
or office diastolic blood pressure ≥110 mmHg.
- HT in patients <40y
- sudden worsening of HT
- presentation of accelerated HT: 180/110 mmHg 
with signs of papilloedema and/or retinal 
haemorrhage
- poor response to treatment
- elevated creatinine or reduced eGFR
- isolated hypokalemia
Yes: refer if one or more of the conditions in  
the previous column is met. 
Notably, the NICE-guideline applies to both general 
practitioners (GPs), and medical specialists.
American College of Cardiology/American Heart 
Association Task Force Guideline for the Prevention, 
Detection, Evaluation, and Management of  
High Blood Pressure in Adults 
(United States of America, 2017)22
Normal BP: <120/80 mmHg.
Elevated BP: 120-129/<80 mmHg.
Stage 1 HT: systolic 130-139 or diastolic 80-89 mmHg.
Stage 2 HT: systolic ≥140 or diastolic ≥90 mmHg. 
Out-of-office BP measurements are recommended 
to confirm the diagnosis of HT and for evaluation of 
BP-lowering therapy.
In the presence of HT, and any of the following 
concurrent conditions:
- age <30y
- resistance to antihypertensive treatment
- hypokalemia (spontaneous or diuretic induced)
- muscle cramps or weakness
- incidentally discovered adrenal mass
- obstructive sleep apnea
- family history of early-onset HT or stroke
No
The Management of Primary Aldosteronism:  
Case Detection, Diagnosis, and Treatment:  
An Endocrine Society Clinical Practice Guideline
(United States of America, 2016)23
HT >140/90 mmHg Patients with:
- sustained BP >150/100 mm Hg on each of  
three measurements obtained on different days
- HT (BP >140/90 mm Hg) resistant to three 
conventional antihypertensive drugs (including  
a diuretic), or controlled BP (<140/90 mmHg)  
on ≥ four antihypertensive drugs
- HT and spontaneous or diuretic-induced 
hypokalemia
- HT and adrenal incidentaloma
- HT and sleep apnea
- HT and a family history of early onset HT  
or cerebrovascular accident at a young age  
(<40 years)
- all hypertensive first-degree relatives of patients 
with PA
Yes: explicit recommendations for referral by primary 
care physicians of patients with suspected PA to 
specialized centres for further work-up.
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Table 1  Summary of guidelines concerning the definition of hypertension  
and diagnosing secondary hypertension
Guideline 
(country, year)
Criteria for the diagnosis of HT
In which patients should screening  
for secondary hypertension be considered?
Patients in primary care  
specifically addressed?
Dutch guideline for Cardiovascular  
Risk Management
(Netherlands, 2012)11
Office systolic BP >140mmHg  
(150-160 mmHg in patients ≥80 years).
HBPM systolic >135mmHg.
ABPM systolic >130mmHg.
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- therapy resistant HT, defined as a systolic BP 
>140 mmHg despite the use of three different 
classes of antihypertensive agents in adequate 
dosage
Yes (primary care guideline): refer if one or more of 
the conditions in the previous column is met.
NICE-guideline, Hypertension in adults:  
diagnosis and management
(United Kingdom, 2016)21
If office BP is ≥140/90 mmHg offer ABPM to confirm 
the diagnosis of HT. If a person is unable to tolerate 
ABPM, HBPM is a suitable alternative to confirm the 
diagnosis of HT. 
Stage 1 HT: office BP ≥140/90mmHg and 
subsequent mean daytime ABPM or mean HBPM 
≥135/85 mmHg.
Stage 2 HT: office BP ≥160/100mmHg and 
subsequent mean daytime ABPM or mean HBPM 
≥150/95 mmHg or higher.
Severe hypertension: office systolic BP ≥180 mmHg 
or office diastolic blood pressure ≥110 mmHg.
- HT in patients <40y
- sudden worsening of HT
- presentation of accelerated HT: 180/110 mmHg 
with signs of papilloedema and/or retinal 
haemorrhage
- poor response to treatment
- elevated creatinine or reduced eGFR
- isolated hypokalemia
Yes: refer if one or more of the conditions in  
the previous column is met. 
Notably, the NICE-guideline applies to both general 
practitioners (GPs), and medical specialists.
American College of Cardiology/American Heart 
Association Task Force Guideline for the Prevention, 
Detection, Evaluation, and Management of  
High Blood Pressure in Adults 
(United States of America, 2017)22
Normal BP: <120/80 mmHg.
Elevated BP: 120-129/<80 mmHg.
Stage 1 HT: systolic 130-139 or diastolic 80-89 mmHg.
Stage 2 HT: systolic ≥140 or diastolic ≥90 mmHg. 
Out-of-office BP measurements are recommended 
to confirm the diagnosis of HT and for evaluation of 
BP-lowering therapy.
In the presence of HT, and any of the following 
concurrent conditions:
- age <30y
- resistance to antihypertensive treatment
- hypokalemia (spontaneous or diuretic induced)
- muscle cramps or weakness
- incidentally discovered adrenal mass
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The Management of Primary Aldosteronism:  
Case Detection, Diagnosis, and Treatment:  
An Endocrine Society Clinical Practice Guideline
(United States of America, 2016)23
HT >140/90 mmHg Patients with:
- sustained BP >150/100 mm Hg on each of  
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with PA
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care physicians of patients with suspected PA to 
specialized centres for further work-up.
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Chapter 1
renal sodium reabsorption (with concomitant water reabsorption) and renal potassium 
excretion (Figure 1). The ensuing increase in circulating volume inhibits renin and 
aldosterone secretion by negative feedback. In patients with PA volume expansion 
and inhibition of aldosterone secretion are uncoupled, as evidenced by a suppressed 
renin level.28 Therefore, PA is characterized by inappropriately high plasma aldosterone 
levels for sodium status, and by suppressed renin levels.
 Previously, PA was thought to be a rare cause of hypertension (prevalence <1% 
of the hypertensive population). However, over the last 25 years it has become clear 
that PA is more frequent, affecting 1% to 23% of all hypertensive patients.29,30 This 
wide range indicates uncertainty regarding the prevalence, and it might be explained 
by variability in diagnostic procedures, differences in patient selection (primary care, 
referral centres, severity of hypertension), and the current reappraisal of the 
normokalemic variant of PA.31-34
Table 1  -Continued
Guideline 
(country, year)
Criteria for the diagnosis of HT
In which patients should screening  
for secondary hypertension be considered?
Patients in primary care  
specifically addressed?
Hypertension Canada’s 2017 Guidelines  
for diagnosis, risk, assessment, prevention,  
and treatment of hypertension in adults 
(Canada, 2017)24
Automated device: office BP ≥135/85 mmHg.
Sphygmomanometer: office BP ≥140/90 mmHg.
HBPM: mean ≥135/85 mmHg.
ABPM daytime: mean ≥135/85 mmHg.
ABPM: 24-hours ≥130/80 mmHg.
ABPM or HPBM is preferred, but not obligate  
to diagnose HT.
Hypertensive patients with one of the following:
- unexplained spontaneous hypokalemia 
(potassium <3.5 mmol/L) or marked diuretic-
induced hypokalemia (potassium <3.0 mmol/L)
- resistance to treatment with ≥3 drugs
- an incidental adrenal adenoma
No
Guideline for the diagnosis and management  
of hypertension in adults 
(Australia, 2016)25
Optimal BP: <120/80 mmHg.
Normal BP: 120-129 and/or 80-84 mmHg.
High normal: 130-139 and/or 85-89 mmHg.
Grade 1 (mild) HT: 140-159 and/or 90-99 mmHg.
Grade 2 (moderate) HT: 160-179 and/or  
100-109 mmHg.
Grade 3 (severe) HT: ≥180 and/or ≥110 mmHg.
Isolated systolic HT: >140 and <90 mmHg.
It should be considered in patients with HT, 
especially those with moderate-to-severe or 
treatment-resistant HT, and those with hypokalemia. 
Referral to a specialist for investigation is 
recommended when PA is suspected. 
Yes
The Japanese Society of Hypertension  
Guidelines for the Management of Hypertension 
(Japan, 2014)26
BP ≥140/90 mmHg
ABPM or HPBM is preferred but not obligate to 
diagnose HT. HBPM is preferred over ABPM. 
Selective screening of high-risk groups for  
PA such as those with resistant (refractory) HT, 
grade II-III HT, and hypokalemia.
No
However, the Japan Endocrine Society has a  
PA-guideline which is especially developed for GPs 
(2009): ‘… recommends measurement of plasma 
renin activity and plasma aldosterone concentration 
in all patients initially diagnosed as hypertensive …’ 27
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General introduction
Signs suggestive of PA are hypokalemia (spontaneous or diuretic-induced), therapy 
resistant hypertension, a family history of PA, or an incidentaloma in the presence of 
hypertension. However, specific clinical features are often lacking, and this is part of 
the explanation why it has been reported that the diagnosis of PA may be delayed by 
a mean of eight years.35
 There are two major subtypes of PA: the aldosterone-producing adenoma (30% 
to 50% of the cases, also known as Conn’s disease), and bilateral adrenal hyperplasia 
(50% to 70% of the cases; Figure 1). Treatment of an aldosterone-producing adenoma 
differs from treatment of bilateral adrenal hyperplasia. An adenoma is preferably 
removed by adrenalectomy,36-38 while bilateral adrenal hyperplasia is treated with a 
mineralocorticoid receptor antagonist (such as spironolactone or eplerenone).39 
Because of these different treatment strategies, subtype differentiation is pivotal for 
selecting those patients with PA who are suitable for surgical treatment.
Table 1  -Continued
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Guideline for the diagnosis and management  
of hypertension in adults 
(Australia, 2016)25
Optimal BP: <120/80 mmHg.
Normal BP: 120-129 and/or 80-84 mmHg.
High normal: 130-139 and/or 85-89 mmHg.
Grade 1 (mild) HT: 140-159 and/or 90-99 mmHg.
Grade 2 (moderate) HT: 160-179 and/or  
100-109 mmHg.
Grade 3 (severe) HT: ≥180 and/or ≥110 mmHg.
Isolated systolic HT: >140 and <90 mmHg.
It should be considered in patients with HT, 
especially those with moderate-to-severe or 
treatment-resistant HT, and those with hypokalemia. 
Referral to a specialist for investigation is 
recommended when PA is suspected. 
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The Japanese Society of Hypertension  
Guidelines for the Management of Hypertension 
(Japan, 2014)26
BP ≥140/90 mmHg
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Selective screening of high-risk groups for  
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General introduction
Timely and correct detection of PA is relevant for four reasons: 
1)  Hypertension due to underlying autonomous aldosterone secretion causes 
more severe cardiovascular damage than the same blood pressure levels in 
patients with essential hypertension.40-42
2)  PA requires specific treatment: not only the hypertension should be controlled, but 
the deleterious effects of the aldosterone excess should be counteracted as well.23
3)  Outcomes of treatment are superior in patients with younger age, and a shorter 
duration of hypertension.43-46
4)  Quality of life is significantly lower in patients with untreated PA compared to patients 
with essential hypertension, and it improves or even normalizes by specific 
therapy.47,48
Diagnostic work-up in primary alDosteronism 
The diagnostic workup for PA comprises three steps: case detection, confirmation, 
and subtype differentiation.23 For detection of PA the Endocrine Society guideline 
recommends to measure plasma aldosterone and renin levels in a venous blood 
sample with calculation of the aldosterone-to-renin ratio (ARR). This screening test is 
suitable for application in primary care. If the results of these tests suggest the 
presence of PA, referral to a specialist (internist or endocrinologist) is needed to 
confirm or refute the diagnosis (due to the need for specialized investigations, e.g. a 
confirmation test, computed tomography etc.). As both aldosterone and renin may 
be influenced by many factors, a blood sample must be drawn under prespecified 
conditions: mid-morning after the patient has been out of bed for two hours, and the 
patient has been sitting for 5-15 minutes. The use of antihypertensive medication 
should be stopped or adjusted, as some of these agents can interfere with the test 
results (e.g. beta blockers suppress renin).23 An elevated ARR is suspect for PA, and 
therefore requires further testing.49
 Cut-offs of the ARR for screening for PA vary widely in literature due to the use 
of different measurement units, which depend on the type of biochemical assay. The 
Endocrine Society guideline provides cut-off values of the ARR for the different 
measurement units, but leaves room for different cut-offs.23 There is still no definite 
agreement on the optimal ARR cut-off value.
 Because of its limited specificity, an elevated ARR by itself is not sufficient to 
definitely diagnose PA. A confirmation test is mandatory by demonstrating non-
suppressible aldosterone secretion. Only patients who present with ‘spontaneous 
hypokalemia, plasma renin below detection levels, plus plasma aldosterone 
concentration >20 ng/dL (550 pmol/L)’ may not need further confirmatory testing.23 
In all other cases the Endocrine Society guideline recommends to choose one of 
four confirmation tests: the oral sodium loading test, the intravenous sodium loading 
test, the fludrocortisone suppression test, or the captopril challenge test.23 The work-up 
for subtype differentiation of PA is the last step to determine the most appropriate 
treatment. We will not discuss this, as this is beyond the context of this thesis.
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Chapter 1
screening for primary alDosteronism in primary care
In the Netherlands the diagnosis and treatment of hypertension typically belong to 
the domain of the GP, who generally follows the Dutch CVRM guideline to diagnose 
and treat hypertension.11 With regard to secondary hypertension the guideline advises 
to consider a underlying cause of hypertension if a patients presents with clinical 
clues for such underlying cause.11 This guideline has no specific recommendations 
on how to diagnose PA. Regarding PA, the guideline advises to refer patients with 
hypertension and hypokalemia, or patients with therapy resistant hypertension for 
specialist consultation. However, as hypokalemia is absent in approximately 70% 
of all patients with PA, it is likely that the majority of PA patients will be missed if the 
current Dutch CVRM guideline is followed.50 In addition, most GPs are unfamiliar with 
PA and its diagnostic process. Consequently, screening for PA is rarely performed in 
primary care. This results in a delay before the diagnosis of PA is made, and targeted 
treatment can be initiated. The diagnostic difficulties are illustrated by a typical patient 
as described in the following patient vignette (Box 1).
 In this patient, the difficult to control blood pressure appeared to be caused by 
underlying PA. The duration between the diagnosis of hypertension and the diagnosis 
of PA in this clinical example was almost two years. This case is not unusual in clinical 
practice, not only in the Netherlands but worldwide. Although two years is too long to 
detect PA, the mean delay is even longer.35,51 The current practice raises the question: 
is the current Dutch CVRM guideline really up to date to diagnose secondary causes 
of hypertension, in particular PA? For comparison of the recommended strategies of 
the most relevant international guidelines for screening for secondary hypertension, 
in particular specified for the primary care setting, see Table 1.
 In this thesis we describe several studies that address the question whether 
screening for PA in all newly diagnosed hypertensive patients should be introduced 
as a standard procedure in primary care. For justification of screening for a disease 
we need to consider the ten suitability criteria (or principles) of Wilson and Jungner 
(World Health Organization, 1968) (Table 2, left column).52 Table 2, right column, 
shows that when applied to the detection of PA, several criteria are not fully met.
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Box 1  Patient vignette 
Just a patient with difficult-to-control hypertension?
Mrs. P is a 58 year old woman who visits her GP in 2015 because of dizziness. She works as 
an employee at a bank and perceives a high level of job stress. Her office blood pressure 
is 164/99 mmHg. The GP considers her blood pressure to be related to the stress at work, 
to the menopause, or to both factors, and advises her to perform home blood pressure 
measurements. 
 Two months later Mrs. P hands in an average home blood pressure of 154/98 mmHg 
(normal <135/85 mmHg). Standard blood tests for hypertension are unremarkable, including a 
plasma potassium of 3.6 mmol/L (normal 3.5-4.5 mmol/L). Assessment of the cardiovascular 
risk profile according to the Dutch CVRM guideline11 indicates no smoking and no family 
history of cardiovascular disease. Body mass index is 26 kg/m2 and physical exercise is rarely 
performed. A total cholesterol to high-density lipoprotein cholesterol ratio of 5.8 indicates her 
10-years risk for cardiovascular disease to be 11%. The GP initially recommends lifestyle 
changes: reduction of job-related stress and engaging in more regular physical exercise.
 Four months later home blood pressure is 158/98 mmHg and therefore the GP starts 
the antihypertensive amlodipine (5 mg daily). Two months later our patient returns with a home 
blood pressure of 150/90 mmHg. Mrs. P admits she forgot her medication a few times and 
the GP also discusses with her the obstacles to change her lifestyle more extensively. She is 
absorbed by her work, so exercising and preparing dinner with fresh ingredients is still not a 
priority. She promises to intensify exercise together with a friend to two times a week. A new 
evaluation is scheduled in six months but then her home blood pressure has not substantially 
decreased: 156/92 mmHg. The GP prescribes additional lisinopril (10 mg daily) and two weeks 
later her blood pressure is 146/88 mmHg, plasma potassium is 3.6 mmol/L and the eGFR is 
unchanged within the normal range. 
 For the time being the GP is satisfied with this result, and a next visit is scheduled in four 
months. At that point it appears that Mrs. P home blood pressure has not improved at all: 
154/92 mmHg. She insists she takes her medication every morning, and she feels tired and 
‘shaky’. The GP decides to add chlorthalidone 12,5 mg once daily. One month later plasma 
potassium has decreased to 3.3 mmol/L. The GP advises a potassium enriched diet, but despite 
eating a lot of beans, tomatoes, and bananas, potassium remains too low: 3.1 mmol/L after 
two weeks. While using now three antihypertensive agents, Mrs. P remains hypertensive: 
150/90 mmHg. Therefore, the GP switches from chlortalidone to spironolactone 25mg. 
Three months later she returns being very tired, and although plasma potassium has 
increased to 3.7 mmol/L, her blood pressure is still uncontrolled: 148/92 mmHg. Because of 
the persistent difficulty to control blood pressure satisfactorily, the GP consults with her 
colleague internist in the hospital who advises referral because of the suspicion of PA. 
The internist advises to stop the spironolactone and lisinopril (as these interfere with 
biochemical testing in the diagnostic work-up for PA), and to start potassium suppletion. 
In the hospital the diagnosis of PA is confirmed as documented by an elevated plasma 
aldosterone, suppressed renin, elevated ARR, and a positive saline infusion test.
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Table 2  Criteria of early disease detection by Wilson and Jungner applied to 
screening for primary aldosteronism in Dutch primary care
Criteria for screening in general
Criteria applied for screening for primary 
aldosteronism 
1. The condition sought should be an 
important health problem.
PA is an important health problem in a 
considerable number of patients (assuming 
an incidence of 5%, there are approximately 
5000 new patients with PA per year in the 
Netherlands). In addition, PA carries a high risk 
of cardiovascular complications, and untreated 
PA is associated with a poor quality of life.
2. There should be an accepted treatment 
for patients with recognized disease.
Treatment depends on the subtype of 
PA: an adenoma is preferably treated by 
adrenalectomy, while bilateral hyperplasia 
should be treated with mineralocorticoid 
receptor antagonists. Both treatments are 
highly effective.
3. Facilities for diagnosis and treatment 
should be available.
In the Netherlands healthcare facilities for 
diagnosis and treatment of PA are widely 
available.
4. There should be a recognizable  
latent or early symptomatic stage.
Early symptoms consist of hypertension,  
and in some patients of hypokalemia. 
5. There should be a suitable test  
or examination.
A suitable test is available for screening:  
a venous blood sample for measurement of 
aldosterone and renin.
6. The test should be acceptable to  
the population.
The screening test can be performed in primary 
care by adding the screening to the standard 
laboratory tests, which are performed when 
hypertension is diagnosed.
7. The natural history of the condition, 
including development from latent  
to declared disease, should be 
adequately understood.
The pathogenetic mechanism of PA, and 
development from latent to declared disease, 
are reasonably well understood.
8. There should be an agreed policy on 
whom to treat as patients.
After screening a confirmation test will confirm 
or refute the diagnosis of PA, thus guiding 
which patients will benefit from PA specific 
treatment.
9. The cost of case finding (including 
diagnosis and treatment of patients 
diagnosed) should be economically 
balanced in relation to possible 
expenditure on medical care as a whole.
An early diagnosis of PA might be cost-
effective, but it is unknown if this is valid for  
the Dutch population.
10. Case-finding should be a continuing 
process and not a “once and for all” 
project.
Screening for PA can be easily incorporated  
in standard hypertension care.
PA, primary aldosteronism.
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In conclusion, there are several criteria for early screening for PA in primary care that 
are not yet met. Several aspects, such as the prevalence of PA in primary care,53,54 
and cost-effectiveness55,56 are insufficiently known. In addition, it is also uncertain 
whether PA has already caused cardiovascular damage at the stage when the 
hypertension is detected for the first time, which would give additional weight to 
arguments for early screening. 
 However, there are also well-founded reasons to consider detection of PA at an 
early stage in the primary care setting:
1) Hypertension is almost invariably diagnosed in primary care.
2) Due to interference of antihypertensive medication with the ARR, screening 
for PA is best done when the patient takes no antihypertensive medication. 
This is most easily done in newly diagnosed cases of hypertension. In addition, 
a wash-out period of antihypertensive medication in case of later screening 
is not without risk.57
3) Although the exact prevalence of PA in primary care is still a matter of debate, 
even in case of a low proportional prevalence, the absolute number of patients 
with PA is high.
4) PA-induced cardiovascular damage may be reversible by proper early treatment 
of PA.58,59
5) Using the ARR for early detection of PA may have an additional advantage. Even 
if the ARR does not indicate the possibility of PA, it reflects the state of the renin-
angiotensin-aldosterone system, especially the renin component, and thus may 
predict the presence or absence of an antihypertensive response to ACE-inhibitors, 
angiotensin receptor blockers, calcium channel blockers, and diuretics. If this is 
proven to be true, it would mean that measurement of the ARR in hypertensive 
patients might be even a more cost-effective tool, since it both excludes PA and 
directs antihypertensive therapy.
OBJECTIVES AND OUTLINE OF THE THESIS
The major inspiration for the studies described in this thesis came from this question: 
should screening for PA be introduced in primary care? To address this question we 
first want to address the following specific objectives in the studies reported in this 
thesis: 
1) To assess the prevalence of PA in previous studies carried out in both primary 
care and referral centres, we describe a meta-analysis of studies that were 
performed to assess the prevalence of PA in Chapter 2.
2) To assess the proportion of patients with PA in patients with newly diagnosed 
hypertension in Dutch general practice. In Chapter 3 the prevalence of PA in 
Dutch primary care centres is estimated in patients with newly diagnosed 
hypertension.
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3) To assess the presence of cardiovascular and renal damage in patients with 
newly diagnosed hypertension and PA at the time of diagnosing hypertension in 
primary care. In Chapter 4 we explore cardiovascular damage in patients with 
newly diagnosed hypertension with and without PA.
4) To study whether the blood pressure response to antihypertensive treatment in 
patients with newly diagnosed hypertension in general practice can be predicted 
by the level of the ARR. In Chapter 5 the association between the status of the 
RAAS (expressed as ARR) and the blood pressure response to antihypertensive 
treatment within one year of treatment is assessed. 
In Chapter 6 we summarize the main findings of this thesis, and finish with a discussion 
of the clinical implications, recommendations for future research, and key messages.
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For health care planning and allocation of resources, realistic estimation of the 
prevalence of primary aldosteronism is necessary. Reported prevalences of primary 
aldosteronism are highly variable, possibly due to study heterogeneity.
objective
Our objective was to identify and explain heterogeneity in studies that aimed to 
establish the prevalence of primary aldosteronism in hypertensive patients.
Data sources
PubMed, EMBASE, Web of Science, Cochrane Library, and reference lists from 
January 1, 1990, to January 31, 2015, were used as data sources. 
stuDy selection
Description of an adult hypertensive patient population with confirmed diagnosis of 
primary aldosteronism was included in this study. 
Data extraction
Dual extraction and quality assessment were the forms of data extraction.
Data synthesis
Thirty-nine studies provided data on 42510 patients (nine studies, 5896 patients from 
primary care). Prevalence estimates varied from 3.2% to 12.7% in primary care and 
from 1% to 29.8% in referral centers. Heterogeneity was too high to establish point 
estimates (I2 = 57.6% in primary care; 97.1% in referral centers). Meta-regression 
analysis showed higher prevalences in studies 1) published after 2000, 2) from 
Australia, 3) aimed at assessing prevalence of secondary hypertension, 4) that were 
retrospective, 5) that selected consecutive patients, and 6) not using a screening test. 
All studies had minor or major flaws.
conclusions
This study demonstrates that it is pointless to claim low or high prevalence of primary 
aldosteronism based on published reports. Because of the significant impact of a 
diagnosis of primary aldosteronism on health care resources and the necessary 
facilities, our findings urge for a prevalence study whose design takes into account 
the factors identified in the meta-regression analysis.
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INTRODUCTION
Primary aldosteronism (PA) is assumed to be the most frequent form of secondary 
hypertension. However, the actual prevalence of PA is a matter of continuing debate. 
Clarity regarding the prevalence of PA is highly relevant, as it has strong implications 
for future policy decisions concerning screening strategies for PA.
 Identifying PA as the underlying cause of (therapy resistant) hypertension is 
considered important for two reasons. First, PA is associated with an increased rate 
of cardiovascular complications.1-3 Second, specific treatment by mineralocorticoid 
receptor antagonists or adrenalectomy is effective in reducing these cardiovascular 
complications4-6 and health costs.7 Therefore, an early diagnosis and treatment of 
PA are key for increasing the chance of improvement and even cure of hypertension, 
and for preventing cardiovascular complications.8-10
 In primary care centers, reported prevalences vary from 6% to 13%; in secondary 
care centers, prevalences of 23% to almost 30% have been reported.11-13
 In this article, we provide a systematic review and meta-analysis on the 
prevalence of PA in both primary care and referral centers, conducted according to 
the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines.14 
In our attempt to obtain a reliable estimate of the prevalence of PA, we encountered 
substantial methodological heterogeneity. Therefore, we also set out to identify those 
factors that contribute to the wide variability in estimates of PA prevalence, using 
meta-regression analysis.
METHODS
Data sources anD searches
The objectives and methods of this meta-analysis, including databases that were to 
be searched, search terms, inclusion criteria, and method of analysis were defined 
before the start of the review and not modified thereafter. Reporting of this systematic 
review is in accordance with the MOOSE statement, a structured checklist for reporting 
meta-analyses.14
 We conducted a systematic search on four electronic databases: PubMed, 
EMBASE, Web of Science, and the Cochrane Library were searched for English, 
German, French, Spanish, and Dutch articles on the prevalence of PA published 
between January 1, 1990, and January 31, 2015. We used the following search terms:
((“Hyperaldosteronism” [Mesh]) OR (hyperaldosteronism [Title/Abstract]) OR (aldo-
steronism [Title/Abstract]) OR (Conn syndrome [Title/Abstract]) OR (Conns syndrome 
[Title/Abstract]) OR (Conn’s syndrome [Title/Abstract]) OR (hyperaldosteronism 
[Other Term]) OR (aldosteronism [Other Term]) OR (Conn syndrome [Other Term]) 
OR (Conn’s syndrome [Other Term]))
AND
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 30
30
Chapter 2
((“Prevalence” [Mesh]) OR (prevalence [Title/Abstract]) OR (prevalences [Title/
Abstract]) OR (occurrence [Title /Abstract]) OR (occurrences [Title/Abstract]) OR 
(“Incidence” [Mesh]) OR (incidence [Title/Abstract]) OR (incidences [Title/Abstract]) 
OR (“Epidemiology” [Mesh]) OR (“epidemiology” [Subheading]) OR (epidemiology 
[Title/Abstract]) OR (epidemiologic [Title/Abstract]) OR (epidemiological [Title/
Abstract]) OR (prevalence [Other Term]) OR (prevalences [Other Term]) OR 
(incidence [Other Term]) OR (incidences [Other Term]) OR (occurrence [Other Term]) 
OR (occurrences [Other Term]) OR (epidemiology [Other Term]) OR (epidemiologic 
[Other Term]) OR (epidemiological [Other Term])) (see Supplementary File 1).
 We checked reference lists of all provisionally included studies (i.e. studies that 
were eligible for further assessment) and reviews for additional, relevant studies 
published in or after 1990. When articles could not be retrieved from electronic 
databases or national university archives, we contacted the corresponding authors.
 We merged search results from the four databases and checked automatically 
and manually for duplicates (SK and TD). We used no restrictions other than language 
and year of publication. Studies published before 1990 were excluded to reduce 
excessive diversity in used assays, cut-off values and confirmation tests. The final 
literature search was performed on February 17, 2015.
stuDy selection
Two researchers (SK and TD) independently assessed eligibility of retrieved articles 
on title and abstract. Full-text articles were retrieved if necessary.
Studies were considered eligible for inclusion if they met the following criteria:
1) Data presented as an original study, short report, or letter on the prevalence 
of PA;
2) Prospective, retrospective, or cross-sectional study design;
3) Study population of adult patients (≥18 years of age) with hypertension;
4) Use of a confirmation test (intravenous sodium loading test (IV SLT), oral SLT, 
captopril suppression test, or fludrocortisone suppression test) to verify the diagnosis 
of PA (performed in at least 50% of the patients with positive screening test).13
Studies were excluded if:
1) The prevalence of PA was investigated in patient groups with a specific morbidity 
(e.g. diabetes mellitus);
2) The article was a case report;
3) The reported prevalences were solely based on the aldosterone-to-renin ratio 
(ARR) or on another screening test, computed tomography scan results, adrenal 
venous sampling, blood pressure response to spironolactone or on post-operative 
histopathology reports.
Disagreements on eligibility were resolved by consensus among the two reviewers 
or, when necessary, by a third researcher (JD).
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Data extraction anD quality assessment
Two researchers (SK and TD) independently scored all included studies on a data 
extraction form for author(s), year of publication, country, study design, health care 
setting (primary care or referral center), number of included patients, patient 
characteristics (gender, age, severity of hypertension), number of patients with 
hypokalemia, antihypertensive medication, screening method(s) with cut-off value(s), 
position during screening method (supine vs not supine), number of patients in 
whom screening was positive, confirmation method(s) with cut-off value(s), number 
of patients with a positive screening who underwent confirmation, the prevalence of 
PA, and if the study was included or excluded for analysis. Differences in extraction 
were resolved by consensus or, if necessary, by a third researcher (JD).
 We contacted corresponding authors (by email or telephone) in case of missing 
or ambiguous information. If there was an indication that the same group of patients 
was used in multiple papers on PA prevalence, we contacted corresponding authors 
to check. In case of multiple reports, we included the study in which the methods 
were reported in most detail.
 After the final inclusion, SK and TD rated the methodological quality and risk of 
bias in individual studies using the “Methodological evaluation of Observational 
REsearch (MORE) – Observational Studies of Incidence or Prevalence of Chronic 
Diseases” protocol.15 This protocol comprises the following items:
1) Funding, ethical approval, conflict of interest;
2) Aim of the study and study design;
3) External validity: population, patient selection, inclusion criteria, sampling bias;
4) Internal validity: source of measurements, validation and reliability of estimates, 
type of outcome.
The MORE protocol provides a descriptive quality assessment of individual studies 
without an overall quality score.
Data synthesis anD analysis
To estimate the prevalence of PA, we computed random effect pooled proportions 
for primary care and referral centers separately.16 Logit transformation was used to 
get quantities from prevalence. 
 To explore sources of heterogeneity, we performed random effects logistic 
regression analysis with prevalence of PA as dependent variable.17,18 We based the 
choice of variables on controversies discussed in the Endocrine Society guideline13 and 
on our expectations of explanatory factors for bias in prevalence studies. We 
distinguished three categories of potential predictors of prevalence estimates:
1) Time: studies published in different periods (two categories: 1990 till 2000, and 
after 2000);
2) Geographic region where studies were performed: Asia, Australia, Europe, Latin 
America, and United States of America;
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3) Factors concerning study design:
 a) Data collection (prospective or retrospective);
 b)  Study objective (to assess the prevalence of PA, to assess the prevalence of 
secondary hypertension, other);
 c)  Method of patient selection (consecutive, convenience, self selection). We defined 
convenience as arbitrarily selected individuals from the target population other 
than general such that each individual had uncontrolled probability of selection;19
 d) Limited to therapy resistant hypertension or not;
 e)  Plasma potassium level at inclusion (normokalemia or hypokalemia (serum 
potassium ≤3.5 mmol/L));
 f)  Medication regimen (medication adjusted according to the Endocrine Society 
guideline, medication adjusted otherwise, only mineralocorticoid receptor 
antagonists discontinued or medication unchanged);13
 g)  Potassium level at confirmation testing (corrected hypokalemia or normokalemia);
 h)  Type of screening test (ARR-based test, no screening test, other screening 
test);
 i)  Number of screening tests (one test or multiple tests);
 j) Patient position during screening tests (supine or not supine);
 k)  Cut-off levels used for screening tests (unrestrictive or restrictive). We included 
only studies using ARR-based tests. Unrestrictive was arbitrarily defined as 
an ARR cut-off value of 20-60 (aldosterone in ng/dL and renin in ng/mL/h); 
restrictive was defined as an ARR cut-off level of more than 60 or an ARR 
cut-off level of 20-60 with a plasma aldosterone level of more than 15 ng/dL and/
or a suppressed renin level.
 l)  Percentage of patients with positive screening who underwent a confirmation 
test (100% or ≥80% or 50-80%);
 m)  Type of confirmation test (IV SLT, oral SLT, captopril suppression test, fludro-
cortisone suppression test13);
 n)  Cut-off levels used for the IV SLT confirmation test (unrestrictive or restrictive). 
Unrestrictive was defined if the used cut-off level of plasma aldosterone after 
saline was at least 8 ng/dL, and restrictive if that cut-off level was lower than 
8 ng/dL. The number of studies concerning other confirmation tests were too 
low for analysis of the effects of different cut-off levels.
We explored the association of each of these factors with the estimate of the 
prevalence of PA individually in a univariate analysis. To correct for correlations 
between factors among studies, we built a model with the set of explanatory factors 
that remained significant in a multivariable model. We set the entry level of potentially 
valid predictors for the model at p=0.10. Because of the relatively low number of 
studies in primary care, we could only develop a model for referral centers.
 Because gender is not considered a factor in the diagnosis of PA and studies 
were unselective with respect to gender, we did not take gender into account in the 
statistical analysis. 
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 33
33
Systematic review of prevalence of primary aldosteronism
Association between predictive factors and the prevalence estimates of PA was 
reported as odds ratios (OR) and their 95% confidence intervals (CI). Prevalence of 
PA as predicted by the model was compared with the observed prevalence in the 
articles. 
statistical analysis
We used the statistical package Meta 4.1-0 in the program R version 3.1.3 
(R Foundation for Statistical Computing) to build forest plots and to compute the 
random effect pooled proportions. Package Meta 4.1-0 is specialized to perform 
meta-analyses. We also used the program SAS, version 9.2 (SAS Institute Incorporated), 
to perform a random effect logistic regression analysis using Procedure Glimmix 
(Proc Glimmix). In this model, the prevalence of PA is predicted by six explanatory 
variables. We used study as subject in the analysis, which means that the linear 
predictor contains an intercept term that randomly varies the level of the study. 
RESULTS
search results anD stuDy selection
The literature search in PubMed, EMBASE, Web of Science, and the Cochrane 
Library provided 2614 articles, of which 1679 remained after removal of duplicate 
entries. After review of title and abstract, we excluded 1586 papers (Figure 1), with 
93 potentially relevant articles remaining. By reference checking, four more articles 
were found, of which one was also included. After full-text reading of all provisionally 
included articles, we excluded 60 articles (Supplementary Table 1). The main 
reason for exclusion was the lack of a confirmation test to verify the diagnosis of PA 
(31 studies). Two articles reported on more than one study, resulting in 39 studies (patient 
cohorts) derived from 36 articles. Overall concordance on (de)selection of studies 
between the two raters was high: interrater agreement was 95%, Cohen’s kappa was 
0.89 (0.79 - 0.99).
prevalence of primary alDosteronism in primary care
Of the 39 studies included, nine were performed within a primary care setting (Table 1; 
Supplementary Table 2). The number of patients included ranged from 52 to 3000 
(median 347), with a total of 5896. PA prevalences ranged from 3.2% to 12.7%.
prevalence of primary alDosteronism in referral centers
Thirty studies were conducted in hypertension referral centers, providing data for 
36614 patients (Table 1; Supplementary Table 2).1,20-56 The number of included 
patients varied from 50 to 7343 (median 322.5). PA prevalence ranged from 1.0% 
to 29.8%.
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Figure 1  Flow diagram of studies considered for systematic review
*The 36 articles contain 39 studies (=patient cohorts). Mulatero20 and Rossi21 report five and three cohorts, 
respectively, of which four and one, respectively, were included. The reason for exclusion of the cohorts 
are explained in Supplementary Table 1. As a result 36 (included articles ) + 60 (excluded articles) = 94. 
GRA, glucocorticoid remediable aldosteronism. PA, primary aldosteronism.
Excluded based on title and abstract: 1586  
     Study did not include humans: 34  
     Study did not include adults: 44  
     Study not on primary aldosteronism: 
 Adrenal surgery: 92  
 Aldosterone metabolism: 60  
 Bartter and/or Gitelman syndrome: 41  
 Hypertension, therapy resistant hypertension, heart failure: 259 
            Incidentaloma : 60  
 Other: 228  
     Study on primary aldosteronism, but not prevalence:
            Case reports: 66  
            Clinical aspects: 291  
            GRA and familial PA: 31  
            Guidelines: 3  
            Letters and editorials: 65  
            Histopathology and pathophysiology: 47  
            Meeting abstract (and no article available): 64  
            Reviews and guidelines: 201  
Checking references of remaining articles (n=93) and reviews 
(n=201): 4 new articles, of which 1 included.  
     Excluded:  
            Letters and editorials: 2  
            Clinical aspects: 1  
Remaining  articles: 93 
Pre-included articles: 94   
Excluded articles based on full text: 60 (=61 patient cohorts)  
     No confirmation test in >50% of patients: 30 (31 patient cohorts)  
     Diagnosis of PA based on CT / response to spironolactone: 3  
     Prevalence of PA in a subgroup of patients:  
            Hypertensive emergency: 1  
            Diabetes: 4  
            Normotensive patients: 1  
            Patients suspected to have PA: 2  
            Patient with atrial fibrillation: 1  
            Patients with known adrenal mass: 1  
     Study methods unclear: 8  
     Study not on prevalence of PA: 3  
     Double reporting of same patients in different studies: 5  
     Duplicates: 1   
Full text  evaluation  
Included articles: 36* 
(=39 patient cohorts) 
Abstracts screened 
Articles from PubMed, 
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Figure 2  Forest plot for the prevalence of primary aldosteronism in primary care
Figure 3  Forest plot for the prevalence of primary aldosteronism in referral centres
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Differences across stuDies in the reporteD prevalence of primary 
alDosteronism
Forest plots show the weighted mean and the confidence intervals for the prevalence 
of PA (Figure 2, and Figure 3; Supplementary Figure 1). Heterogeneity (I2) was large: 
in primary care, I2 = 57.6% (0% to 78%); in referral centers, I2 = 97.1% (96.7% to 97.5%). 
Therefore, we used meta-regression analysis to explore possible sources of hetero -
geneity (see page 40).
prevalence of hypokalemia in patients with primary alDosteronism 
Twenty-eight of the 39 studies reported the number of PA patients with hypokalemia. 
In primary care studies, hypokalemia was present in 0% to 37.5% of the patients with 
confirmed PA (n=6). In referral centers, hypokalemia ranged from 0% to 67% among 
patients with confirmed PA (n=22). Five studies (two primary care studies,26,28 
and three studies from referral centers32,34,38) restricted inclusion to normokalemic 
patients (Supplementary Table 3). 
prevalence of primary alDosteronism in patients with varying severity  
of hypertension
Seven studies provided data on patients with resistant hypertension and five studies 
reported on the relation between prevalence of PA and severity of hypertension. 
The weighted man PA prevalence was 5.5%, 4.2%, 10.2%, and 16.4% for high-normal 
blood pressure, stage 1, stage 2, and stage 3 hypertension, respectively.20,24,43,48,50
Differences in Diagnostic methoDs
The methods and cut-offs used for screening and confirmation tests varied widely 
between the included studies. The ARR with or without the use of an absolute level 
of plasma aldosterone, with varying cut-off values and restrictions, was used for 
screening in 29 of 39 studies. In four studies, no screening test was performed and 
in six, other screening tests were used. For confirmation of PA were used: IV SLT 
(n=20), oral SLT (n=7), captopril suppression test (n=5), fludrocortisone suppression 
test (n=4), or a combination of two confirmation tests (n=3).
 Medication regimens during the diagnostic process were reported in most 
studies and varied from unaltered regimen to complete cessation of all hypertensive 
medication. In 15 studies, medication regimen was based on the Endocrine Society 
guideline.13
quality assessment
The results of the quality assessment using the MORE protocol showed that all 
studies had minor flaws including assessment of sampling bias and type of outcome. 
More importantly, five studies were classified as having a major flaw because of a 
patient exclusion rate of more than 10%. For individual quality assessments, see 
Supplementary Table 4, and Supplementary Figure 2. Some descriptive items or 
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items concerning internal and external validity were neither reported nor addressed 
in many studies such as role of funding, precision and reliability of estimates, and 
consideration of sampling bias.
meta-regression analysis
In primary care, univariate analysis showed a significant association between PA 
prevalence and five factors: year of publication (p<0.001), region (p<0.001), study 
objective (p<0.001), medication regimen (p=0.04), and type of screening test (p<0.001) 
(Supplementary Table 5). The highest prevalence estimates were found when the 
publication year was before 2000, when the study was performed in Australia, when 
the primary study objective was other than to assess the prevalence of PA, when 
medication regimen was unchanged, and when no screening test was performed.
 Univariate analysis in referral centers showed a significant association between 
PA prevalence and five variables: year of publication (p=0.04), study objective 
(p=0.02), method of patient selection (p<0.001), type of hypertension (p=0.01), and 
type of screening test (p<0.001). The highest prevalence estimates were found when 
the year of publication was after 2000, when the primary study objective was other 
than to assess the prevalence of PA, when patient inclusion was consecutive, when 
the study population comprised patients with therapy resistant hypertension, and 
when no screening test was performed.
multivariate analysis
By combining the possible explanatory variables in a single model (only possible for 
referral centers), we found a set of six variables to independently affect the prevalence 
of PA: year of publication (p<0.001), region (p=0.002), study design (p=0.004), 
study objective (p=0.044), method of patient selection (p<0.001), and type of 
screening test (p=0.02) (Table 2). This model for referral centers showed the highest 
prevalence in studies that were performed after 2000, when the study was performed 
in Australia, when the study was retrospective, when the study objective was to assess 
the prevalence of secondary hypertension, when patient inclusion was consecutive, 
and in studies in which no screening test was performed. 
 To clarify the prediction of the random effect logistic regression model, we 
provide a table with examples how variation of the six explanatory variables affects 
the predicted prevalence (Supplementary Table 6).
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DISCUSSION
In this systematically performed review and meta-regression analysis we confirm the 
previously reported wide variations in prevalences, both in studies performed in the 
primary care setting (3.2% to 12.7%) and in those performed in referral centers (1.0% 
to 29.8%). Although previous reviews and meta-analysis studies57-59 reported mean 
prevalences, our study shows that it is pointless to provide point estimates in the 
absence of reporting contextual key factors. We established several factors that, at 
least partially, are responsible for the gross heterogeneity among studies on 
prevalence of primary aldosteronism. 
 In our analysis studies in referral centers published after 2000 showed a nearly 
9-fold higher odds for the prevalence than studies before 2000, and this was 
independent from other factors. This might be explained by increasing awareness of 
the presence of primary aldosteronism over time.
 The very first studies that investigated the prevalence of PA were performed in 
centers in Australia in self-selected patients or on the basis of retrospective data.22,32 
Table 2  Solutions for the fixed effects of the random effect logistic regression 
model in referral centers
Variable Description OR OR (95% CI)
Overall  
P-value
Publication year 2000-current vs 1990-2000 9.29 (3.17-27.16) <0.001
Region USA vs Europe 4.88 (2.07-11.57) 0.002
Latin America vs Europe 0.53 (0.28-1.01)
Asia vs Europe 1.50 (0.71-3.17)
Australia vs Europe 5.57 (1.94-15.99)
Study design Retrospective vs Prospective 2.31 (1.39-3.84) 0.004
Study objective Prevalence PA vs Other 1.71 (0.81-3.62) 0.044
Prevalence secondary HT vs Other 2.83 (1.12-7.17)





Consecutive vs Convenience 4.95 (1.82-13.48) <0.001
Self selection vs Convenience 3.40 (0.90-12.89)
Consecutive vs Self selection 1.46 (0.88-2.42)
Screening test No screening vs Other 3.25 (1.51-7.01) 0.02
ARR vs Other 0.75 (0.39-1.43)
No screening vs ARR 4.36 (1.52-12.54)
The model estimates the prevalence of PA as a function of the six above mentioned variables. The resulting 
ORs (according to the model) represent the ratios of the odds for PA of two groups. ARR, aldosterone-to-renin 
ratio. HT, hypertension. OR, odds ratio. PA, primary aldosteronism.
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This might partially explain why studies from Australia have a more than 5.5-fold 
higher odds than those that were carried out in Europe. An alternative explanation is 
that the prevalence of PA is indeed higher in Australia. Studies performed in the 
Unites States also showed nearly 5-fold higher odds. Whether this is due to the same 
reasons as may apply to Australian studies cannot be ascertained. 
 It is plausible that prospective studies are more appropriate to estimate 
prevalences. Our finding that retrospective studies report higher prevalences than 
prospective ones suggest that the current “epidemic” of PA is partly explained by 
reliance on retrospective studies.60
 It is difficult to explain why studies that had the objective to assess the prevalence 
of secondary hypertension showed a nearly 3-fold higher prevalence of PA than 
studies that had other objectives, including studies that had the objective to assess 
specifically the prevalence of PA. However, the latter category was small and this may 
be a fortuitous finding.
 The higher yield in the diagnosis of PA when testing consecutive patients than 
using other methods of patient selection is to be expected since less patients will 
be missed. 
 As a screening test, most studies (n=20) used the ARR. The reliability of the ARR is 
disputed because of its susceptibility to disturbances by external factors, variable 
cut-off levels and its mediocre sensitivity and specificity.26,54,61,62 This might explain 
why studies that did not use any screening test showed the highest prevalences. One 
can speculate that when using the ARR, some patients may be missed and this 
would argue for performing directly a confirmation test when attempting to detect PA.
variation in Diagnostic strategies
The test conditions, medication regimens, and cut-offs used for screening and 
confirmation tests varied largely among the included studies. It is generally accepted 
that patients with an elevated ARR should undergo further confirmatory testing to 
establish the diagnosis of PA.13 For this reason, we chose to include only those 
studies that used some kind of confirmatory testing.
 Because use of medication can affect the laboratory results of plasma aldosterone, 
renin, and ARR, the Endocrine Society guideline advocates adjustment of medication 
so that plasma aldosterone and renin are minimally affected. In contrast, several 
studies have suggested that screening and confirmation testing is still reliable when 
patients continue their antihypertensive medication during testing.63,64 Our meta-
regression model confirms that adjustment of medication regimen has no effect on the 
prevalence of PA. This challenges the Endocrine Society guideline’s recommendation.13
 Hypokalemia is often viewed as a clue to screen for PA although only about 
one-third of the patients with PA presented with hypokalemia. The wide range of 
hypokalemia in the studies underlines that hypokalemia is not a prerequisite for 
further testing for PA. Moreover, (mild) hypokalemia may also reflect diuretic treatment 
of essential hypertension.
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importance of proper prevalence estimates for case iDentification
As recently noted by Funder, considerably less than 1% of the hypertensive patients 
are screened for PA each year, not to mention diagnosed and properly treated.65 
While the prevalence of PA remains under debate, undiagnosed and untreated PA 
has important medical implications, such as the detrimental effect on the cardio-
vascular and renal systems due to aldosterone.1-4,66-74 Proper treatment of PA, both 
surgically or with medication, appears to reduce the risk of both cardiovascular and 
renal complications.71,75 It is therefore self-evident that identifying PA in hypertensive 
patients has important benefits. To design a strategy for identification of PA or to 
allocate health care resources to PA, it is important to know the prevalence of PA 
among hypertensive patients. Although our study shows that this knowledge is 
currently insufficient, it also provides us with clues as to what factors cause under- or 
overestimation of the prevalence of PA. Based on that, we would urge to perform a 
multicontinental prospective study in which consecutive hypertensive patients are 
screened for PA by a standardized confirmation test. 
limitations
We performed separate analyses for primary care and referral centers because the 
variables that determine the prevalence evidently differ between primary care and 
referral centers. Unfortunately, the model built with the set of explanatory factors 
derived from the univariate analysis, could only be used for the studies performed 
in the referral centers because of the relatively low number of studies in the primary 
care setting. A final limitation is that we did not exclude any articles by quality 
assessment because the validated protocol (MORE) we used for our quality 
assessment is not developed to “weight” or to exclude studies. However, studies 
with a “major flaw” according to the MORE protocol, did not show higher or lower 
prevalences than studies without “major flaws” (not shown).
CONCLUSIONS
This study of 5896 patients in primary care and 36614 patients in referral centers 
demonstrates that the wide range in reported prevalences of primary aldosteronism is 
associated with year of publication, study region, study objective, modes of data collection, 
patient selection, and use of screening test. The heterogeneity of studies precludes a 
reliable estimate of the prevalence of PA. Because of the significant impact of a diagnosis 
of primary aldosteronism on health care resources and the necessary facilities, our 
findings urge for better designed prospective prevalence studies. Prerequisites for such a 
study are international or even intercontinental agreement on a uniform screening and a 
confirmation test. Next, a survey by screening and, if screening is positive, a confirmation 
test for PA in all hypertensive patients should be performed, in both primary care and 
referral centers, with all untested patients being accounted for.
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supplementary file 1. search
PubMed
Search: ((((((“Hyperaldosteronism” OR hyperaldosteronism[Title/Abstract]) OR 
aldosteronism[Title/Abstract]) OR Conn syndrome[Title/Abstract]) OR Conns 
syndrome[Title/Abstract]) OR Conn’s syndrome[Title/Abstract]) OR 
(((hyperaldosteronism[Other Term] OR aldosteronism[Other Term]) OR Conn 
syndrome[Other Term]) OR Conn’s syndrome[Other Term])) AND (((((((“Prevalence” OR 
prevalence[Title/Abstract]) OR prevalences[Title/Abstract]) OR occurrence[Title/
Abstract]) OR occurrences[Title/Abstract]) OR ((“Incidence” OR incidence[Title/
Abstract]) OR incidences[Title/Abstract])) OR ((((“Epidemiology” OR 
“epidemiology”[Subheading]) OR epidemiology[Title/Abstract]) OR 
epidemiologic[Title/Abstract]) OR epidemiological[Title/Abstract])) OR 
((((((((prevalence[Other Term] OR prevalences[Other Term]) OR incidence[Other Term]) 
OR incidences[Other Term]) OR occurrence[Other Term]) OR occurrences[Other 
Term]) OR epidemiology[Other Term]) OR epidemiologic[Other Term]) OR 
epidemiological[Other Term])) AND (“1990/01/01”[PDAT] : “2015/01/31”[PDAT]) 
Filters: Dutch; English; French; German; Spanish
Items found: 624
EMBASE
1.  exp hyperaldosteronism/
2.  (hyperaldosteronism or aldosteronism).ti,ab.
3.  (Conn syndrome or Conns syndrome or Conn’s syndrome).ti,ab.
4.  1 or 2 or 3
5. exp prevalence/
6. exp incidence/
7.  (incidence or incidences).ti,ab.
8.  6 or 7
9.  exp epidemiology/
10. (epidemiology or epidemiologic or epidemiological).ti,ab.
11. 9 or 10
12. (prevalence or prevalences or occurrence or occurrences).ti,ab.
13. 5 or 12
14. 8 or 11 or 13
15. 4 and 14
16. limit 15 to ((dutch or english or french or german or spanish) and yr=”1990 -Current”)
17. limit 16 to ((dutch or english or french or german or spanish) and yr=”1990 -Current”)
Items found: 1239
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#1  TOPIC: (hyperaldosteronism) OR TOPIC: (aldosteronism) OR TOPIC: 4086
 (Conn syndrome) OR TOPIC: (Conns syndrome) OR TOPIC: (Conn’s syndrome)
 Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=1990-2015
#2  TOPIC: (prevalence) OR TOPIC: (prevalences) OR TOPIC: (incidence) 1355259
 OR TOPIC: (incidences) OR TOPIC: (occurrence) OR TOPIC: (occurrences)
 OR TOPIC: (epidemiology) OR TOPIC: (epidemiologic)OR TOPIC: 
(epidemiological)
 Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=1990-2015
#3 #2 AND #1 743
 Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=1990-2015
#4 (#2 AND #1) AND LANGUAGE: (English OR Dutch OR French OR 743
 German OR Spanish)




#1 MeSH descriptor: [Hyperaldosteronism] explode all trees 50
#2 MeSH descriptor: [Prevalence] explode all trees 3937
#3 MeSH descriptor: [Incidence] explode all trees 7910
#4 MeSH descriptor: [Epidemiology] explode all trees 43
#5  hyperaldosteronism:ti,ab,kw or aldosteronism:ti,ab,kw or Conn syndrome:ti,ab,kw 100
 or Conns syndrome:ti,ab,kw or Conn’s syndrome:ti,ab,kw
 (Word variations have been searched)
#6 prevalence:ti,ab,kw or prevalences:ti,ab,kw or occurence:ti,ab,kw or 14443
 occurences:ti,ab,kw (Word variations have been searched)
#7 incidence:ti,ab,kw or incidences:ti,ab,kw (Word variations have been searched) 54614
#8 epidemiology:ti,ab,kw or epidemiologic:ti,ab,kw or epidemiological:ti,ab,kw  10554
 (Word variations have been searched)
#9 #2 or #3 or #4 11464
#10 #6 or #7 or #8 75212
#11 #9 or #10 75221
#12 #1 or #5  102
#13 #12 and #11 8
Publication Year from 1990 to 2015
Items found: 8
The final literature search was performed on 17th February 2015 (all databases, by SK).
Total items found: 2614
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Supplementary Table 1  Excluded studies based on full text reading
First author Year Country Setting Remark
No confirmation test in >50% of patients
Cortes1 2000 Chile RC
Daimon2 2014 Japan PC
Denolle3 2000 France RC
Ducher4 2012 France RC
Eide5 2004 Norway RC
Gallay6 2001 USA RC
Gallego7 2007 Spain RC
Garcia8 2011 USA NR
Gombet9 2007 France RC
Gonzaga10 2010 USA RC
Gregori11 2014 Italy RC
Hannemann12 2012 Germany NR
Ito13 2011 Japan PC
Jefic14 2006 USA RC
Lim15 1999 UK PC
Mosso16 1999 Chile PC
Mysliwiec17 2010 Poland RC
Olivieri18 2004 Italy PC
Pardes19 2010 Argentina RC
Rayner20 2000 South Africa RC
Rayner21 2001 South Africa PC
Rosenbaum22 2012 France PC
Rossi23 1998 Italy RC Article comprising three studies: 
2 studies without >50% 
confirmation test were excluded 
from analysis, 1 study was 
included.
Sabio24 2005 Spain RC
Schmiemann25 2012 Germany PC
Schwartz26 2002 USA PC
Sharma27 1994 India RC
Takayanagi28 2000 Japan RC
Volpe29 2012 Sweden PC
Williams30 2006 UK RC
Diagnosis of PA based on computed tomography or reaction to spironolactone
Hood31 2005 UK PC
Niizuma32 2008 Japan RC
Nogueira33 2008 Brasil RC
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Supplementary Table 1  -Continued
First author Year Country Setting Remark
Prevalence of PA in a subgroup of patients
Hypertensive emergency
Börgel34 2010 Germany RC
Diabetes
Li35 2013 China NR
Mukherjee36 2010 Singapore RC
Murase37 2013 Japan RC
Umpierrez38 2007 USA NR
Normotensive patients
Markou39 2013 Greece RC
Patients suspected to have PA
Solar40 2012 Czech rep. RC
Ye41 2012 China RC
Patients with atrial fibrillation
Rossi42 2013 Italy RC
Patients with known adrenal mass
Godula43 2013 Portugal RC
Study methods unclear
Benchetrit44 2002 Israel NR
Gouli45 2011 Greece RC
Mulatero46 2004 Italy RC Article comprising five studies:  
1 study was excluded (Australia)
Mysliwiec47 2012 Poland RC
Papanastasiou48 2014 Greece RC Is the same as Gouli (2011)
Sy49 2012 China PC
Trifanescu50 2013 Romania RC  
Wu51 2014 Taiwan RC
Study not on prevalence of PA
Adlin52 2013 USA NR Study on aldosterone
Kao53 2013 Taiwan NR Clinical aspects
Sakthiswary54 2012 Malasia NR Study on aldosterone
Double reporting of same patients in different studies
Calhoun55 2002 USA NR = Nishizaka 2005
Fardella56 2000 Chile NR = Mosso 2003
Nishikawa57 2000 Japan NR = Omura 2004
Rossi58 2007 Italy NR = Rossi 2006
Rossi59 2010 Italy NR = Rossi 2006
Duplicates
Gordon60 1993 Australia RC Summary of two previously 
reported studies
NR, not reported. PA, primary aldosteronism. PC, primary care. RC, referral center. rep, republic.
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Australia Prospc NR 52 HT
65% male
Age: 56y (7y)d















using MRA were 
excluded)



























Japan Prosp 1995-1999 1020 HT newly diagnosedc
55% male
Age: 52yc
No medication (unless 
budralazin)










USA Prospc 2000-2002 118 HT normoK+
62% male
Age: 29-63yf
All withdrawn 2 weeks No screening NAp Oral SLT
Urinary aldo ≥12 μg/24h 





Sweden Cross NR 200 HT 
% male NR
Age: ≤75yf
Withdrawn 2 weeks, 
CCB allowed










USA Crossc 1996-2005c 347 HT normoK+
54% male
Age: 49y (7y)d




Oral SLT (in 26/26c)





Italy Prosp 1999-2002 3000 HT 
48% male
Age: 51y (6y)











Sweden Cross NR 200 HT newly diagnosed
43% male
Age: 24-75yf





PAC >225 pmol/L (day 4) 
or PAC >305 nmol/L (day 3)
11
 (5.5%)





















Australia Retroc 1992-1993c 199 HT normoK+
50% malec
Age: 54y (16y)








Germany Prosp NR 3900 HT
% male NAc
Age: NAc
Standard Urinary aldosterone 
>50 nmol/24h or 
18-OH-B >20 
nmol/24h






Australia Prosp 1988-1992 74 HT normoK+
% male NAc
Age: NAc
Withdrawn 3 days ARR >2000 pmol/L 
per pmol A1/mL/h 
(PRC)c
ARR >525 pmol/L per 
pmol A1/mL/h (PRA) c
6 (8.1%)
4 (5.4%)
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% male NAc
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Standard Urinary aldosterone 
>50 nmol/24h or 
18-OH-B >20 
nmol/24h
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% male NAc
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(60%), ‘no MRA or 
α-blocker allowed’










Italy Prosp 1997-1999 1046 HT
51% male
Age: 50y (12y)










Germany Prosp 1997-1999 146 HT
% male NAc
Age: NAc










Spain Prospc 2000-2002c 50 RHT normoK+
52% male
Age: 52y (9y)
Withdrawn 7-10 days No screening NAp IV SLT (in 44/50; 
6 excluded due to white 
coat HT)
 <50% suppression of 






Australia Prospc 2000-2002 300 HT
% male NAc
Age: NAc
BB withdrawn 2 
weeks, MRA 4 weeks, 
ARB or ACE-I allowed










Czech Republic Retroc 1997-2001 402 HT
43% male
Age: 51y (12y)














≥6 weeks, rest 
unchanged
Urinary aldo >12 
μg/24h and PRA <1.0 
ng/mL/h
NR Oral SLT (NAc)
Urinary aldo >12 μg/24h 
and PRA <1.0 ng/mL/h 






Italy Retro 1994-2002 7343 HT >160/100mm Hg
% male NAc
Age: NAc
Standardc ARR >40 and PAC 
>15 ng/dL








ACE-I and ARB have 
not been withdrawn 
when the ratio was 
positive under 
treatmentc
ARR>20 and PAC 
>15 ng/dL





Singapore Retro 1995-2001 3850 HT 
% male NAc
Age: NAc
NAc ARR >20 and PAC 
>15 ng/dL




Chile Retro 2000-2002 914 HT
% male NAc
Age: NAc
Interfering drugs such 
as diuretics, ACE-I, 
ARB and BB were 
stopped for ≥15 daysc
ARR >25 NAc FST (in allc)
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≥6 weeks, rest 
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μg/24h and PRA <1.0 
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treatmentc
ARR>20 and PAC 
>15 ng/dL





Singapore Retro 1995-2001 3850 HT 
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Age: NAc
NAc ARR >20 and PAC 
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France Prospc 1997-1999 5438c HT 
% male NAc
Age: NAc
Standard ARR >23 and PAC 
>178 pg/mL and PRA 
≤5 pg/mL and urinary 
aldosterone >23 
μg/24hc
NAc Captopril test (in allc)
<70% suppression of 














58 Oral SLT (in 58/58l)
Urinary aldo >12μg/24h 
and PRA <1.0 ng/mL/h 






Italy Prosp 2001-2004 1125 HT newly diagnosed
56% male
Age: 46y (12y)
Standard ARR ≥40 and/or
post-captopril ARR 




ARR ≥40 plus post-captopril 







Greece Retro 1988-2008c 1616 RHT
51% male
Age: 56y (13y)
Standard ARR >65.16 pmol/L 




IV SLT and FST (in 
338/338c,i)
IV SLT: SAC ≥222 pmol/L





Spain Prosp 2005-2006 183 HT 
61% male
Age: 58y (13y)
Unchanged ARR >30 and PAC 
>20 ng/dL










Use of MRA and 










Italy Retroc 2007-2008 325 HT newly diagnosed
61% malec
Age: 51y (10yc)
Standard ARR >40 and PAC 
>15 ng/dL with 
suppressed PRA






Bulgaria Prospc 2005-2008c 376n HT 
34% malec
Age:48y (14y)c
MRA withdrawn 45 
days, rest stopped 
7-10days. CCB or 
α-blocker allowed
ARR >750 pmol/L per 
ng/mL/h and 
PAC >416 pmol/L





















Argentina Prospc 2006-2009 123 HT
39% male
Age:43y (11y)








Sweden Prosp 2000-2003c 122p HT
61% malec
Age: 56y (12y)c




Oral SLT (in 25/28c)





China Prospc 2007-2010 313 HT
46% male
Age: 46y (13yc)
Standard ARR >25 72
(23%)
Captopril test (in 72/72) ARR 
>13 ng/dL
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Argentina Prospc 2006-2009 123 HT
39% male
Age:43y (11y)








Sweden Prosp 2000-2003c 122p HT
61% malec
Age: 56y (12y)c




Oral SLT (in 25/28c)





China Prospc 2007-2010 313 HT
46% male
Age: 46y (13yc)
Standard ARR >25 72
(23%)
Captopril test (in 72/72) ARR 
>13 ng/dL
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Year


























The Netherlands Prosp 2006-2011c 178 RHT
53 % male
Age: 49y (9y)
MRA and BB 
withdrawn 4 weeks: 
rest unchanged
Screening not used for 
prevalence analysis




Total number 36614 2375
SI conversion factors: to convert aldosterone (ng/dL) to pmol/L, multiply values by 27.74; to convert renin 
(pg/mL) to pmol/L, multiply values by 0.0237.
To preserve authenticity of the original article, we did not convert the cut-off values to conventional units.
A1, Angiotensin 1. ACE-I, angiotensin-converting-enzyme inhibitor(s). aldo, aldosterone. ARB, angiotensin 
receptor blocker. ARR, aldosterone-to-renin ratio. BB, beta blocker. CCB, calcium channel blocker. Cross, 
cross-sectional. FST, fludrocortisone suppression test. HT, hypertension (defined as blood pressure >140/90 
with or without medication. IV SLT, intravenous sodium loading test. LDH, logistic discriminant function. 
MRA, mineralocorticoid receptor antagonist. n, number of patients. NA, non available (data untraceble due 
to elapsed time). NAp, not applicable. normoK+, normokalemia. NR, not reported. Oral SLT, oral sodium 
loading test. PAC, plasma aldosterone concentration. PC, primary care. PRA, plasma renin activity. Prosp, 
prospective. RC, referral center. Retro, retrospective. RHT, resistant hypertension. SAC, serum aldosterone 
concentration. y, year(s).
a Standard (=according to the Endocrine Society guideline13): MRAs stopped for at least 4 weeks, all other 
anti-hypertensive drugs stopped for at least 2 weeks, except for calciumantagonists and α-blockers.
b ARR calculated with PAC in ng/dL and PRA in ng/mL/h, unless stated otherwise.
c Data received from author.
d Standard error of the mean converted to standard deviation.
e Study design: partly retrospective. 305 patients from a previous study were included,55 the other patients 
were prospectively included.
f Mean age and standard deviation not reported.
g The study population consisted of poorly controlled hypertensive patients.
h In this analysis only the hypertensive study population is included.
i Hypertensive patients with elevated ARR performed an intravenous sodium loading test as well as a 
fludrocortisone suppression test.
j In the original article a prevalence of 43/465 is reported. However, 2/465 have not been identified by 
screening and confirmation testing: one patient with a negative FST had a right adrenal adenoma, which 
was detected on CT scanning (histological examination after adrenalectomy confirmed a Conn’s adenoma), 
and one patient had already been diagnosed with PA. In this review, only patients who were assessed by 
our pre-defined inclusion criteria were included in the analysis (prevalence is 41/464 = 8.8%). However, 
usually when cited, a prevalence of 9.2% is reported.56
k Due to missing number of included patients, the study from Australia (Brisbane) is excluded.
l If urinary aldosterone was elevated (>12 μg/24h), but urinary sodium was low (<200 mEq/24h), the 24h 
urinary assessments were repeated after 3 days of dietary salt supplementation. However, if urinary 
aldosterone and urinary sodium exceeds cutoff values during normal diet (routine high sodium diet), 
additional sodium loading was omitted (because of risks and little additional value). So, the confirmatory 
test is the 24h urine under high sodium diet.
m Patients who were analyzed because of an incidentaloma were excluded.
n In this number incidentalomes are excluded (n=376+96=472).
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The Netherlands Prosp 2006-2011c 178 RHT
53 % male
Age: 49y (9y)
MRA and BB 
withdrawn 4 weeks: 
rest unchanged
Screening not used for 
prevalence analysis




Total number 36614 2375
o Patients studied in primary care were excluded due to <50% confirmation test (6/18 = 33%, data confirmed 
by author).
p Information from author by email: the original paper states that the number of patients is 123.
q Including dropouts in analysis.
r All of the patients with elevated ARR underwent the captopril test, and two of the patients underwent an 
intravenous sodium loading test because of the confused results of the captopril test (data received from 
author).
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Supplementary Table 3  Studies in patients with primary aldosteronism reporting 
the number of patients with hypokalemia
PRIMARY CARE
Author (year) Number of  
PA patients assessed
Number of  
patients with hypokalemia (%)
Gordon61 (1993) 6 0 (0%)
Loh62 (2000) 16 6 (37.5%)
Mosso63 (2003) 37 1 (2.7%)
Omura64 (2004) 61 15 (24.6%)
Fogari65 (2007) 177 44 (24.8%)
Westerdahl66 (2011) 11 3 (27.3%)†
Total 308 69
REFERRAL CENTERS
Anderson67 (1994) 62 19 (30%)
Lim68 (2000) 41 2 (4.4%)
Rossi69 (2002) 66 26 (39.4%)
Stowasser70 (2003) 54 7 (13%)














Milliez72 (2005) 124 121 (98%)
Nishizaka73 (2005) 58 23 (39.7%)
Rossi74 (2006) 126 12 (9.6%)
Douma75 (2008) 182 83 (45.6%)
Ribeiro76 (2009) 1 0 (0%)
Di Murro77 (2010) 43 18 (42%)*
Matrozova78 (2010) 38 21 (55.3%)‡
Pedrosa79 (2011) 7 0 (0%)*
Rios80 (2011) 8 4 (50%)
Sigurjonsdottir81 (2012) 17 5 (29%)*
Yin82 (2012) 39 26*(67%)
Sang & Jiang83 (2013) 118 62 (52.5%)
Jansen84 (2014) 27 13 (48.1)
Total 2038 719
*Data obtained from the authors. †Estimated from box plot. ‡Including 12 patients who were diagnosed with 
PA after analysis for incidentaloma. Five studies included only patients with normokalemia.85-89 Six studies 
did not report the number of patients who had hypokalemia.23, 90-94 PA, primary aldosteronism.
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Supplementary Table 5  Univariate analysis
Variable Setting Comparison OR  (95% CI)
Overall 
P-value
Publication year PC 2000-current vs 1990-2000 0.49  (0.38 - 0.64) <0.001
RC 2000-current vs 1990-2000 2.18  (1.04 - 4.58) 0.04
Region PC USA vs Europe 0.99  (0.22 - 4.44) <0.001
PC Latin America vs Europe 0.93  (0.68 - 1.27)
PC Asia vs Europe 0.81  (0.53 - 1.22)
PC Australia vs Europe 1.87  (1.38 - 2.56)
RC USA vs Europe 1.32  (0.33 - 5.29) 0.52
RC Latin America vs Europe 0.56  (0.28 - 1.15)
RC Asia vs Europe 0.89  (0.48 - 1.67)
RC Australia vs Europe 1.08  (0.41 - 2.80)
Study design PC Retrospective vs Prospective NA NA
RC Retrospective vs Prospective 1.33  (0.80 - 2.22) 0.26
Study objective PC Prevalence PA vs Other 0.42  (0.34 - 0.52) <0.001
PC Prevalence secondary HT vs Other NA NA
PC Prevalence PA vs Prevalence 
secondary HT
0.96  (0.77 - 1.18)
RC Prevalence PA vs Other 0.88  (1.63 - 1.95) 0.02
RC Prevalence secondary HT vs Other 0.63  (0.33 - 1.18)
RC Prevalence PA vs Prevalence 
secondary HT
1.40  (1.07 - 1.82)
Patient selection 
method
PC Consecutive vs Convenience 0.73  (0.35 - 1.53) 0.35
PC Self selection vs Convenience NA
PC Consecutive vs Self selection NA
RC Consecutive vs Convenience 1.82  (0.86 - 3.85) <0.001
RC Self selection vs Convenience 0.46  (0.23 - 0.91)
RC Consecutive vs Self selection 3.95  (2.87 - 5.45)
Type of HT PC Therapy resistant HT vs HT NA NA
RC Therapy resistant HT vs HT 2.13  (1.19 - 3.83) 0.01
Patient selection 
on potassium
PC No selection vs Only normokalemic 
patients
0.98  (0.28 - 3.46) 0.97
RC No selection vs Only normokalemic 
patients
1.06  (0.47 - 2.39) 0.88
Patient selection 
on medication
PC Endocrine Society guideline vs 
Unchanged
0.43  (0.33 - 0.56) 0.04
PC Changed vs Unchanged 0.68  (0.42 - 1.12)
PC MRA stop vs Unchanged NA
PC Endocrine Society guideline vs 
Changed
0.63  (0.36 - 1.10)
PC Endocrine Society guideline vs  
MRA stop
1.17  (0.89 - 1.53]
PC Changed vs MRA stop 1.86  (1.13 - 3.05)
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RC Endocrine Society guideline vs 
Unchanged
1.40  (0.58 - 3.38) 0.58
RC Changed vs Unchanged 1.51  (0.57 - 4.04)
RC MRA stop vs Unchanged 2.33  (0.68 - 8.08)
RC Endocrine Society guideline vs 
Changed
0.93  (0.48 - 1.78)
RC Endocrine Society guideline vs  
MRA stop
0.60  (0.22 - 1.64)
RC Changed vs MRA stop 0.65  (0.22 - 1.93)
Potassium levels 
corrected
PC Hypokalemia corrected vs 
Normokalemia
0.98  (0.28 - 3.46) 0.97
RC Hypokalemia corrected vs 
Normokalemia
1.06  (0.47 - 2.39) 0.88
Screening test PC No screening vs Other 2.81  (1.97 - 4.02) <0.001
PC ARR vs Other 1.32  (0.89 - 1.95)
PC No screening vs ARR 2.14  (1.81 - 2.52)
RC No screening vs Other 1.88  (1.23 - 2.88) <0.001
RC ARR vs Other 0.79  (0.43 - 1.46)




PC One measurement vs Multiple 
measurements
0.85  (0.49 - 1.47) 0.49
RC One measurement vs Multiple 
measurements
0.75  (0.39 - 1.46) 0.38
Patient position 
during screening
PC Supine vs Not supine 0.81  (0.50 - 1.31) 0.32




PC All unrestrictive NA NA







PC 100% vs <80% 1.15  (0.39 - 3.40) 0.40
PC >80% vs <80% 0.84  (0.61 - 1.16)
PC 100% vs >80% 1.37  (0.47 - 3.96)
RC 100% vs <80% 1.88  (0.73 - 4.81) 0.24
RC >80% vs <80% 1.12  (0.34 - 3.62)
RC 100% vs >80% 1.68  (0.71 - 3.98)
Type of 
confirmation test
PC IV SLT vs Fludrocortisone 0.88  (0.69 - 1.11) 0.33
PC Oral SLT vs Fludrocortisone 1.09  (0.28 - 4.21)
PC Captopril vs Fludrocortisone 1.24  (0.86 - 1.76)
PC IV SLT vs Oral SLT 0.81  (0.20 - 3.18)
PC IV SLT vs Captopril 0.71  (0.46 - 1.09)
PC Oral SLT vs Captopril 0.88  (0.22 - 3.57)
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RC IV SLT vs Fludrocortisone 1.30  (0.53 - 3.23) 0.38
RC Oral SLT vs Fludrocortisone 2.08  (0.52 - 8.36)
RC Captopril vs Fludrocortisone 1.86  (0.72 - 4.79)
RC IV SLT vs Oral SLT 0.63  (0.20 - 1.96)
RC IV SLT vs Captopril 0.70  (0.41 - 1.18)
RC Oral SLT vs Captopril 1.12  (0.35 - 3.63)
Cut-off IV SLT PC Restrictive vs Unrestrictive NA NA
RC Restrictive vs Unrestrictive 0.85  (0.43 - 1.73) 0.64
ARR, aldosterone-to-renin ratio. IV SLT, intravenous sodium loading test. HT, hypertension. NA, not 
applicable. OR, odds ratio. Oral SLT, oral sodium loading test. PA, primary aldosteronism. PC, primary care. 
RC, referral center.
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Supplementary Figure 1  Bar plot for the prevalence of primary aldosteronism
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Supplementary Figure 2  Quality assessment of the 39 included studies using  
the MORE criteria
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Primary aldosteronism is the most frequent cause of secondary hypertension. 
Reported prevalences of primary aldosteronism vary considerably because of a large 
heterogeneity in study methodology. 
aim
To examine the proportion of patients with primary aldosteronism among patients 
with newly diagnosed, never treated hypertension. 
Design anD setting
A cross-sectional study set in primary care.
methoDs
General practitioners measured aldosterone and renin in adult patients with newly 
diagnosed, never treated hypertension. Patients with elevated aldosterone-to-renin 
ratio and increased plasma aldosterone concentration underwent a saline infusion 
test to confirm or exclude primary aldosteronism. The source population was 
meticulously assessed to detect possible selection bias.
results
Of 3748 patients with newly diagnosed hypertension, 343 patients were screened 
for primary aldosteronism. In 9 of 74 patients with an elevated aldosterone-to-renin 
ratio and increased plasma aldosterone concentration the diagnosis of primary 
aldosteronism was confirmed by a saline infusion test, resulting in a prevalence of 
2.6% (95% confidence interval 1.4 to 4.9). All patients with primary aldosteronism 
were normokalemic and 8 out of 9 patients had sustained blood pressure >150/100 
mmHg. Screened patients were younger (p<0.001) or showed higher blood pressure 
(p<0.001) than non-screened patients. 
conclusion
In this study a prevalence of primary aldosteronism of 2.6% in a primary care setting 
was established, which is lower than estimates reported from other primary care 
studies so far. This study supports the screening strategy as recommended by the 
Endocrine Society Clinical Practice Guideline. The low proportion of screened patients 
(9.2%), of the large cohort of eligible patients, reflects the difficulty of conducting 
prevalence studies in primary care clinical practice. 
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INTRODUCTION
Primary aldosteronism (PA) is the most frequent cause of secondary hypertension. 
Large variations of its prevalence have been reported, ranging from <1% to 30%.1-5 
This variance can be explained by the heterogeneity of studies owing to differences 
in patient selection, variability in diagnostic procedures, healthcare setting, and 
region of the world.6
 Three aspects determine the clinical relevance of a diagnosis of PA. First, PA 
carries a high cardiovascular complication rate, independently of the level of blood 
pressure.7-9 Second, PA requires specific treatment, depending on the underlying 
subtype: adrenal surgery for an aldosterone-producing adenoma, and a mineralo-
corticoid receptor antagonist in bilateral adrenal hyperplasia.1 Third, quality of life is 
adversely affected by PA, and may improve after specific therapy such as an 
adrenalectomy.10-12 Together with the long delay of eight years13 in diagnosing PA in 
hypertensive patients, screening for PA in all patients with newly diagnosed hyper - 
tension might be beneficial. However, the Endocrine Society Clinical Practice 
Guideline does not advocate early screening for PA in patients with new hypertension 
apart from specific subgroups, such as patients with sustained blood pressure 
>150/100 mmHg on each of three measurements, and cases of hypertension and 
spontaneous hypokalemia.1 The National Institute for Health and Care Excellence 
guideline advises ‘simply to be aware of signs and symptoms and refer on the basis of 
a high index of suspicion’, for example, young onset hypertension (aged <40 years).14,15 
In the Netherlands, the primary care guideline for hypertension recommends that 
only patients with hypertension and hypokalemia and those with therapy resistant 
hypertension should be referred on suspicion of secondary hypertension.16 
 The primary objective of this study was to assess the proportion of patients with 
PA among patients with newly diagnosed, never treated hypertension presenting at 
Dutch primary care centres. Our secondary objective was to study selection bias in 
general practitioners’ referral of patients for screening for PA.17
METHODS
stuDy setting anD Design
In this cross-sectional study patients from 55 primary care centres, from the Nijmegen 
region in the Netherlands, were recruited from 1 August 2013 to 31 December 2015 
(Supplementary File 1). 
 The screening consisted of two phases. In the first biochemical screening phase, 
the plasma aldosterone-to-renin ratio (ARR) and plasma aldosterone concentration 
were determined in patients with newly diagnosed hypertension prior to starting 
antihypertensive treatment. In the second confirmatory phase, patients with an 
elevated ARR and elevated plasma aldosterone concentration underwent a saline 
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infusion test (SIT) to verify autonomous aldosterone secretion. The SIT is one of the 
four confirmation tests that is recommended by the Endocrine Society to confirm or 
exclude the diagnosis of PA.1 A definite diagnosis of PA was made if saline loading 
failed to suppress the plasma aldosterone level.
 Reporting of this study is in concordance with the STrengthening the Reporting 
of OBservational studies in Epidemiology (STROBE) statement.18,19
 This study was approved by the Ethics Committee of the Radboud university 
medical center and all patients gave informed consent.
participants anD recruitment
Eligible patients had newly diagnosed, untreated hypertension and were aged ≥18 
years. Hypertension was diagnosed according to the guideline of the European 
Society of Hypertension.20 In brief, hypertension was diagnosed when: 1) office 
blood pressure was ≥140/90 mmHg on two or more different encounters within six 
months; 2) home blood pressure measurement (electronic device) was ≥135/85 
mmHg; 3) 24-hour ambulatory blood pressure monitoring (ABPM) was ≥130/80 
mmHg; or 4) daytime ABPM was ≥135/85 mmHg.
 Every participating general practitioner (GP) was asked to draw a blood sample 
in eligible patients for measurement of plasma aldosterone and renin. This blood 
sample was obtained in the morning after the patients had been sitting for five 
minutes. Exclusion criteria were: (prior) use of antihypertensive medication, 
hypertensive crisis, heart failure class II-IV (according to the New York Heart 
Association21), estimated glomerular filtration rate of <45 ml/min/1.73m2, pregnancy, 
breast feeding, diabetes mellitus, and presence of severe comorbidity (defined as 
seriously interfering with diagnostics or possible therapy). Patients who required 
immediate antihypertensive treatment (according to the GP) received specific 
medication with minimal effects on renin and aldosterone levels.1
proceDures
From 1 August 2013 to 14 December 2014, plasma aldosterone was measured using 
the Coat-A-Count aldosterone radioimmunoassay (RIA) from Siemens Medical 
Solutions Diagnostics (United States of America). From 15 December 2014 to 31 
December 2015, plasma aldosterone was measured by the Active Aldosterone RIA 
kit from Beckman Coulter (Czech Republic). Plasma renin concentration was 
measured using the DSL-25100 active renin immunoradiometric assay (IRMA) from 
Diagnostic Systems Laboratories (United States of America).
 The cut-off level of the ARR was >40 pmol/mU in combination with a plasma 
aldosterone of >400 pmol/L. The SIT consisted of intravenous infusion of two litres of 
sodium chloride 0.9% over four hours with the patient in the semi-recumbent position. 
After four hours blood was sampled for measurement of aldosterone. Usually, the 
aldosterone level will decrease after infusion of saline. In case of autonomous 
aldosterone secretion the negative feedback system is insufficient and aldosterone 
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 83
83
Prevalence of primary aldosteronism in primary care
levels remain too high. A plasma aldosterone concentration of >280 pmol/L was 
considered as definite PA, while an aldosterone level of <140 pmol/L excluded PA. 
In case of indeterminate values of 140 to 280 pmol/L the SIT was repeated. If still 
indeterminate, a diagnosis was reached by consensus after deliberation among 
clinical experts of the Department of Internal Medicine.
Data collection anD processing
Data of all patients with newly diagnosed hypertension were extracted from the 
Electronic Health Records (EHRs) of the 55 participating centres. The dataset 
included demographics, clinical characteristics, biochemical test results, prescribed 
medication, and diagnoses coded according to the International Classification of 
Primary Care (ICPC).22 
 Inclusion criteria were applied to select all patients with a new diagnosis of 
hypertension: ICPC code hypertension (K86 or K87) between 1 August 2013 and 31 
December 2015, or, when an ICPC code was not available, elevated blood pressure 
measurements were included according to the criteria described in the section 
‘Participants and recruitment’ (above). For further details of inclusion criteria when an 
ICPC code was unavailable see Supplementary File 2. 
statistical analysis
Based on a population of nearly 200000 subjects (from 55 primary care centres), an 
incidence of hypertension of 0.6% yearly,23,24 and a participation rate of 40%, this 
study aimed to enrol approximately 1100 patients. Anticipating a prevalence of PA of 
5%, at least 931 patients were required to be included to estimate the prevalence of 
PA with an accuracy of 1.4% and a confidence level of 95%.
 The statistical package SPSS Statistics version 22.0.0.1 was used to analyse 
the data. The proportion of patients with PA among patients with newly diagnosed 
hypertension was calculated by dividing the number of patients with confirmed PA by 
the number of patients with newly diagnosed hypertension who were screened for 
PA by using the ARR, plasma aldosterone, and the SIT. The total group of patients 
with newly diagnosed hypertension was extracted from the EHRs. To study selection 
bias between the screened and non-screened group, and taking into account the 
clustering of patients within practices, multilevel analyses25 to calculate P-values 
were used. To assess if known patient characteristics influenced the referral for 
biochemical screening of PA, a multivariate multilevel logistic regression analysis 
with age, blood pressure, and comorbidity was entered into the model. Practice 
variation for biochemical screening was assessed by the intraclass correlation 
coefficient (ICC).
 Independent samples t-tests for all screened patients were used to compare 
means between the PA and non-PA group, and a bootstrap test was used to 
corroborate the results.26 Analysis of variance (ANOVA) was used to assess 
differences in means in case of three groups. Chi-square tests were used to 
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 84
84
Chapter 3
determine associations between categorical variables. Fisher’s exact test was used 
in case of small sample size. As renin values showed a skewed distribution median 
and interquartile ranges (IQR) were calculated, using Mann-Whitney and Kruskal- 
Wallis tests to compare groups. Patients who did not complete the screening (n=18) 
were excluded from analyses.
RESULTS
characteristics of the total stuDy population
Out of 7205 patients with newly diagnosed hypertension that were identified, 3748 
were found to be eligible after application of exclusion criteria (Figure 1). Of these 
patients, 361 patients (9.6%) were tested by measuring ARR and plasma aldosterone 
(Figure 1). Eighteen patients did not undergo a SIT for various reasons (Supplementary 
File 3). Therefore, 343 completed screening for PA (9.2%). Baseline characteristics 
between the group that proceeded to a SIT and the group that did not were 
comparable (Supplementary Table 1).
prevalence of primary alDosteronism 
Of all 361 biochemically screened patients, 92 (25.5%) showed an elevated ARR in 
combination with increased plasma aldosterone. Nine of 74 patients who underwent 
SIT showed insufficient aldosterone suppression, confirming the diagnosis of PA, 
and 18 patients declined SIT or had a contraindication for SIT (Figure 1). Hence, 
the prevalence of PA in patients with newly diagnosed hypertension was 9 out of 343 
or 2.6% (95% CI 1.4 to 4.9). All nine patients with PA were normokalemic, and eight 
of them had sustained blood pressure >150/100 mmHg. As expected, the nine 
patients with PA had lower values of serum potassium and renin, and higher values 
of plasma aldosterone than patients without PA (Table 1). 
 Six patients had inconclusive test results after the first SIT and refused further 
diagnostic tests. Based on contextual information discussed at the expert meeting, 
the diagnosis of PA remained inconclusive. Hypertension of these six patients was 
treated with a mineralocorticoid receptor antagonist. Of the 74 patients who underwent 
SIT, 12 patients started immediate antihypertensive treatment after the diagnosis of 
hypertension (according to the Endocrine Society guideline).1 None of these patients 
had a positive confirmation test.
 When comparing the SIT positive group to the SIT negative group, serum potassium 
and renin levels were significantly lower in the SIT positive group than in the SIT 
negative group (Table 2). 
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Figure 1  Study flowchart
*Multiple patients were excluded by two or more exclusion criteria. ARR, aldosterone-to-renin ratio. eGFR, 
estimated glomerular filtration rate. SIT, saline infusion test.
Patients  with newly   
diagnosed hypertension  
n=7205 
Patients  with newly   
diagnosed hypertension  
n=3748 
Excluded (n=3457*): 
- Patients  <18 years : 24 
- Previous diagnosis of hypertension: 207 
- Use of antihypertensive medication: 2314  
- Hypertensive  crisis: 2 
- Heart failure: 156  
- Renal failure (eGFR of <45 ml/min/1.73m2): 395 
- Diabetes mellitus: 1265 
- Severe comorbidity, seriously interfering with diagnostics: 4 
- No informed consent: 1 
Patients tested for plasma 
 aldosterone, renin and ARR  
n=361 
Patients  with elevated  ARR and 
increased plasma aldosterone  
n=92 
Patients  not tested 
n=3387 
Patients  with normal ARR 
 and plasma aldosterone  
n=269 
Patients  who declined SIT or 












Processed on: 24-9-2018 PDF page: 86
86
Chapter 3












Male, n (%) 334/9 173 (51.8) 4 (44.4) 0.74
Age (years) 334/9 53.4 ± 11.2 54.3 ± 9.2 0.76
BMI (kg/m2), n (%) 213/9 0.50
≤25 47 (22.1) 1 (11.1)
>25 - ≤30 96 (45.1) 6 (66.7)
>30 70 (32.9) 2 (22.2) 0.40
Smoking status, n (%) 163/9
Current 36 (22.1) 2 (22.2)
Former 55 (33.7) 1 (11.1)
Never 72 (44.2) 6 (66.7)
Blood pressure
Systolic BP (mmHg) 332/9 163.8 ± 13.4 158.6 ± 10.2 0.17
Diastolic BP (mmHg) 329/9 96.3 ± 9.9 95.3 ± 9.1 0.75
ABPM (mmHg) 47/2 154.2 ± 15.7 166.5 ± 9.2 0.28
ABPMday (mmHg) 42/1 159.3 ± 15.6 161.0 ± NA NA
Home BP (mmHg) 2/0 160.0 ± 0 NA NA
Heart rate (beats/min) 192/7 75.2 ± 12.6 68.6 ± 12.8 0.22
Biochemical parameters
Potassium (mmol/L) 332/9 4.43 ± 0.33 4.11 ± 0.26 0.006
Sodium (mmol/L) 332/9 141.7 ± 2.0 141.7 ± 2.6 0.95
Creatinine (μmol/L) 332/9 78.8 ± 14.6 75.8 ± 13.1 0.51
Aldosterone (pmol/L) 334/9 360.9 ± 220.5 668.4 ± 118.1 <0.001
Renin* (pmol/L) 334/9 0.78 (0.58-1.33) 0.48 (0.34-0.68) 0.003
ARR (pmol/mU) 334/9 29.8 ± 22.8 105.3 ± 48.6 0.002
Glucose (mmol/L) 301/9 5.4 ± 1.0 5.4 ± 0.5 0.75
Cardiovascular morbidity
OSAS, n (%) 334/9 5 (1.5) 0 (0) 1.00
Atrial fibrillation, n (%) 334/9 2 (0.6) 0 (0) 1.00
Stroke, n (%) 334/9 2 (0.6) 0 (0) 1.00
Myocardial infarction, n (%) 334/9 2 (0.6) 0 (0) 1.00
Data are presented as mean ± standard deviation unless stated otherwise. *median (interquartile range). 
ABPM, systolic ambulatory blood pressure monitoring. ABPMday, daytime systolic ambulatory blood pressure 
monitoring. ARR, aldosterone-to-renin ratio. BMI, body mass index. Diastolic BP, office diastolic blood 
pressure. Home BP, home systolic blood pressure. min, minute. NA, not available. OSAS, obstructive sleep 
apnea syndrome. PA, primary aldosteronism. Systolic BP, office systolic blood pressure.
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 87
87



























































































































































































   
   
 ≤
25
   






   




















































   






   





   






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Processed on: 24-9-2018 PDF page: 89
89
Prevalence of primary aldosteronism in primary care
screeneD versus non-screeneD patients
Screened patients were younger, had higher blood pressure, and had higher serum 
potassium levels than non-screened patients. More patients in the non-screened 
group suffered from stroke (Table 3). Multivariate multilevel logistic regression 
analysis showed an independent effect on biochemical screening of age, systolic 
blood pressure, and previous stroke (p<0.001, p<0.001, p=0.016, respectively). 
Referral for biochemical screening was more likely in younger patients (odds ratio 
(OR) 0.96, 95% CI 0.95 to 0.97), and in patients with higher blood pressure (OR 1.06, 
95% CI  1.05 to 1.07). Patients who suffered from stroke had a lower chance to be 
referred for screening (OR 0.17, 95% CI 0.04 to 0.72) (Supplementary Table 2). 
Intraclass correlation coefficient was 0.22, which indicates a considerable variation 
in referral for screening among centres.
DISCUSSION
summary
In this primary care study the prevalence for primary aldosteronism in patients 
with newly diagnosed hypertension is 2.6%. This number is lower than reported 
prevalences from other primary care studies so far. The low number of screened 
patients (9.2%) of the large cohort of eligible patients reflects the difficulty in studying 
prevalence of primary aldosteronism in primary care clinical practice, when the daily 
routine of GPs collides with a study protocol.
strengths anD limitations 
This study set out to screen for PA in patients with newly diagnosed hypertension in 
a primary care setting. In many countries, the initial diagnosis of hypertension is 
predominantly made by GPs in primary care centres where there is no referral bias 
as is the case in prevalence studies from referral centres. A strength of this research 
was that specific subgroups in which PA may be more or less prevalent were 
excluded, such as patients with diabetes mellitus27-29 and patients with a hypertensive 
crisis.30 Another strong aspect of this study was that all patients were not treated with 
antihypertensive drugs at the time of inclusion or any time before. This minimises any 
confounding effects of these drugs on plasma aldosterone and renin.1 Finally, a 
strong feature of the research was that the total source population was examined for 
incomplete screening and possible selection bias by digital scrutiny of the EHRs.31 
 Concerning the reliability and validity the ARR is generally considered the best 
first-line screening test for hypertensive patients in whom there is clinical suspicion 
of PA.32,33 Yet, the ARR as an exploratory screening test has its limitations as it is 
influenced by many factors.34,35 Selection bias was assessed by the use of ICPC 
codes from EHR data. These ICPC codes depend on the quality of recording. 
Because GPs may not always assign an ICPC code for hypertension,36 the patients 
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Table 3  Baseline characteristics of all patients with newly diagnosed hypertension
Variable










   Male, n (%) 343/3387 177 (51.6) 1586 (46.8) 0.15
   Age (years) 343/3387 53.4 ± 11.1 58.5 ± 13.4 <0.001
   BMI (kg/m2), n (%) 
       ≤25
       >25 - ≤30









   Smoking status, n (%)
       Current 
       Former










   Systolic BP (mmHg) 341/2880 163.6 ± 13.3 156.3 ± 11.8 <0.001
   Diastolic BP (mmHg) 338/2880 96.3 ± 9.9 89.8 ± 9.5 <0.001
   ABPM (mmHg) 49/229 154.7 ± 15.6 147.0 ± 12.9 0.001
   ABPMday (mmHg) 43/204 159.4 ± 15.4 152.1 ± 12.8 0.003
   Home BP (mmHg) 2/12 160.0 ± 0 144.0 ± 5.2 NA
   Heart rate (beats/min) 199/1659 75.0 ± 12.6 74.5 ± 12.1 0.74
Biochemical parameters
   Potassium (mmol/L) 341/1785 4.42 ± 0.34 4.37 ± 0.37 0.04
   Sodium (mmol/L) 341/1685 141.7 ± 2.0 141.9 ± 2.1 0.08
   Creatinine (μmol/L) 341/1996 78.8 ± 14.6 78.9 ± 15.2 0.87
   Aldosterone (pmol/L) 343/0 369.0 ± 223.8 NA NA
   Renin# (pmol/L) 343/0 0.77 (0.58-1.31) NA NA
   ARR (pmol/mU) 343/0 31.8 ± 26.6 NA NA
   Glucose (mmol/L) 310/1786 5.43 ± 1.01 5.45 ± 0.83 0.55
Cardiovascular morbidity
   OSAS, n (%) 343/3387 5 (1.5) 41 (1.2) 0.71
   Atrial fibrillation, n (%) 343/3387 2 (0.6) 52 (1.5) 0.17
   Stroke, n (%) 343/3387 2 (0.6) 156 (4.6) 0.003
   Myocardial infarction, n (%) 343/3387 2 (0.6) 32 (0.9) 0.60
Data are presented as mean ± standard deviation unless stated otherwise. *P-value calculated by univariate 
multilevel analyses. #median (interquartile range). ABPM, systolic ambulatory blood pressure monitoring. ABPMday, 
daytime systolic ambulatory blood pressure monitoring. ARR, aldosterone-to-renin ratio. BMI, body mass index. 
Diastolic BP, office diastolic blood pressure. Home BP, home systolic blood pressure. min, minute. NA, not available. 
OSAS, obstructive sleep apnea syndrome. PA, primary aldosteronism. Systolic BP, office systolic blood pressure.
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with elevated blood pressure measurements without an ICPC code were also 
included. This improved case finding, but may have been too sensitive as the number 
of patients with newly diagnosed hypertension (n=3748) was higher than expected 
(Supplementary Table 3).
comparison with existing literature 
In this primary care study the proportion of patients with PA in patients with newly 
diagnosed hypertension was 2.6%. This is lower than reported in previous primary 
care studies that performed a confirmation test in at least half of biochemically 
screened  patients, ranging from 3.2%  to 11.5%.37-46 The two studies that restricted 
their study population to patients with newly diagnosed hypertension found a 
prevalence of 5.5% and 6.0%.40,45 Two other studies included only normokalemic 
patients with hypertension and established prevalences of 3.2% and 12.7%.41,43
 Several explanations for the low prevalence in this research have to be 
considered. First, studies vary considerably in their methods and screening cut-offs. 
In this research a relatively low cut-off value for the ARR of >40 pmol/mU was 
deliberately used with the aim to miss as few PA patients as possible.47,48 To prevent 
too many false-positive test results due to low renin hypertension, the criterion of a 
minimum plasma aldosterone level of 400 pmol/L was added.49 However, the cut-off 
for the SIT in this study was quite strict. 
 In 26 patients an elevated ARR was found without an increased plasma 
aldosterone. These patients did not undergo a SIT and this might have also 
contributed to our low prevalence seen in this study. In addition, 18 eligible patients did not 
undergo the SIT and six other patients had inconclusive test results (Figure 1). 
Under the theoretical assumption that these 24 patients might have PA, the virtual 
prevalence would be maximally 9.1% (33/361). However, this possibility is unlikely. 
 Screened patients were younger and had higher blood pressures as compared 
to non-screened patients. This indicates that GPs intuitively followed the screening 
recommendation of the Endocrine Society guideline,1 which recommends screening 
of patients with blood pressure >150/100 mmHg. In addition, for unknown reasons, 
GPs were less likely to perform biochemical screening in patients with newly 
diagnosed hypertension who suffered from a stroke. Apparently, GPs screened 
patients with a higher a priori chance of having PA and may have missed patients 
with a lower chance of having PA. It is therefore conceivable that this selective 
screening has contributed to an underestimation of the real PA prevalence. In 
addition, GPs might consider stroke as ‘severe comorbidity’, which was an exclusion 
criteria for participation in this research. 
 The present study illustrates that, despite a straightforward clinical protocol, an 
unbiased selection of patients for screening for PA is very hard to achieve in a primary 
care setting. The protocol in this research, intentionally designed to minimise bias, is 
apparently not compatible with routine daily practice in primary care.17,50 This is 
reflected in the discrepancy between the a priori calculated sample size and the 
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number of included patients in this research. Although the planned number of screened 
patients was not reached, nonetheless a prevalence estimate was achieved with a 
narrow confidence margin (95% CI 1.4% to 4.9%). 
 Because the definition of hypertension may differ between countries, for 
example, the UK and the Netherlands15,16 and population characteristics may vary, 
the denominator in the prevalence estimate may also differ between countries. 
Moreover, the authors’ experience in the current research raises the question of 
whether similar potential selection bias might have confounded previously published 
primary care studies on the prevalence of PA. To assess the prevalence of PA more 
precisely and to circumvent selection bias, rigorous screening of all patients with 
newly diagnosed hypertension is required. Employing a computerised algorithm 
without involvement of the GP in the selection process might be a better screening 
strategy, for example, a pop-up in the screen when an elevated blood pressure is 
added for the second time or when an ICPC code for hypertension is entered.
implications for research anD practice
As previous studies have shown that hypokalemia is only present in a minority of PA 
patients, it should be noted that all PA patients in the current study were normokalemic. 
This re-emphasises that the absence of hypokalemia as a reliable clinical marker to 
exclude PA should be considered obsolete.51
 A diagnosis of PA has enormous consequences, both on patients’ well-being 
and on healthcare logistics and costs. Early screening followed by adequate 
treatment may not only improve quality of life, it may also be cost-saving.52 Although 
the low prevalence, as found in this study, does not support indiscriminate screening of 
all new hypertensive patients for PA, all patients in this research project would 
have been missed following the current primary care guideline. In contrast, if the 
recommendations of the Endocrine Society guideline had been used, eight of the 
nine PA patients would have been picked up as they had a sustained blood pressure 
of >150/100 mmHg. It might be, therefore, reasonable to adopt the recommendations 
of the Endocrine Society guideline also in the field of primary care, so that the 
detection rate of PA may be improved.1 
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SUPPLEMENTARY FILES
supplementary file 1. recruitment of primary care centres
We telephoned general practitioners to explain the need and purpose of this study. 
If they were willing to participate, we visited them for explanation and instructions. 
We built a website with information for patients as well as professionals. For daily 
consultation professionals could call a special phone number. During the study all 
involved professionals received periodic newsletters. We aimed to maximise protocol 
compliance by adapted laboratory forms, and repeated reminders.
supplementary file 2. selection of the source population
We selected our source population of patients with newly diagnosed hypertension 
by applying the following inclusion: 1) ICPC code hypertension (K86 or K87) between 
August 1st 2013 and December 31st 2015, or 2) when an ICPC code was not available, 
we included elevated blood pressure measurements according to the criteria 
described in ‘Participants and recruitment’. Office blood pressure measurements 
had to be noted from February 1st 2013 to December 31st 2015, at least one 
measurement had to be performed on or after August 1st 2013. Elevated home blood 
pressure measurements and (daytime) ABPMs were included from August 1st 2013 
to December 31st 2015. If patients fulfilled the second inclusion criterion, we checked 
if an ICPC code hypertension had been created before August 1st 2013. If so, these 
patients were subsequently excluded because their diagnosis of hypertension could 
not be new. 
supplementary file 3. reasons why patients haD no saline infusion test
Seven patients declined because it was too bothersome for them, two patients 
declined because of the costs of additional testing, two patients required referral to 
a cardiologist (this was noticed during the telephonic contact between researcher 
and GP prior to SIT), two patients needed to take care for an ill relative, two patients 
suffered from travel anxiety, one patient did not want to be notified of the screening 
results (‘right of not knowing’, in which patients could consent to perform an additional 
blood sample, while refusing to be noticed of the test result), and for two patients the 
reason for drop-out was missing.
GP, general practitioner. SIT, saline infusion test.
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 98
98
Chapter 3
Supplementary Table 1  Baseline characteristics of patients with elevated 
aldosterone-to-renin ratio and increased plasma aldosterone who had a saline 











   Male, n (%) 74/ 18 24 (32.4) 4 (22.2) 0.37
   Age (years) 74/ 18 51.8 ± 10.5 55.7 ± 10.7 0.22
   BMI (kg/m2), n (%) 
       ≤25
       >25 - ≤30









   Smoking status, n (%)
       Current 
       Former










   Systolic BP (mmHg) 74/ 18 163.5 ± 13.2 162.0 ± 11.2 0.74
   Diastolic BP (mmHg) 74/ 18 97.1 ± 9.7 95.1 ± 7.4 0.35
   ABPM (mmHg) 16/ 0 161.3 ± 17.2 NA NA
   ABPMday (mmHg) 16/ 0 163.5 ± 18.5 NA NA
   Home BP (mmHg) 1/ 0 160.0 ± NA NA NA
   Heart rate (beats/min) 47/ 10 74.7 ± 13.4 75.9 ± 11.4 0.61
Biochemical parameters
   Potassium (mmol/L) 73/ 18 4.34 ± 0.37 4.41 ± 0.43 0.53
   Sodium (mmol/L) 73/ 18 141.9 ± 2.2 141.6 ± 1.9 0.70
   Creatinine (μmol/L) 73/ 18 79.7 ± 13.6 74.6 ± 13.0 0.28
   Aldosterone (pmol/L) 74/ 18 593.6 ± 225.9 585.7 ± 179.7 0.99
   Renin# (pmol/L) 74/ 18 0.64 (0.54-0.76) 0.68 (0.52-0.79) 0.93
   ARR (pmol/mU) 74/ 18 67.7 ± 30.1 64.6 ± 21.7 0.72
   Glucose (mmol/L) 70/ 18 5.16 ± 0.72 5.36 ± 0.69 0.58
Cardiovascular morbidity
   OSAS, n (%) 74/ 18 0 (0) 0 (0) NA
   Atrial fibrillation, n (%) 74/ 18 0 (0) 0 (0) NA
   Stroke, n (%) 74/ 18 1 (1.4) 0 (0) NA
   Myocardial infarction, n (%) 74/ 18 0 (0) 0 (0) NA
Data are presented as mean ± standard deviation unless stated otherwise. *P-value calculated by univariate 
multilevel analyses. #median (interquartile range). ABPM, systolic ambulatory blood pressure monitoring. 
ABPMday, daytime systolic ambulatory blood pressure monitoring. ARR, aldosterone-to-renin ratio. BMI, body 
mass index. Diastolic BP, office diastolic blood pressure. Home BP, home systolic blood pressure. Min, minute. 
NA, not available. OSAS, obstructive sleep apnea syndrome. PA, primary aldosteronism. Systolic BP, office 
systolic blood pressure. SIT, saline infusion test.
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Supplementary Table 2  Multivariate multilevel logistic regression analysis of 
patients characteristics that may influence referral for screening for primary 
aldosteronism
Variable OR (95% CI) P-value
Demographics
   Gender (male) 0.89 (0.70-1.14) 0.36
   Age (years) 0.96 (0.95-0.97) <0.001
Blood pressure
   Systolic BP (mmHg) 1.06 (1.05-1.07) <0.001
Comorbidity
   OSAS 1.04 (0.37-2.94) 0.95
   Atrial fibrillation 0.64 (0.14-2.84) 0.55
   Stroke 0.17 (0.04-0.72) 0.016
   Myocardial infarction 1.67 (0.35-8.07) 0.52
CI, confidence interval. OR, odds ratio. OSAS, obstructive sleep apnea syndrome. Systolic BP, office systolic 
blood pressure.
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Supplementary Table 3  Baseline characteristics of patients with newly diagnosed 













   Male, n (%) 2042/1706 964 (47.2) 803 (47.1) 0.84
   Age (years) 2042/1706 57.4 ± 13.1 58.9 ± 13.5 0.03
   BMI (kg/m2), n (%) 
       ≤25
       >25 - ≤30









   Smoking status, n (%)
       Current 
       Former










   Systolic BP (mmHg) 1546/1693 160.6 ± 13.4 153.8 ± 10.0 <0.01
   Diastolic BP (mmHg) 1543/1693 93.2 ± 10.0 88.0 ± 8.8 <0.01
   ABPM (mmHg) 165/113 151.9 ± 14.0 143.2 ± 11.6 <0.01
   ABPMday (mmHg) 152/96 156.6 ± 13.4 148.40 ± 12.2 <0.01
   Home BP (mmHg) 6/8 145.3 ± 5.4 147.0 ± 9.1 0.35
   Heart rate (beats/min) 929/939 74.9 ± 11.9 74.2 ± 12.3 0.31
Biochemical parameters
   Potassium (mmol/L) 1238/906 4.35 ± 0.38 4.41 ± 0.34 0.01
   Sodium (mmol/L) 1177/867 141.7 ± 2.2 142.1 ± 2.1 0.001
   Creatinine (μmol/L) 1335/1020 78.5 ± 15.1 79.2 ± 15.1 0.77
   Aldosterone (pmol/L) 242/119 403.2 ± 234.1 332.1 ± 203.1 0.005
   Renin# (pmol/L) 242/119 0.76 (0.56-1.33) 0.76 (0.57-1.21) 0.08
   ARR (pmol/mU) 242/119 35.5 ± 29.3 29.3 ± 22.1 0.07
   Glucose (mmol/L) 1195/919 5.45 ± 0.88 5.44 ± 0.83 0.93
Cardiovascular morbidity
   OSAS, n (%) 2042/1706 28 (1.4) 18 (1.1) 0.48
   Atrial fibrillation, n (%) 2042/1706 22 (1.1) 32 (1.9) 0.06
   Stroke, n (%) 2042/1706 77 (3.8) 81 (4.7) 0.049
   Myocardial infarction, n (%) 2042/1706 19 (0.9) 15 (0.9) 0.86
Data are presented as mean ± standard deviation unless stated otherwise. *P-value calculated by univariate 
multilevel analyses. #median (interquartile range). ABPM, systolic ambulatory blood pressure monitoring. ABPMday, 
daytime systolic ambulatory blood pressure monitoring. ARR, aldosterone-to-renin ratio. BMI, body mass 
index. Diastolic BP, office diastolic blood pressure. Home BP, home systolic blood pressure. ICPC, International 
Classification of Primary Care. min, minute. K86, ICPC code for ‘hypertension without organ damage’. K87, 
ICPC code for ‘hypertension with organ damage’. NA, not available. OSAS, obstructive sleep apnea syndrome. 
PA, primary aldosteronism. Systolic BP, office systolic blood pressure. SIT, saline infusion test.
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Patients with primary aldosteronism (PA) have a higher risk of cardiovascular 
complications compared to patients with essential hypertension (EHT) and similar 
blood pressure levels. It is unclear whether cardiovascular damage is already present 
at the time of diagnosing hypertension. The aim of this exploratory study was to 
assess cardiovascular organ damage in patients who were screened for PA at the 
time of diagnosing hypertension in primary care. 
methoDs 
We prospectively assessed cardiovascular damage in six patients with newly 
diagnosed PA and 24 matched patients with EHT at the time when hypertension was 
diagnosed in the primary care. We performed detailed cardiovascular assessment, 
including ankle-brachial index, echocardiography, flow-mediated vasodilation, 
carotid ultrasonography, central aortic blood pressure, pulse wave velocity, and 
urinary albumin-to-creatinine ratio measurement.
results
Two of the six patients with PA versus none of the patients with EHT (p=0.04) fulfilled 
the criteria of concentric LVH (>115 g/m2 in men and >95 g/m2 in women). After 
adjustment for gender, age and blood pressure, left ventricular mass index was 
higher in the patients with PA than in the patients with EHT. We did not observe 
differences in the other outcome measures between the patient groups. 
conclusion
At the time of the diagnosis of hypertension, patients with PA have a higher frequency 
of LVH than patients with EHT. If confirmed in larger studies, this finding suggests that 
early biochemical testing for PA, and specific treatment of PA, might contribute to the 
prevention of further progression of cardiovascular damage due to inadequately 
treated PA. 
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INTRODUCTION
Primary aldosteronism (PA) is characterized by unilateral or bilateral autonomous 
overproduction of aldosterone in the adrenal cortex. PA is the most common cause 
of secondary hypertension, with prevalences varying from 3% to 12% in primary care 
versus 1% to 30% in referral centres.1,2
 According to the Endocrine Society guideline, the diagnosis of PA should be 
considered in specific patients with hypertension.3 However, in daily clinical primary 
care practice, this recommendation on testing for PA is commonly omitted, as 
general practitioners are generally not aware of this guideline.4 To complicate matters 
further, hypokalemia, previously considered to be a prerequisite for a diagnosis of 
PA, is present in only less than 40% of the PA patients. So, this biomarker has limited 
utility to incite appropriately testing for PA.5 For these reasons the diagnosis of PA 
has been reported to be delayed for up to eight years.6 
 The delay in a timely diagnosis of PA is potentially harmful for patients for at 
least two reasons. First, treatment of PA differs from usual antihypertensive treatment 
in patients with essential hypertension (EHT). Patients with PA require specific treatment: 
those with a unilateral aldosterone-producing adenoma are advised to undergo 
adrenalectomy, whereas those with bilateral aldosterone overproduction are treated 
with a mineralocorticoid receptor antagonist (MRA), such as spirono lactone.3 
Second, patients with PA have a higher risk of cardiovascular complications in 
comparison to patients with EHT with similar blood pressure levels.7 This may be 
explained by a direct effect of aldosterone unopposed by appropriate treatment 
during the long pre-diagnostic phase, inducing cardiovascular organ damage well 
before diagnosis. The higher risk of cardiovascular complications in patients with PA 
suggests the need for timely biochemical testing for PA in (newly diagnosed) hyper- 
tensive patients to prevent further development of cardiovascular organ damage. 
 In this explorative study in the primary care setting, we prospectively assessed cardio- 
vascular and renal damage in patients in whom PA was detected at the time when 
hypertension was diagnosed for the first time. A group of newly diagnosed patients 
with EHT, matched for gender, age and blood pressure, served as a control group. 
METHODS
stuDy population
We included all patients over 18 years with newly diagnosed never treated hyper- 
tension from 55 primary care centres in the Netherlands from August 1st 2013 to 
December 31st 2015. In the context of a previous study on the prevalence of PA, the 
participating patients had plasma aldosterone and renin measured at the time of 
diagnosing hypertension, and before starting antihypertensive treatment. This study 
has been described in detail elsewhere.8 
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The diagnosis of hypertension was made according to the current guideline by the 
European Society of Hypertension.9 In brief, hypertension was diagnosed: 1) if the 
average office blood pressure of at least two blood pressure measurements per day 
was ≥140/90 mmHg on two or more different visits within six months, or 2) if 24-hour 
ambulatory blood pressure measurement (ABPM) was ≥130/80 mmHg. 
 Patients with newly diagnosed hypertension were screened for PA by 
measurement of plasma aldosterone and renin. In case of an aldosterone-to-renin 
ratio (ARR) of >40 pmol/mU and a plasma aldosterone concentration of >400 pmol/L, 
an intravenous sodium loading test (SLT; two litres NaCl 0.9% in four hours) was 
performed. Diagnosis of PA was made when the aldosterone concentration exceeded 
280 pmol/L after sodium loading. Patients were considered to have EHT if ARR values 
were ≤40 pmol/mU with a concomitant low baseline aldosterone level of ≤400 pmol/L 
(ARRneg), or an aldosterone value of ≤280 pmol/L after SLT (ARRposSLTneg). During 
biochemical testing, patients did not use medication that interfered with aldosterone 
and renin levels.3
 We included all patients diagnosed with PA, and applied the following exclusion 
criteria: age <18 years, hypertensive crisis, heart failure classes II-IV (defined by the 
New York Heart Association10), diabetes mellitus, estimated glomerular filtration rate 
of <45 ml/min/1.73m2, pregnancy or breast feeding, and severe comorbidity that 
would seriously interfere with study procedures. We applied similar exclusion criteria 
for the patients with EHT. We matched the patients with PA with the patients with EHT 
for gender, age, and baseline blood pressure. For every patient with PA, we included 
four control patients with EHT: one ARRposSLTneg patient, and three ARRneg patients. 
This numeric relation corresponds to the ratio ARRpos/ARRneg that was found among 
patients with newly diagnosed EHT in primary care.8
 This study was approved by the Ethics Committee of the Radboud university 
medical center. All patients provided written informed consent before enrollment. The 
study was conducted in accordance with Good Clinical Practices, and the Declaration 
of Helsinki, and was prospectively registered at ClinicalTrials.gov by number 
NCT01728493.
clinical Data
We collected the following clinical data: body mass index (BMI), medication use, 
smoking status (pack years (PY)), previous and family history of cardiovascular 
disease, alcohol intake per day (units of 10 g), physical exercise (standard defined as 
30 minutes/day during five or more days/week), snoring (defined as light or heavy 
according to the patients’ judgement) or diagnosis of obstructive sleep apnea 
syndrome (OSAS), and history of gestational hypertension. We expressed the 
 antihypertensive medication in daily defined doses (DDD), as defined by the World 
Health Organisation.11 From August 1st 2013 to December 14th 2014, plasma 
aldosterone was measured using the Coat-A-Count aldosterone radioimmunoassay 
(RIA) from Siemens Medical Solutions Diagnostics (United States of America). From 
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December 15th 2014 to December 31st 2015, plasma aldosterone was measured 
by the Active Aldosterone RIA kit from Beckman Coulter (Czech Republic). Plasma 
renin concentration was measured using the DSL-25100 active renin immuno-
radiometric assay (IRMA) from Diagnostic Systems Laboratories (United States of 
America). Baseline plasma concentrations of creatinine, potassium, cholesterol, 
high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and 
triglycerides were determined using standard assays in a central laboratory (SHO, 
Velp, the Netherlands). 
stuDy protocol
In patients with PA and ARRposSLTneg patients with EHT, ankle brachial index (ABI) 
and urinary albumin-to-creatinine ratio (uACR) were performed during their admission for 
SLT. Echocardiography was carried out shortly after this. We performed measurements 
of the other cardiovascular risk markers during a separate visit. In ARRneg patients 
with EHT, all measures were obtained during a single visit (Table 1).
We measured the brachial blood pressure in the supine position using a manual 
sphygmomanometer (Welch Allyn, Leiden, the Netherlands), in a quiet room after a 
period of five minutes rest according to the guideline.12 All patients abstained from 
caffeine, alcohol, and products rich on vitamin C and/or flavonoids 24 hours before 
the measurements. We performed the measurements at least six hours after fasting. 
We asked the patients not to smoke six hours before the experiments, and to refrain 
from exercise during 24 hours before the measurements. Patients took their 
medication after finishing all vascular measurements on the day of the experiments.13,14 
We assessed the following seven primary outcomes: 









ABI, and uACR 1 1 18
Echocardiography 4 6 19
FMD, cIMT, central aortic blood pressure, and PWV 19* 12 18
*5 patients. ABI, ankle-brachial index. ARR, aldosterone-to-renin ratio. cIMT, carotid intima-media thickness. 
FMD, flow-mediated dilation. PA, primary aldosteronism. PWV, pulse wave velocity. SLT, intravenous sodium 
loading test. uACR, urinary albumin-to-creatinine ratio.
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For the measurement of the ABI we used the standardized technique as described by 
the American Heart Association.15 In brief, we performed limb pressure measurements 
after at least five minutes of rest in the supine position. All limb pressure measurements 
were done by Doppler (Dopplex D900, Huntleigh Healthcare Ltd, Cardiff, UK) in the 
following sequence: right brachial artery, right tibial posterior artery, right dorsal pedal 
artery, left tibial posterior artery, left dorsal pedal artery, and left brachial artery. When 
the pressure between both brachial arteries exceeded 10 mmHg, we performed a 
second measurement of the right brachial artery and discarded the first measurement. 
We expressed the ABI as the highest lower-extremity blood pressure, divided by the 
highest blood pressure in both arms. 
echocarDiography
Standard echocardiographic examinations were carried out with subjects in the 
partial left decubitus position using a commercially available instrument (GE Vivid E9, 
General Electric, Horten, Norway), equipped with the multifrequency 1.5 to 4.0 MHz 
M5S transducer. End-diastolic and end-systolic left ventricular internal diameters 
(LVIDd, LVIDs), interventricular septum and posterior wall thicknesses (PWT) were 
measured from two dimensional parasternal long axis view, from which left ventricular 
mass index (LVMI) was calculated according to the American Society of Echocardio-
graphy guidelines and normalized by body surface area.16 Relative wall thickness 
(RWT) was calculated as 2 × PWT/LVIDd. A normal LVMI was defined as ≤115 g/m2 
in men, and ≤95 g/m2 in women. We defined eccentric hypertrophy as an increased 
LVMI (>115 g/m2 in men, and >95 g/m2 in women) with a RWT <0.42, and concentric 
hypertrophy as an increased LVMI with a RWT >0.42. Furthermore, concentric 
remodeling was defined as a normal LVMI, but increased RWT (>0.42).16 Left 
ventricular (LV) filling, in casu diastolic LV function was assessed by the standard 
pulsed and tissue Doppler technique.17 The following parameters were considered: 
the early diastolic mitral peak flow velocity (E), the late diastolic mitral peak flow 
velocity (A), their ratio (E/A ratio), and the average of both maximal early diastolic 
tissue velocity of the medial and lateral mitral annulus (E’) and the average E/E’.
flow-meDiateD Dilation (fmD)
An experienced researcher of the Department of Physiology of the Radboud university 
medical center measured brachial FMD in a darkened, temperature-controlled room of 
22.1 ± 0.4 °C using a 10-MHz multifrequency linear-array probe attached to a high- 
resolution ultrasound machine (Terason T3000, Burlington, USA) according to the 
guideline of Thijssen et al.14 The researcher was blinded for the diagnosis. Briefly, 
a sphygmomanometer blood pressure cuff was positioned around the forearm and 
the brachial artery was imaged proximally of the antecubital fossa. After one minute of 
baseline recordings of diameter and blood flow velocity, the cuff was inflated for five 
minutes, at a pressure of 200 mmHg or at least 50 mmHg above systolic blood pressure 
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(SBP). We captured changes in brachial artery diameter and blood flow velocity 
30 seconds before cuff deflation until three minutes post-deflation, and analyzed 
the recordings offline in a blinded fashion using computer-assisted software, utilizing 
edge-detection and wall-tracking. We expressed the FMD as the % change in diameter 
((peak diameter after deflation minus baseline diameter)/baseline diameter x 100%). 
carotiD intima-meDia thickness (cimt)
The cIMT was measured by high resolution B-mode ultrasound with a 7.5-MHz 
linear-array transducer (Esaote Biomedica, Genoa, Italy). We measured the intima 
and media of the left and right common carotid artery far wall over a 1 cm segment 
caudally from the carotid bulb, in three different angles of 90, 120 and 180°. 
The integrated software of the Esaote platform uses radio-frequency technology 
to provide six measures, calculated as means from real-time values, obtained during 
six cardiac cycles. The standard deviation (SD) of these six mean measures was 
directly visible and the data were accepted if the SD did not exceed 20 μm. 
We calculated the mean diameter and cIMT from 18 measures (six means times 
three angles) of every patient for the left and right carotid artery. We thoroughly 
scanned the extracranial carotid arteries for the presence of plaques. A plaque was 
defined as a focal wall thickening of ≥50% compared to the surrounding vessel wall, 
or a local cIMT greater than 1.5 mm, according to the consensus statement from the 
American Society of Echocardiography.18 
central aortic blooD pressure anD pulse wave velocity (pwv)
With the patient in the supine position, we performed pulse wave analysis of the right 
radial artery using applanation tonometry (SphygmoCor, AtCor Medical, Australia). 
The SphygmoCor software generates the central aortic blood pressure and 
augmentation index (AIx) from a ten second recording after calibration for peripheral 
blood pressure. We discarded measurements that did not meet the quality control 
criteria of the software. We recorded the median of three valid central aortal blood 
pressure measurements. For the assessment of the aortic PWV, we measured the 
pressure waves at the sites of the right carotid artery and the right femoral artery. 
The SphygmoCor software automatically calculates the transit time as the delay 
between the R-spike in the electrocardiogram, and the arrival of the pressure waves 
at the recording sites. We estimated the travel distance by subtracting the distance 
from the carotid tonometer location to the sternal notch from the distance between 
the sternal notch to the femoral tonometer location.19 In all patients we performed 
three measurements and recorded the median PWV. When the difference between 
the first and second PWV was ≤0.5 m/s, we did not perform a third measurement and 
recorded the mean PWV of these two measurements.20 The quality of the pressure 
wave was directly analyzed by the Sphygmocor software. If the SD was ≥10% of the 
PWV measurement, we discarded the measurement and replaced it by a novel 
measurement, up to a maximum of six attempts. 
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urinary albumin-to-creatinine ratio (uacr)
The uACR was measured in a single urine sample by the Department of Clinical 
Chemistry of the Radboud university medical center. Urinary albumin was measured 
using a nephelometric technology (BN II analyzer, Siemens, the Netherlands). Urinary 
creatinine was analyzed by Cobas 8000, Roche Diagnostics, the Netherlands). 
statistical analysis
For the analysis of the data, we used IBM SPSS Statistics 22. We expressed all values 
as mean ± SD. We considered a significance value of <0.05 (two-sided). Differences 
between patients with PA and patients with EHT were compared using an independent 
t-test. Because of the small sample size, we checked the robustness of the independent 
t-test with bootstrapping. Differences in proportions were compared using the Fisher’s 
exact test (two-sided). For comparisons between more than two groups, we used a 
one-way ANOVA. We compared each of the single outcome measures between the 
patients with PA and EHT using a general linear model with correction for gender, age 
and blood pressure. Central aortic blood pressures were corrected only for gender 
and age, because the Sphygmocor software calculates the central blood pressure 
and AIx from the brachial blood pressure. 
RESULTS
patients anD clinical characteristics
Of the patients with newly diagnosed hypertension, nine were diagnosed with PA.8 
Of these patients, three patients declined to participate in the present study. Therefore, 
we included six patients with PA and 24 matched control patients with EHT in our 
study. For an overview of the selection of our study population see Figure 1. In this 
total group of 30 patients, the diagnosis of hypertension was based on office blood 
pressure measurements in 26 patients, and on APBM in four patients.9 Four patients 
with PA had bilateral aldosterone overproduction, and one had a unilateral 
 aldosterone-producing adenoma. In one patient laterality could not be determined, 
as this patient refused adrenal venous sampling and computed tomography. 
One of the six patients with PA dropped out, because of recently diagnosed breast 
cancer. We did not perform FMD, PWV and central aortic blood pressure in this 
patient. Due to technical problems, we excluded the results of FMD in one patient 
with EHT. In two patients with EHT we did not obtain a valid PWV (SD >10% of the 
mean PWV) due to obesity. 
 There were no differences in baseline characteristics between the patients with 
PA and EHT regarding cardiovascular risk factors and laboratory screening, except 
for differences in plasma aldosterone, ARR, and potassium values (Table 2). None of 
the patients had hypokalemia. 
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In the PA and the ARRposSLTneg patients, ABI and uACR were assessed after a mean 
period of one month after the diagnosis of hypertension (Table 1). The patients with 
PA did not use any antihypertensive medication at that time, and their SBP was 
significantly higher compared to ARRneg patients (Table 3A). During echocardio-
graphy, two patients with PA used antihypertensive medication. In the other four 
patients with PA, antihypertensive treatment started after echocardiography. 
 Echocardiography was performed 3.7 ± 2.9, 6.3 ± 9.2, and 19.1 ± 7.2 months after 
the diagnosis of hypertension in PA, ARRposSLTneg patients (with EHT), and ARRneg 
patients (with EHT), respectively (p<0.01). During assessment of FMD, cIMT, PWV, 
and central aortic blood pressure, blood pressure levels and DDD of antihypertensive 
drugs were comparable between patients with PA and patients with EHT (Table 3B). 
The general practitioner had started antihypertensive drugs in 12 of the 24 patients 
with EHT without reaching target blood pressure levels of <140/90 mmHg (RR 151 
± 15/93 ± 10 mmHg).9 The remaining 12 patients did not use antihypertensive 
agents, and their blood pressure was 164 ± 19/89 ± 6 mmHg. 
Figure 1  Overview of the selection process of the patients
Patients  with primary 
aldosteronism 
n=9 





Eligible  patients with 
primary aldosteronism 
n=6 
Ankle-brachial  index, echocardiography, flow-mediated dilation, carotid 
intima-media  thickness, pulse wave velocity, central  aortic blood 
pressure , and urinary  albumin-creatinine  ratio in patients with primary 
aldosteronism (n=6), ARRpos SLTneg (n=6), and ARR neg (n=18). 
ARR posSLT neg 
n=15 
Exclusion  (n=3) 
- No informed consent: 3 
Not matched 
n=322 
Matched patients with 




Exclusion  (n=4) 
- No informed consent: 4 
Exclusion  (n=22) 
- Exclusion  criteria met: 12 
- No informed consent: 4 
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Male, n (%) 3 (50) 12 (50) 1.00
Age (years) 55.8 ± 9.1 56.6 ± 8.3 0.85
Cardiovascular risk factors
BMI (kg/m2) 26.6 ± 2.9 28.4 ± 3.4 0.23
Units alcohol/day 1.0 ± 1.2 1.2 ± 1.8 0.73
Smoking, n (%) 0.12
Current 1 (16.7) 0
Former 1 (16.7) 12 (50)
PYa 23 ± 30 21 ± 19 0.96
Daily exercise
Less than standard (%) 2 (33.3) 6 (25.0) 0.21
1st degree family history 
CVD (%) 2 (33.3) 17 (70.8) 0.33
Unknown (%) 0 1 (4.2)
2nd degree family history 0.35
CVD (%) 0 9 (37.5)
Unknown (%) 0 2 (8.3)
Gestational hypertension (%) 1 (33.3) 6 (50.0) 1.00
Snoring 0.08
Light (%) 1 15
Heavy (%) 2 2
OSAS (%) 1 0 0.20
Diagnosis
Reason of visit 0.19
Complaints (%) 4 (66.7) 7 (29.2)
High blood pressure at screening test (%) 2 (33.3) 8 ( (33.3)
At clinic for other reason (%) 0 9 (37.5)
 SBP (mmHg) 169 ± 9 164 ± 11 0.24
DBP (mmHg) 104 ± 7 97 ± 9 0.07
Laboratory screening
Potassium (mmol/L) 4.1 ± 0.3 4.5 ± 0.3 0.03
Sodium (mmol/L) 141 ± 3 142 ± 2 0.36
MDRD (mL/min) 78 ± 8 74 ± 13 0.29
Aldosterone (pmol/L) 721 ± 90 338 ± 218 <0.01
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Renin (pmol/L) 0.6 ± 0.3 2.1 ± 3.5 0.05
ARR (pmol/mU) 104.9 ± 57.6 26.8 ± 22.7 0.02
Fasting glucose (mmol/L) 5.4 ± 0.6 5.5 ± 0.7 0.88
Cholesterol (mmol/L) 6.8 ± 1.2 5.9 ± 1.0 0.15
HDL (mmol/L) 1.5 ± 0.5 1.5 ± 0.4 0.98
LDL (mmol/L) 4.6 ± 0.8 4.1 ± 0.9 0.23
Triglycerides (mmol/L) 2.8 ± 2.6 1.3 ± 0.6 0.22
Data are presented as mean ± standard deviation unless stated otherwise. aFor current and former 
smokers. BMI, body mass index. CVD, cardiovascular disease. DBP, diastolic blood pressure. MDRD, 
‘modification of diet in renal disease’, equation to estimate the glomerular filtration rate from serum creatinine. 
OSAS, obstructive sleep apnea syndrome. SBP, systolic blood pressure.
Table 3A  Blood pressure and antihypertensive treatment during assessment of 









Brachial SBP in mmHg 172 ± 15 172 ± 23 154 ± 10 0.01
Brachial DBP in mmHg 100 ± 10 91 ± 6 92 ± 7 0.05
Duration of hypertension (months) 1.0 ± 0.9 1.0 ± 1.1 18.0 ± 7.1 <0.01
Medication use
Number of patients taking  
antihypertensive drugs (%)
0 1 (16.7) 11 (61.1) 0.01
Thiazides (%) 0 0 3 (16.7) 1.00
ACE inhibitors (%) 0 0 6 (33.3) 0.30
ARB (%) 0 0 1 (5.6) 1.00
CCB (%) 0 1 (16.7) 2 (11.1) 1.00
BB (%) 0 0 0
MRA (%) 0 0 0
Statin use (%) 0 0 2 (11.1) 1.00
Data are presented as mean ± standard deviation unless stated otherwise. ACE, angiotensin converting 
enzyme. ARB, angiotensin receptor blocker. ARR, aldosterone-to-renin ratio. BB, beta blocker. CCB, calcium 
channel blocker. DBP, diastolic blood pressure. EHT, essential hypertension. MRA, mineralocorticoid receptor 
antagonist. PA, primary aldosteronism. SBP, systolic blood pressure. SLT, intravenous sodium loading test.
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The unadjusted primary outcome measures are presented in Table 4A. None of the 
patients had eccentric LVH, whereas two female patients with PA had concentric LVH 
on echocardiography (p=0.03). Concentric remodelling was present in two patients 
with PA (33.3%) and five patients with EHT (20.8%; p=0.60). LVMI was higher among 
patients with PA, but the difference with patients with EHT was not significant in the 
unadjusted analysis. After correction for blood pressure, gender, and age, LVMI was 
significantly higher in patients with PA compared to patients with EHT (90.50 ± 7.73 
versus 70.70 ± 3.61 g/m2, respectively; p=0.04). There was no increased frequency 
of diastolic dysfunction, atrial dilation, and carotid plaques in patients with PA 
compared to control patients with EHT. 
 The adjusted mean values of the single outcome measures, with correction for 
gender, age and baseline blood pressure are depicted in Table 4B. We did not 
observe differences in ABI, cIMT, FMD, central blood pressure, AIx, PWV, and uACR 
between patients with PA compared to patients with EHT (Table 4).
Table 3B  Blood pressure and antihypertensive treatment during assessment of 










Brachial SBP in mmHg 139 ± 17.6 156 ± 26 154 ± 10 0.14
Brachial DBP in mmHg 86 ± 14 88 ± 10 92 ± 7 0.41
Duration of hypertension (months) 18.8 ± 7.4 12.3 ± 6.0 18.0 ± 7.1 0.20
Medication use
Number of patients taking  
antihypertensive drugs (%)
5 (83.3) 2 (33.3) 11 (61.1) 0.09
Thiazides (%) 0 1 (16.7) 3 (16.7) 1.00
ACE inhibitors (%) 0 1 (16.7) 6 (33.3) 0.30
ARB (%) 0 1 (16.7) 1 (5.6) 1.00
CCB (%) 2 (40.0) 2 (33.3) 2 (11.1) 0.27
BB (%) 0 1 (16.7) 0 1.00
MRA (%) 4 (80.0) 0 0 0.00
Statin use (%) 2 (40.0) 0 2 (11.1) 0.17
Data are presented as mean ± standard deviation unless stated otherwise. ACE, angiotensin converting 
enzyme. ARB, angiotensin receptor blocker. ARR, aldosterone-to-renin ratio. BB, beta blocker. CCB, 
calcium channel blocker. DBP, diastolic blood pressure. EHT, essential hypertension. MRA, mineralocorti-
coid receptor antagonist. PA, primary aldosteronism. SBP, systolic blood pressure. SLT, intravenous sodium 
loading test.
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Table 4A  Primary outcome measures, unadjusted
PA EHT P-value
ABI
Left ABI 1.1 ± 0.0 1.1 ± 0.1 0.76
Right ABI 1.1 ± 0.1 1.1 ± 0.1 0.53
Echocardiography
Concentric hypertrophy (%) 2 (33.3) 0 (0) 0.03
Concentric remodeling (%) 2 (33.3) 5 (20.8) 0.60
LVMI (g/m2) 83.48 ± 16.72 72.48 ± 16.92 0.19
Diastolic dysfunction (%) 3 (50.0) 11 (45.8) 1.00
Atrial dilation (%) 2 (33.3) 5 (20.8) 0.60
FMD*
Baseline diameter (cm) 0.439 ± 0.114 0.407 ± 0.057 0.57
% change (diameter) 4.3 ± 3.3 4.6 ± 3.0 0.88
Time to peak (seconds) 54.4 ± 33.5 73.7 ± 47.9 0.32
cIMT**
Carotid plaques (%) 1 (20.0) 8 (33.3) 1.00
Left cIMT (μm) 733.8 ± 188.8 747.0 ± 150.5 0.89
Right cIMT (μm) 732.7 ± 177.5 727.6 ± 135.2 0.96
Central aortic blood pressure**
Central SBP (mmHg) 130 ± 18 145 ± 15 0.15
Central DBP (mmHg) 87 ± 14 92 ± 8 0.49
Central AIx (%) 28.4 ± 7.8 30.7 ± 8.0 0.55
PWV*** (m/s) 8.7 ± 1.3 9.6 ± 1.7 0.21
uACR (mg/mmol) 3.4 ± 3.6 3.9 ± 13.0 0.89
*in PA (n=5) and EHT (n=23). **in PA (n=5). ***in PA (n=5) and EHT (n=22). Data are presented as mean ± 
standard deviation unless stated otherwise. ABI, ankle-brachial index. AIx, augmentation index. cIMT, carotid 
intima-media thickness. DBP, diastolic blood pressure. EHT, essential hypertension. FMD, flow-mediated 
dilation. LVMI, left ventricle mass index. PA, primary aldosteronism. PWV, pulse wave velocity. SBP, systolic 
blood pressure. SLT, intravenous sodium loading test. uACR, urinary albumin-to-creatinine ratio.
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In a Dutch primary care population we screened patients with newly diagnosed 
hypertension for PA.8 We demonstrated that the proportion of patients with LVH was 
higher in patients with PA as compared to patients with EHT. There were no differences 
in ABI, FMD, cIMT, central aortic blood pressure, PWV, and uACR between patients 
with PA and EHT. 
 The prevalence of LVH in patients with PA is in the range of 20% to 60% in referral 
centres.7,21-23 This high proportion of LVH in these studies may be due to persistent 
exposure to high circulating aldosterone levels, since the diagnosis and treatment of 
PA are delayed.6 In our study, echocardiography was performed in patients with 
newly diagnosed hypertension, with hardly any delay in the diagnosis of PA. Our 
findings therefore suggest that in patients with PA, LVH is already present at the time 
of diagnosing hypertension. 




Left ABI 1.1 ± 0.0 1.1 ± 0.0 0.70
Right ABI 1.1 ± 0.0 1.1 ± 0.0 0.56
Echocardiography
LVMI (g/m2) 90.50 ± 7.73 70.70 ± 3.61 0.04
FMD*
% change (diameter) 4.47 ± 1.48 4.63 ± 0.66 0.92
Time to peak (seconds) 67.0 ± 21.9 71.6 ± 9.7 0.85
cIMT**
Left cIMT (μm) 748.8 ± 62.0 743.4 ± 26.8 0.94
Right cIMT (μm) 741.4 ± 62.9 725.3 ± 27.3 0.82
Central aortic blood pressure**
Central SBP (mmHg) 131 ± 7 145 ± 3 0.07
Central DBP (mmHg) 87 ± 4 92 ± 2 0.25
Central AIx (%) 29.0 ± 3.5 30.7 ± 1.6 0.67
PWV*** (m/s) 9.0 ± 0.7 9.5 ± 0.3 0.55
uACR (mg/mmol) 5.1 ± 5.6 3.4 ± 2.6 0.80
*in PA (n=5) and EHT (n=23). **in PA (n=5). ***in PA (n=5) and EHT (n=22). Data are presented as mean ± 
standard deviation unless stated otherwise. ABI, ankle-brachial index. AIx, augmentation index. cIMT, carotid 
intima-media thickness. DBP, diastolic blood pressure. EHT, essential hypertension. FMD, flow-mediated 
dilation. LVMI, left ventricle mass index. PA, primary aldosteronism. PWV, pulse wave velocity. SBP, systolic 
blood pressure. SLT, intravenous sodium loading test. uACR, urinary albumin-to-creatinine ratio.
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In addition to the increased prevalence of LVH, LVMI was higher in patients with PA 
compared to patients with EHT after correction for gender, age, and baseline blood 
pressure (Table 4). LVMI is a strong and independent predictor of future cardiovascular 
events.24 It has been shown that every g/m2 increase in LVMI results in a hazard ratio 
of 1.013 to 1.015 for the risk of cardiovascular events in the general population.24 
 To prevent progressive cardiovascular damage, it might be important to screen 
for PA as early as possible. However, it remains challenging when and who to screen. 
In our study there were no differences in baseline characteristics between patients 
with PA and patients with EHT. Moreover, none of the patients with PA presented 
with hypokalemia, which is one of criteria to screen for PA according to the Endocrine 
Society guideline. This guideline recommends screening also in case of sustained 
blood pressure >150/100 mmHg.3 In our cohort, 83% of the patients with PA had a 
blood pressure above 150/100 mmHg on separate visits at the time of diagnosing 
hypertension, which highlights the relevance of this clinical clue in the primary 
care setting. 
 Our findings of an increased risk of LVH in patients with PA, but lack of 
differences in other surrogate endpoints of target organ damage between patients 
with PA and EHT, suggests that the toxic effects of aldosterone affect mainly the 
heart but not other organ systems. However, others have shown that patients with PA 
have more morphological and functional vascular damage, and an impaired 
endothelial function, when compared to matched patients with EHT.25-29 Importantly, 
the patients in these studies were not included at the time hypertension was 
diagnosed for the first time. Therefore, we speculate that aldosterone-mediated 
effects on the vascular system may become manifest later on, and thus might be 
prevented by early diagnosis and adequate treatment. 
strengths anD limitations
The strength of our study is that the diagnosis of PA was made without a substantial 
delay. Furthermore, the diagnoses of PA and EHT were based on stringent criteria, 
according to the international guideline of the Endocrine Society.3 Another strength 
of our study is that we assessed cardiovascular damage using the combination of 
seven different cardiovascular risk markers. The results of our study might be helpful 
in the design and sample size calculation of future prospective trials.
 A major limitation of the study is the limited power to detect differences in 
outcomes between the study groups, except for LVH. During the two year inclusion 
period, an ARR was measured in less than 10% of the patients with newly diagnosed 
hypertension.8 Only nine patients were diagnosed with PA, which resulted in a lower 
power than anticipated for the current study. Our study was designed as a prospective 
cohort study, but given the lagging recruitment it has a explorative character.
 Other limitations are the timing of the vascular investigations due to logistic 
difficulties, and the ensuing difference in medication use across the groups. We 
assessed ABI, uACR, and echocardiography in the patients with PA and ARRposSLTneg 
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patients with EHT shortly after their diagnosis. In patients with EHT, these outcomes 
were assessed approximately 18 months after the diagnosis (Table 1). Fifty percent 
of these patients used antihypertensive drugs during a mean period of 16 ± 8 months 
at the time of the vascular investigations. One might argue that therapy-related 
improvements in the EHT group may have accounted for the differences in LVH and 
LVMI between patients with PA and patients with EHT. However, half of the patients 
with EHT were not treated despite being hypertensive with, in some cases, a stage 2 
hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure 
≥100 mmHg). Moreover, in the treated patients, blood pressure control appeared to 
be poor. Therefore, the longer duration of hypertension and the inadequate treatment 
of 50% of the patients with EHT, may have stimulated LVH in the control group. The 
fact that we still found an increased prevalence of LVH in patients with PA argues for 
aldosterone being the culprit of LVH. 
 During FMD, carotid ultrasonography, PWV and central aortic blood pressure, 
blood pressure levels did not differ between patients with PA and patients with EHT, 
as shown in table 3B. However, both patient groups used antihypertensive medications 
that may have altered the outcomes of these vascular risk markers (Table 3B).30 
CONCLUSIONS
We found a higher prevalence of LVH in newly diagnosed hypertensive patients 
with PA compared to newly diagnosed patients with EHT in whom PA was excluded. 
This finding suggests that screening for PA with subsequent treatment at the time 
of diagnosing hypertension might be useful to prevent further progression of 
cardiovascular damage. 
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Individualized antihypertensive treatment based on specific biomarkers such as 
renin may lead to more effective blood pressure control in patients with newly 
diagnosed essential hypertension. Recent studies suggested that the plasma 
aldosterone-to-renin ratio (ARR) may also be a candidate predictor for this purpose.
objective
To assess whether the ARR is associated with the blood pressure response to 
antihypertensive treatment in patients with newly diagnosed hypertension. 
methoDs
In this prospective cohort study in primary care, we determined the ARR in patients 
with newly diagnosed hypertension prior to starting treatment. Treatment was 
categorized in five groups: no medication, use of angiotensin-converting-enzyme 
inhibitor or angiotensin receptor blocker, use of calcium channel blocker, use of 
diuretic, or use of beta blocker. We examined the relation between the ARR and blood 
pressure response within one year of treatment, taking into account the type of 
antihypertensive treatment and adjusting for gender, age, baseline blood pressure, 
and comorbidity. 
results
Out of 304 patients, we used 947 measurements (727 no medication, 220 medication) 
for analysis. There was no association between the ARR and the response in blood 
pressure, and this applied to each treatment group. Target blood pressure, defined 
as systolic blood pressure <140 mmHg, was reached in 31% of patients. There was 
no association between the ARR and reaching target blood pressure (OR 1.002, 95% 
CI 0.983 to 1.022). 
conclusion
The ARR is not associated with the response in blood pressure within one year of 
antihypertensive treatment in primary care. 
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INTRODUCTION
Despite a wide variety of treatment options, target blood pressure is not reached in 
many patients with hypertension.1-3 This can be explained by various factors such as 
poor therapy adherence, secondary hypertension, comorbidity, and biological factors. 
Although numerous studies have demonstrated that all classes of antihypertensive 
drugs are similarly effective in reducing blood pressure,4,5 it is also known that 
sub groups of patients respond better to specific classes of antihypertensive treatment. 
For example, in young hypertensive patients blood pressure is better controlled with 
an angiotensin-converting-enzyme inhibitor (ACE-I), angiotensin receptor blocker 
(ARB) or a beta blocker,6,7 and in black patients with hypertension blood pressure 
response is superior to a calcium channel blocker (CCB) or a diuretic.8 It is plausible 
to assume that personalized treatment guided by specific individual characteristics 
or biomarkers may lead to more effective blood pressure reduction.9,10
 Of the studies that assessed biomarkers, several studies focussed on treatment 
guided by the activity of the renin-angiotensin-aldosterone system. In particular renin 
has been studied as a biomarker to guide antihypertensive treatment. Patients with 
low renin levels were considered as having a high (intravascular) volume hypertension 
and therefore proposed to be candidates for diuretic treatment, while patients with 
high renin levels were considered more sensitive for treatment with a renin-lowering 
beta blocker.11,12
 The plasma aldosterone-to-renin ratio (ARR) reflects the level of aldosterone 
secretion in relation to renin secretion. The ARR is predominantly used as a screening 
test for primary aldosteronism, the most frequent cause of secondary hypertension.13,14 
The prevalence of primary aldosteronism is estimated to be 2-5% in primary care, but this 
varies between studies due to differences in diagnostic methods.15,16 Apart from 
primary aldosteronism some patients with essential hypertension may also display 
high ARR levels, although still in the normal range.17 Patients with a high ARR display 
an inappropriate high level of aldosterone in relation to renin. From the patho-
physiological point of view, the high blood pressure in patients with a high ARR is 
considered to be due to an increased renal retention of sodium and water. Therefore 
these patients may be particularly sensitive for treatment with diuretics and 
mineralocorticoid receptor antagonists.18 However, it is unclear whether or not the 
ARR can be used as a patient-specific biomarker in patients with newly diagnosed 
essential hypertension to predict the response to antihypertensive treatment. 
 For several reasons it would be very helpful if an easy to use and cheap test 
would be available to predict blood pressure response to antihypertensive treatment. 
First, such a test, if effective, could markedly contribute to a more rapid optimization 
of antihypertensive treatment. Second, it could lead to less side-effects as not all 
drugs would need to be tried. Finally, such an approach might result in lower health 
care costs as patients achieve the target blood pressure more rapidly, thus reducing 
the associated hypertensive complications. 
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In this primary care observational study, we measured the ARR in patients with newly 
diagnosed hypertension prior to starting antihypertensive treatment. Our primary 
objective was to assess whether the ARR is associated with the blood pressure 
response in patients after a maximum of one year of treatment, and whether this 
association varied over the main specific classes of antihypertensive medication 
used in primary care (ACE-inhibitors, ARBs, beta blockers, CCBs, thiazide diuretics). 
Our secondary objective was to study the association between baseline ARR level 
and the number of patients that achieved a target systolic blood pressure of <140 
mmHg within one year of treatment.
METHODS
stuDy setting anD stuDy population 
In this prospective cohort study we recruited patients from 55 primary care centres in 
the Nijmegen region in the Netherlands from August 1st 2013 to December 31st 2015. 
We included all patients over 18 years with newly diagnosed never treated hyper -
tension. In the context of a previous study on the prevalence of primary aldosteronism, 
the participating patients had a measurement of plasma aldosterone and renin before 
starting antihypertensive treatment. This study is described in detail elsewhere.15 
All patients had an office blood pressure measurement at baseline, at least two weeks 
of antihypertensive treatment, and at least one visit with office blood pressure 
measurement within twelve months of follow-up. For generalizability of the study 
results to patients with essential hypertension, patients with primary aldosteronism 
were excluded from this patient cohort as they require specific therapy according to 
the Endocrine Society guideline.19 Other exclusion criteria were: hypertensive crisis, 
heart failure class II-IV (according to the New York Heart Association), estimated 
glomerular filtration rate of <45 ml/min/1.73m2, pregnancy, breast feeding, diabetes 
mellitus, and severe comorbidity (defined as seriously interfering with diagnostics or 
therapy). All patients were on a liberal salt diet.
 This study was approved by the Ethics Committee of the Radboud university 
medical center and all patients gave informed consent. All general practitioners (GPs) 
approved extraction of their Electronic Health Records (EHRs) by written permission 
and informed their patients. Patients were given the opportunity to decline the use of 
their de-identified data. This method complies with the Code of Conduct for Health 
Research which has been approved by the Data Protection Authorities in conformity 
with the applicable Dutch privacy legislation. Reporting of this study is in concordance 
with the STrengthening the Reporting of OBservational studies in Epidemiology 
(STROBE) statement.20
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proceDures
Hypertension was defined according to the guideline of the European Society of 
Hypertension.1 In brief, hypertension was diagnosed if average office blood pressure 
of at least two blood pressure measurements per day was ≥140/90 mmHg on two or 
more different visits within six months. 
 In the period from August 1st 2013 to December 14th 2014, plasma aldosterone 
was measured using the Coat-A-Count aldosterone radioimmunoassay (RIA) from 
Siemens Medical Solutions Diagnostics (Unites States of America). From December 
15th 2014 to December 31st 2015, plasma aldosterone was measured by the Active 
Aldosterone RIA kit from Beckman Coulter (Czech Republic). Plasma renin 
concentration was measured using the DSL-25100 active renin immunoradiometric 
assay (IRMA) from Diagnostic Systems Laboratories (United States of America).
Data collection anD processing
We extracted data from the EHRs of the participating centres. The dataset included 
demographics, clinical characteristics, biochemical test results and prescribed 
medications. As in this study secondary analyses were performed, we refer to the 
parent study for the sample size calculation, and a full overview of the extraction 
process.15 In brief, patients were included if they had: 1) an International Classification 
of Primary Care (ICPC)21 code hypertension (K86 or K87) between August 1st 2013 
and December 31st 2015, or 2) when an ICPC code was not available, if they had had 
two visits to their general practice documenting elevated blood pressure values as 
described in ‘Procedures’. For each included patient we extracted all office blood 
pressure values at baseline (i.e. the date of diagnosis of hypertension), and those 
obtained during one year after the initial diagnosis. Antihypertensive treatment was 
initiated by the GP, and comprised the use of an antihypertensive agent in combination 
with lifestyle advice according to the guideline. Blood pressure measurements were 
categorized in five treatment groups, in which each blood pressure measurement 
and the corresponding antihypertensive treatment was set. Because treatment could 
change over time, patients could change from treatment categories throughout the 
observation period and thus contribute to the analysis of more than one anti-
hypertensive treatment. For the follow-up we excluded blood pressure values that 
were measured within less than two weeks prior to the start or change of an anti-
hypertensive agent, because we considered a time lapse of less than 14 days too 
short to achieve a maximal antihypertensive effect.1
 Medication was encoded using the Anatomical Therapeutic Chemical (ATC) 
classification system: 1) angiotensin-converting-enzyme inhibitor or angiotensin 
receptor blocker, 2) calcium channel blocker, 3) diuretic, or 4) beta blocker 
(Supplementary File 1). Blood pressure measurements without an ATC code were 
set in the ‘no medication’ group. 
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We used the statistical package IBM SPSS Statistics version 22.0 to analyse the data. 
In case of normally distributed data, mean and SD were given. In case of skewed 
distribution, we calculated median and interquartile ranges. Next to patient level 
analyses, we analyzed a dataset using all blood pressure measurements for each 
patient during follow-up. Relevant differences in baseline characteristics have been 
described. For the outcome variable delta systolic blood pressure, the mean 
differences with its 95% confidence interval (95% CI) between the medication group(s) 
and the no medication group is presented. Because of the hierarchical structure of 
our study (repeated blood pressure measurements nested within patients), we 
performed multilevel analyses for the ARR and the blood pressure response. 
Statistical significance level was set at two-tailed P-value <0.05.
 To assess if the ARR was associated with the response in blood pressure in relation 
to antihypertensive treatment, we used a multivariate multilevel linear regression 
analysis adjusted for gender, age, baseline systolic blood pressure and comorbidity 
entered into the random intercept model.22 The interaction term (treatment group by 
ARR) tests the difference in the association between the ARR and the response in 
systolic blood pressure for the five groups. The response in systolic blood pressure 
is defined as the baseline minus the follow-up systolic blood pressure measurement. 
We performed a sensitivity analysis to be able to compare our results with other 
literature, using logarithmic scale of ARR in relation with blood pressure decline.23
 To assess the association between the ARR and the number of patients on 
target blood pressure after one year of treatment, we used logistic regression 
analysis. Patients had reached target blood pressure if their last blood pressure 
measurement within twelve months from baseline was <140/90mmHg.
RESULTS
Of the initial 361 patients in whom an ARR was available, 57 patients had to be excluded 
from the analyses for the following reasons: 1) missing baseline or follow-up blood 
pressure measurements (n=45), 2) only blood pressure measurements during the use 
of multiple agents (n=3), or 3) a diagnosis of primary aldosteronism (n=9). Consequently, 
304 patients with a total of 947 blood pressure measurements were used for the 
analysis. Baseline characteristics were comparable between included (n=304) and 
excluded patients (n=57; Supplementary Table 1). The majority of patients had an ICPC 
code for hypertension (n=210; 69.1%). Median number of blood pressure measurements 
per patient after baseline was two (interquartile range one to four measurements), with 
a range of one to ten measurements. During the follow-up period, 110 patients (36.2%) 
used antihypertensive medication and 194 did not. Figure 1 presents a flow diagram of 
the included patients in relation to blood pressure measurements. Table 1 shows 
patients characteristics for the medication and no medication group on patient level. 
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The number of blood pressure measurements for the medication and no medication 
group are shown in Table 2. Baseline characteristics between both groups were 
comparable. For delta systolic blood pressure, there was a clinically relevant 
difference between the groups of -13.0 mmHg (95% CI -15.5 to -10.5).
 Table 3 shows the baseline characteristics of each of the five groups. Prescribed 
medication (n=220) consisted of 37.3% ACE inhibitors or ARBs, 21.4% CCBs, 33.6% 
diuretics, and 7.7% of beta blockers. In the ‘ACE-I or ARB’ group more blood pressure 
measurements were available in males than in females, patients with blood pressure 
Figure 1  Flow diagram for included patients in relation to blood pressure 
measurements
*Some patients have been treated by >1 antihypertensive agent. ACE-I, angiotensin converting enzyme 
inhibitor. ARB, angiotensin receptor blocker. ARR, aldosteron-to-renin ratio. CCB, calcium channel blocker.
Patients  with newly  diagnosed 
hypertension  and an ARR
(n=361)
Patients  with newly  
diagnosed hypertension  
(n=304)
 = 
947 blood pressure  measurements
Excluded (n=57):
-  Missing baseline or follow-up blood pressure
   measurement (n=45)
-  Solely blood pressure measurements during 
    the use of multiple agents (n=3)
-  Diagnosis of primary aldosteronism (n=9)
Hypertensive  patients who did not 
use antihypertensive  agents
(n=194)
=
727 blood pressure  measurements




82 blood pressure  
measurements




74 blood pressure  
measurements  




17 blood pressure  
measurements




220 blood pressure  measurements




47 blood pressure  
measurements
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   Male, n (%) 304/194/110 154 (50.7) 99 (51.0) 55 (50.0)
   Age (years) 304/194/110 53.4 ± 11.4 52.8 ± 11.3 54.6 ± 11.7
   BMI (kg/m2), n (%) 
       ≤25 
       >25 - ≤30











   Smoking status, n (%)
       Current
       Former












   Systolic BP (mmHg) 304/194/110 163.8 ± 13.1 162.4 ± 12.2 166.4 ± 14.3
   Diastolic BP (mmHg) 301/192/109 96.3 ± 9.6 96.0 ± 9.6 96.8 ± 9.8
   Heart rate (beats/min) 181/113/68 75.3 ± 12.7 73.5 ± 12.7 78.3 ± 12.0
Biochemical parameters
   Potassium (mmol/L) 302/193/109 4.43 ± 0.34 4.42 ± 0.34 4.44 ± 0.35
   Sodium (mmol/L) 302/193/109 141.8 ± 1.99 141.8 ± 1.9 141.7 ± 2.1
   Creatinine (μmol/L) 302/193/109 78.8 ± 14.4 79.5 ± 14.3 77.5 ± 14.6
   Aldosterone (pmol/L)* 304/194/110 345.5 (214.8 - 460.0) 337.5 (200.5 - 485.5) 346.5 (233.5 - 440.3) 
   Renin (pmol/L)* 304/194/110 0.77 (0.58 - 1.31) 0.75 (0.58 - 1.26) 0.86 (0.59 - 1.43)
   ARR (pmol/mU)* 304/194/110 25.2 (14.2 - 45.2) 25.2 (14.2 - 49.7) 25.5 (13.8 - 41.7)
   Glucose (mmol/L) 279/180/99 5.4 ± 0.9 5.3 ± 0.8 5.5 ± 1.2
Cardiovascular morbidity
   Atrial fibrillation, n (%) 304/194/110 2 (0.7) 1 (0.5) 1 (0.9)
   OSAS, n (%) 304/194/110 4 (1.3) 3 (1.5) 1 (0.9)
   MI, n (%) 304/194/110 2 (0.7) 1 (0.5) 1 (0.9)
   Stroke, n (%) 304/194/110 1 (0.3) 0 1 (0.9)
Data are presented as mean ± standard deviation, unless stated otherwise. *median (interquartile range). ARR, 
aldosterone-to-renin ratio. BP, office blood pressure. BMI, body mass index. MI, myocardial infarction. OSAS, 
obstructive sleep apnea syndrome.
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measurements in the diuretic group were slightly older, patients who receive CCBs 
had a higher aldosterone, patients who receive beta blockers had a higher renin, 
patients in the CCBs groups had a higher ARR, and baseline systolic blood pressure 
was comparable between all groups. Within each treatment group systolic blood 
pressure showed a significant decline. Mean differences of response for each 
medication group compared to the no medication group (reference) are -16.4 (95% 
CI -21.3 to -11.6) for the CCB group, -15.2 (95% CI -18.9 to -11.4) for the ACE-I or ARB 
group, -9.7 (95% CI -17.6 to -1.7) for the beta blocker group, and -9.3 mmHg (95% CI 
-13.3 to -5.3) for the diuretic group. 
 Multivariate multilevel linear regression analysis showed no association between 
the ARR and the blood pressure response within one year of treatment in the total 
group (regression coefficient 0.050, (95% CI -0.009 to 0.110), Table 4). There was no 
association between the ARR and the blood pressure response for the medication and 
no medication group (Table 4), but there was a significant difference in starting value of 
blood pressure response (i.e. a significant difference in intercept, p<0.001; Figure 2, 
Supplementary Tables 2 and 3). Subgroup analysis showed no significant association 
of the ARR and the response in blood pressure within each of the groups (Table 4). The 
interaction term between the ARR and the five treatment groups was non-significant 
(p=0.77) with a significant intercept (p<0.001, Figure 2, Supplementary Tables 4 and 5). 
 In our sensitivity analysis we found no correlation between log ARR and the 
response in blood pressure for all groups (p=0.61).
 During the last blood pressure measurement 87 patients used antihypertensive 
medication (35 ACE-I or ARB, 14 CCB, 28 diuretic, and 10 beta blocker). Of these 
patients target systolic blood pressure was reached in 27 patients (31%). There was 
no association between ARR and the number of patients reaching target blood 
pressure (odds ratio 1.002, 95% CI 0.983 to 1.022). 
Table 2  Baseline characteristics of all blood pressure measurements and response 





Male, n (%) 117 (53.2) 359 (49.4)
Age 55.3 ± 11.6 53.3 ± 11.7
Aldosterone¶ 362.0 (241.3 - 441.0) 359.0 (231.0 - 475.0)
Renin¶ 0.86 (0.61 - 1.33) 0.77 (0.58 - 1.29)
ARR¶ 27.2 (13.5 - 44.3) 27.0 (14.5 - 46.7)
Baseline SBP 166.3 ± 13.9 164.0 ± 13.3
Delta SBP# -18.3 ± 18.4 -5.3 ± 16.0
Data are presented as mean ± standard deviation, unless stated otherwise. ¶median (interquartile range). 
#Delta SBP: the response in systolic blood pressure, defined as the baseline systolic blood pressure minus the 
follow-up systolic blood pressure. ARR, aldosterone-to-renin ratio. SBP, systolic blood pressure.
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Table 4  Multivariate multilevel linear regression analysis of the aldosterone-to-renin 
ratio and response in blood pressure
Blood pressure response* 
(n=947)
ß# (95% confidence interval)
ARR 0.050 (-0.009 - 0.110)
ARR
   All medication
   No medication
0.048 (-0.044 - 0.139)
0.047 (-0.014 - 0.108)
ARR
   ACE-I or ARB
   CCB
   Diuretic
   Beta blocker
   No medication
0.110 (-0.019 - 0.239)
0.010 (-0.186 - 0.206)
-0.005 (-0.155 - 0.145)
0.155 (-0.480 - 0.789)
0.049 (-0.012 - 0.110)
*Blood pressure response in systolic blood pressure, defined as the baseline minus the follow-up systolic 
blood pressure measurement. #Adjusted for age, gender and baseline blood pressure. ACE-I, angiotensin-
converting-enzyme inhibitor. ARB, angiotensin receptor blocker. ARR, aldosterone-to-renin ratio. CCB, 
calcium channel blocker. ß, regression coefficient.
Figure 2  Association between the aldosterone-to-renin ratio and response in 
systolic blood pressure for the different treatment groups*
*adjusted for clustering, gender, age, and baseline blood pressure. ACE-I, angiotensin-converting-enzyme 













































In this study we found no significant association between the ARR and the response 
in systolic blood pressure for the total medication group nor for the subgroups of 
antihypertensive agents after one year of treatment. Therefore, the ARR has no 
predictive value for the response in blood pressure to antihypertensive treatment in 
this primary care patient group. In patients that used antihypertensive agents target 
blood pressure was reached in 31% within one year after the initial diagnosis.
strengths anD limitations
A strong aspect of our study is the study setting of primary care as in many countries 
treatment of hypertension is started and monitored in primary care.24,25 Moreover, all 
included patients had not previously been treated with antihypertensive drugs at the 
time of aldosterone and renin measurement, which eliminates any confounding 
effects of these drugs on the ARR.19 Finally, we set relevant exclusion criteria by 
excluding groups which might confound the results and interpretation of the ARR, 
e.g. patients with diabetes. 
 As we included only patients with newly diagnosed hypertension and guidelines 
recommend to start lifestyle advice in newly diagnosed patients, the size of our study 
is limited to the medication groups. Since we did not include patients who needed 
referral to the hospital we did not have follow-up measurements of blood pressure in 
the primary care setting for these patients. Finally, 68 patients (22.4%) with less than 
one year follow-up were included, because they were included in the last phase of 
our inclusion period.
comparison with existing literature 
Previous studies have suggested that hypertensive patients with a high ARR respond 
favourably to spironolactone.26 Parthasarathy et al. studied the antihypertensive 
response of spironolactone compared to bendroflumethiazide in two groups of 
antihypertensive patients, one with high and one with low ARR, and found no 
predictive effect of the ARR. However, patients with high ARR were not tested for 
primary aldosteronism, and participants were not newly diagnosed hypertensive 
patients.27,28 Prisant et al. performed an ad hoc analysis in which baseline ARR levels 
did not predict the antihypertensive response to eplerenone in combination with an 
ACE-I or ARB.29 Mahmud et al. examined the effect of spironolactone on 30 
hypertensive never treated patients, and found a significant correlation between the 
log ARR and the decline in blood pressure.23 All studies so far are uncontrolled and 
performed in a small number of patients. It is therefore not possible to draw 
conclusions on the value of the ARR in relation to the blood pressure response when 
mineralocorticoid receptor antagonists are used as monotherapy in essential 
hypertension. In our sensitivity analysis we transformed the ARR in log ARR, but 
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results remained non-significant. It should be noted that in our study not one patient 
was treated by mineralocorticoid antagonists, because in the Netherlands mineralo-
corticoid receptor antagonists are not used in primary practice for monotherapy in 
essential hypertension.30 As we provided no instructions about the use of specific 
antihypertensive agents, our study reflects daily clinical practice. 
 Several large scale studies have promulgated the beneficial effects of thiazide 
diuretics in essential hypertension. Although a Cochrane review concluded that 
achieving target blood pressure is only partly responsible for the risk reduction of 
antihypertensive treatment, no inferences can be made about the association of the 
blood pressure lowering effect and the height of the ARR.31 In our study, the 
antihypertensive effect of diuretics was similar over the entire range of ARRs (Figure 2).
 Although lifestyle advice is recommended by the guideline for each patient with 
hypertension we were not able to monitor this from the EHR data, however the 
decline in blood pressure in the no medication group could have been the result of 
this.32,33
implications for research anD practice
This explorative study in primary care does not provide evidence that a simple and 
cheap test like the ARR is helpful in predicting whether and which antihypertensive 
treatment in primary care is effective. In our study no patients were treated with a 
mineralocorticoid receptor antagonist such as spironolactone, although previous 
studies have shown that a high ARR does predict a favourable blood pressure 
response to this drug.23,26-28 Overall, these results cast doubt on the value of the 
ARR as a therapeutic marker.34 However, the ARR remains useful as a diagnostic 
marker for primary aldosteronism in hypertensive patients.13,19
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supplementary file 1. treatments groups
• Treatment 1: no use of antihypertensive agents, treatment consists of lifestyle 
advise (salt reduction etc.).
• Treatment 2: use of angiotensin-converting-enzyme inhibitors and angiotensin 
receptor blockers. This category contains the agents with ATC-code C09A*, 
C09C*, and C09X*.
• Treatment 3: use of calcium channel blockers. This category includes ATC-codes 
C08C*, C08D*, and C08E*.
• Treatment 4: use of diuretics. This category contains ATC-code C03A*, C03B*, 
C03C*, and C03D*.
• Treatment 5: use of beta blockers. This category contains ATC-code C07A*.
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Supplementary Table 2  Tests of fixed effects of the aldosterone-to-renin ratio  
and response in blood pressure for no medication versus all medication
Source Numerator df F P-value
Intercept 1 111,237 0,000
Medication 1 45,424 0,000
ARR 1 2,152 0,143
Medication * ARR 1 0,000 0,993
Gender 1 1,384 0,240
Age 1 0,000 0,996
Baseline systolic blood pressure 1 58,041 0,000
ARR, aldosterone-to-renin ratio.
Supplementary Table 3  Estimates of the fixed effects of the aldosterone-to-renin 
ratio and response in blood pressure for no medication versus all medication






Intercept -20,664078 2,120563 -9,745 0,000 -24,828872 -16,499283
No medication 12,737516 1,889910 6,740 0,000 9,028395 16,446638
All medication 0 0 . . . .
ARR 0,047603 0,046421 1,025 0,306 -0,043541 0,138747
No medication * ARR -0,000427 0,045545 -0,009 0,993 -0,089818 0,088963
All medication * ARR 0 0 . . . .
Gender (M) 1,655311 1,406811 1,177 0,240 -1,114653 4,425275
Gender (F) 0 0 . . . .
Age -0,000284 0,059611 -0,005 0,996 -0,117676 0,117108
Baseline systolic BP -0,395051 0,051854 -7,618 0,000 -0,497174 -0,292929
ARR, aldosterone-to-renin ratio. BP, blood pressure. F, female. M, male.
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Supplementary Table 4  Tests of fixed effects of the aldosterone-to-renin ratio and 
response in blood pressure for the five treatment groups
Source Numerator df F P-value
Treatment group 4 13,039 0,000
ARR 1 0,752 0,386
Treatment group * ARR 4 0,460 0,765
Gender 1 2,022 0,156
Age 1 0,030 0,863
Baseline systolic blood pressure 1 55,131 0,000
ARR, aldosterone-to-renin ratio.
Supplementary Table 5  Estimates of the fixed effects of the aldosterone-to-renin 
ratio and response in blood pressure for the five treatment groups






Intercept -8,160489 1,555027 -5,248 0,000 -11,220669 -5,100308
ACE-I or ARB -17,014798 2,657359 -6,403 0,000 -22,229952 -11,799643
CCB -12,750063 4,816451 -2,647 0,008 -22,202574 -3,297551
Diuretic -7,803866 3,153428 -2,475 0,014 -13,992666 -1,615065
BB -12,041658 7,078807 -1,701 0,089 -25,934105 1,850789
No medication 0 0 . . . .
ARR 0,048929 0,031148 1,571 0,117 -0,012362 0,110219
(ACE-I or ARB) * ARR 0,061051 0,064766 0,943 0,346 -0,066062 0,188165
CCB * ARR -0,038784 0,100725 -0,385 0,700 -0,236466 0,158898
Diuretic * ARR -0,053978 0,075236 -0,717 0,473 -0,201638 0,093683
BB * ARR 0,105670 0,323515 0,327 0,744 -0,529253 0,740592
No medication * ARR 0 0 . . . .
Gender (M) 2,014237 1,416594 1,422 0,156 -0,774687 4,803162
Gender (F) 0 0 . . . .
Age -0,010361 0,059849 -0,173 0,863 -0,128215 0,107493
Baseline systolic BP -0,386034 0,051991 -7,425 0,000 -0,488423 -0,283645
ACE-I, angiotensin-converting-enzyme inhibitor. ARB, angiotensin receptor blocker. ARR, aldosterone-to-
renin ratio. BB, beta blocker. BP, blood pressure. CCB, calcium channel blocker. F, female. M, male.
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General discussion and summary
Some medical specialists support indiscriminate screening for primary aldosteronism 
(PA) in all patients with hypertension,1-3 whereas others recommend selective screening 
in subgroups of patients with hypertension.4-6 The aim of this thesis was to obtain data to 
assess whether screening for PA in all patients with newly diagnosed hypertension 
might be useful in Dutch primary care. 
 Because of reported wide variations in the prevalence of PA, we first needed 
to gain insight into the methodologies that were used to assess this prevalence. 
We performed a systematic review and meta-analysis to estimate the prevalence of 
PA in primary care as well as referral centres, and to determine factors that could 
explain the large variety in prevalences. Secondly, we needed to assess the prevalence 
of PA in Dutch primary care, as this information is pertinent for policy making. Thirdly, 
if an excess of cardiovascular damage in PA patients already exists at the time 
hypertension is diagnosed for the first time, this would be an additional argument 
to support early screening. We therefore also aimed to assess the extent of 
cardiovascular damage at the time of diagnosing hypertension. Finally we explored 
the potential of the aldosterone-to-renin ratio (ARR), which we used to screen for PA, 
to predict the presence or absence of an antihypertensive response to the main 
classes of antihypertensive agents in patients in whom PA was excluded. 
 In this closing chapter the main findings of our research are summarized, 
followed by methodological considerations, and a discussion on how our findings 
relate to the previous literature. The chapter ends with clinical implications, 
recommendations for future research, and final conclusions. 
SUMMARY OF THE MAIN FINDINGS
In Chapter 2 we present our systematic review and meta-analysis, in which we 
included 39 studies. These provided data on 42510 patients, of which 5896 patients 
(nine studies) were assessed in primary care. Prevalence estimates varied from 3.2% 
to 12.7% in primary care, and from 1% to 29.8% in referral centers. Heterogeneity was 
too high to provide point estimates (I2 = 57.6% in primary care, and 97.1% in referral 
centers). Meta-regression analysis showed higher prevalences in studies: 1) published 
after 2000, 2) from Australia, 3) aimed at assessing prevalence of secondary 
hypertension, 4) that were retrospective, 5) that selected consecutive patients, and 
6) not using a screening test. This study demonstrates that it is not possible to 
provide an accurate estimate of the prevalence of PA based on previous reports.
 The prevalence of PA in a study in Dutch primary care is described in Chapter 3. 
In this cross-sectional study, we identified 3748 adult patients with a new diagnosis of 
hypertension. Of them, 343 patients were screened for PA according to the Endocrine 
Society guideline.4 In nine out of 74 patients with an elevated ARR and increased 
plasma aldosterone concentration, the diagnosis of PA was confirmed by a saline 
infusion test. The resulting prevalence of 2.6% (95% confidence interval (CI) 1.4% to 
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4.9%) is lower than previously reported in primary care studies. Notably, all patients 
with PA were normokalemic, and eight out of nine patients had a sustained blood 
pressure of >150/100 mmHg. The low proportion of screened patients (9.2%) of the 
large cohort of eligible patients, reflects the difficulty of conducting prevalence 
studies in primary care clinical practice.
 As it was unclear whether cardiovascular complications of excess aldosterone 
secretion are already present at the time of diagnosing hypertension and PA, we 
carried out an explorative study. In this study we assessed patients with PA and a 
matched group of patients with essential hypertension, in whom we applied a set of 
validated non-invasive measurements for cardiovascular function. We present this 
study in Chapter 4. Measurements were performed at the time when hypertension 
was diagnosed, or as soon as possible thereafter. Left ventricular hypertrophy was 
more frequent in patients with PA compared to patients with essential hypertension. 
We did not observe differences between patients with PA and patients with essential 
hypertension in all other parameters (ankle-brachial index, other echocardiographic 
features, flow-mediated vasodilation, carotid intima-media thickness, central aortic 
blood pressure, pulse wave velocity, and urinary albumin-to-creatinine ratio). 
 In Chapter 5 we describe our findings of the level of the ARR in relation to 
the blood pressure response within one year of antihypertensive treatment in 
304 patients. Treatment was categorized into five groups: no medication, use of 
angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker 
(ARB), use of a beta blocker (BB), use of a calcium channel blocker (CCB), or use 
of a diuretic. We did not find an association between the level of the ARR and the 
response in blood pressure within one year of antihypertensive treatment, irrespective 
of the type of antihypertensive treatment. There was also no association between the 
ARR level and the number of patients reaching target blood pressure (defined as 
systolic blood pressure <140 mmHg), and this target was reached in only 31% of the 
treated patients within one year of therapy. Consequently, the ARR cannot serve as 
biomarker to guide antihypertensive therapy. 
METHODOLOGICAL CONSIDERATIONS
systematic review anD meta-analysis
A particular strength of the systematic review (Chapter 2), is that we excluded studies 
that used a confirmation test in less than half of the patients with a positive screening 
test. Not performing a confirmation test indicates a potential of overdiagnosis of PA 
and is at variance with the stepwise approach to the diagnosis of PA, first screening 
and then confirmation, recommended by the Endocrine Society guideline.4 Another 
strength is that we analyzed studies from primary care and referral centres separately, 
as we suspected that the variables that determine the prevalence in these two settings 
were different. 
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 147
147
General discussion and summary
The systematic review has some limitations. It was not possible to build an explanatory 
model with the set of factors derived from the univariate analysis, as the number of 
studies performed in the primary care setting was too low. Another limitation is that 
we could not exclude articles of low quality, as the protocol that we followed for 
quality assessment (the Methodological evaluation of Observational Research, 
MORE) was not developed to ‘weigh’ or to exclude studies. However, it was possible 
to identify those studies which suffered from ‘major flaws’ according to the MORE 
protocol, and we found no difference in prevalences between studies with and 
without major flaws.
stuDies performeD in primary care
The major strength of both our prevalence study (Chapter 3), and the study in which 
we assessed the ARR as a therapeutic marker (Chapter 5), is the primary care study 
setting, as primary care is in most countries the setting in which hypertension is 
typically diagnosed, treated and monitored.7-9 In contrast to prevalence studies in 
referral centers, screening in the primary care setting is not expected to be associated 
with referral bias. Another strength of our design is that specific subgroups in which 
PA may be more prevalent were excluded, such as patients with a hypertensive 
crisis.10 Of additional relevance is the inclusion of patients with newly diagnosed 
hypertension, who were free from antihypertensive medication at the time of inclusion 
when biochemical testing was performed. This enabled us to exclude possible 
confounding effects of such agents on plasma aldosterone and renin.4 Another 
strength was that we used a stringent prospective study protocol. However, despite 
this straightforward clinical protocol, an unbiased selection of patients for screening 
for PA appeared also very hard to achieve in a primary care setting.11-13 Where this 
remains hidden in most studies, we were able to mine the Electronical Health 
Records (EHRs) of the total source population for incomplete screening and possible 
selection bias.14 To our knowledge, this approach has never been reported before in 
primary care studies that addressed the prevalence of PA.
 Our studies inevitably also have limitations. One of the largest bottlenecks we 
experienced was the limited compliance of general practitioners (GPs) to refer all 
patients with newly diagnosed hypertension for screening of PA, which resulted in a 
low proportion of patients who were really screened. This might be due to several 
causes, such as high administrative work load for GPs, and insufficient personnel 
support.15 Since we had not expected this lack of ‘inclusion compliance’ at this scale, 
identifying the reasons for it was not part of our study. Another limitation concerns 
the reliability and validity of the screening test. The ARR is generally considered the 
best screening test for hypertensive patients who have a clinical suspicion of PA, and 
it is the screening test of choice as recommended by the Endocrine Society 
guideline.4,16 Since its reliability as a screening test has been challenged,17 we tried 
to overcome a potential insufficient sensitivity by decreasing the cut-off values for the 
ARR. In addition, a practical drawback was the change of the aldosterone assay 
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during the study, resulting in a slight change in reference values. However, we could 
not demonstrate any impact of this change on the results of our study. 
 Selection bias was assessed by the use of International Classification of Primary 
Care (ICPC) codes from the EHRs. These ICPC codes depend on the quality of 
recording. As GPs may not always assign an ICPC code for hypertension,18,19 patients 
with elevated blood pressure at more than two occasions without an ICPC code were 
also included in our study. This case finding may have been too sensitive as we found 
3748 patients with newly diagnosed hypertension, whereas based on the total study 
sample and the inclusion period we expected 2758 patients with newly diagnosed 
hypertension.20 Moreover, we were only allowed to extract specific tables from the 
EHRs, as we had no access to free text due to privacy regulations. Hence, if GPs 
failed to note blood pressure measurements and laboratory results in the correct 
table of the EHR, this led to missing data in our baseline characteristics, thus to the 
loss of patients or data for the analyses. Finally, it was not possible to check in the 
EHRs whether lifestyle advice was indeed given, nor whether attention was paid to 
the adherence to the lifestyle advice as part of the follow-up. 
carDiovascular Damage stuDy
In our explorative study on cardiovascular damage we used multiple well-established 
and sensitive techniques to assess cardiovascular organ damage (Chapter 4). In addition, 
the diagnoses of PA and essential hypertension were based on stringent criteria 
according to the Endocrine Society guideline.4 Moreover, in the patients with PA and 
essential hypertension cardiovascular organ damage was assessed at the first time 
when the diagnosis of hypertension were made, or as soon as possible thereafter.
 A major limitation is the low power for all outcome measures due to the small 
number of patients we could enroll. Although we expected to recruit 40 newly 
diagnosed patients with PA in the prevalence study of Chapter 3, only six patients 
could be included. This was due to: 1) the low recruitment of patients in our prevalence 
study, which resulted in a lower than expected absolute number of patients with PA, 
2) the lower than expected prevalence we found,21 and 3) a drop-out of three out of 
nine patients with PA for various reasons. Despite the small sample size, two patients 
with newly diagnosed hypertension and PA had left ventricular hypertrophy. This 
contrasts to the control group of hypertensive patients without PA, of whom none 
showed left ventricular hypertrophy. Another limitation was that some patients with 
hypertension had been treated for some time when the echocardiography was 
performed. Treatment related regression of eventual left ventricular hypertrophy 
might have resulted in underestimation of patients with early cardiac damage.22,23 
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HOW DO OUR FINDINGS RELATE TO PREVIOUS STUDIES?
systematic review anD meta-analysis
Previous reviews and meta-analysis studies reported mean prevalences of PA.24-26 
However, our study shows that calculating mean prevalences was not possible due 
to gross heterogeneity across studies, and this applies to both primary care as well 
as referral centres. Several factors were responsible for the reported variations in 
prevalence of PA. Studies carried out in referral centers published after the year 2000 
showed approximately a nine times higher chance to find a higher prevalence than 
studies published before 2000, and this was independent from other factors. This 
might be explained by increasing awareness of the presence of PA over time, and by 
the use of different cut-offs for the screening and confirmation tests.27 The very first 
studies that investigated the prevalence of PA were performed in centers in Australia 
in self-selected patients or on the basis of retrospective data.28,29 This might partially 
explain why studies from Australia have a more than five times higher chance to find 
a higher prevalence than studies that were carried out in Europe. An alternative 
explanation is that the prevalence of PA is indeed higher in Australia.
 Our finding that retrospective studies report higher prevalences than prospective 
ones suggests that the current ‘epidemic’ of PA is partly explained by reliance on 
retrospective studies.30 It illustrates that prospective studies are more reliable to 
estimate prevalences.31
 The Endocrine Society guideline advocates adjustment of antihypertensive 
agents before screening, as plasma aldosterone and renin may be affected by this 
medication.4 In contrast, several studies have suggested that screening and 
confirmation testing is still reliable when patients continue their antihypertensive 
medication during testing.32,33 Our meta-regression model confirms that adjustment 
of medication regimen has no effect on the prevalence of PA. Although this casts 
doubt on the recommendation of the Endocrine Society guideline, good comparative 
studies are lacking and therefore adapting the medication regimen as proposed by 
the Endocrine Society still seems the most appropriate way to screen for PA.
prevalence stuDy
The prevalence of PA of 2.6% in our study appeared to be lower than might be 
expected from previously published prevalence studies carried out in primary care. 
In the latter studies in which at least half of the patients had undergone a confirmation 
test for PA, the prevalence varied from 3.2% to 11.5%.28,34-42 Several explanations 
for the lower prevalence in our study have to be considered. First, we restricted our 
study sample to patients with newly diagnosed hypertension. We found two studies 
that also restricted their study population to patients with newly diagnosed 
hypertension.36,41 Omura et al. aimed to assess the prevalence of secondary 
hypertension among patients with newly diagnosed hypertension, and found a 
prevalence of PA of 6%.36 According to our meta-analysis (Chapter 2), studies 
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showed higher prevalences of PA if the study objective was to assess the prevalence 
of secondary hypertension. Although in this meta-analysis we were only able to 
determine responsible factors for higher prevalences in referral centres, it might be 
very well possible that (some of) these factors also apply to primary care. Moreover, 
the higher prevalence in this study may be explained by insufficiently defined 
confirmatory testing, which may have confounded their results. Another explanation 
is that the prevalence of PA is indeed higher in Japan. Westerdahl et al. confirmed a 
diagnosis of hypertension by a 24-hour ambulatory blood pressure monitoring 
(ABPM; inclusion if the blood pressure was >140/90 mmHg), and found a prevalence 
of PA of 5.5%.41 The higher prevalence found in this study might be explained by the 
confirmation of a diagnosis of hypertension by an ABPM using a higher cut-off level 
for hypertension than usual.43 As a result, their study population consisted of patients 
with more severe hypertension, and PA is known to be more prevalent in more severe 
hypertension.4 In our study we did not confirm the diagnosis by ABPM, as in Dutch 
primary care an ABPM is not considered mandatory to confirm a diagnosis of 
hypertension.9 Moreover, we aimed to interfere minimally in daily clinical practice in 
this study. Therefore, it might be possible that we performed screening of PA in 
patients with a false-positive diagnosis of hypertension (e.g. white-coat hypertension).
 Second, our lower prevalence might be due to our quite strict cut-off for the 
confirmation test of 280 pmol/L (10 ng/dL) for aldosterone, which is in accordance 
with the recommendations of the Endocrine Society guideline.4 Using a strict cut-off 
level may result in a lower prevalence, and in higher numbers of false-negative test 
outcomes. Lower cut-offs have also been proposed by several other studies.44,45 
However, as sensitivity is a prerequisite for screening, we deliberately chose a 
relatively low screening cut-off of 40 pmol/mU for the ARR, as the higher ARR cut-off 
as suggested by the Endocrine Society may lack sufficient sensitivity.17,46-49 To 
improve specificity we added the extra requirement of a minimum plasma aldosterone 
level of 400 pmol/L to the screening test.50 
 Third, in our study 26 patients (7.6%) had an elevated ARR with a plasma 
aldosterone lower than 400 pmol/L. Therefore, these patients did not qualify for a 
confirmation test. Adding the ‘elevated plasma aldosterone criterion’ is subject to 
debate, as some patients with PA do not have increased aldosterone levels above the 
upper reference limit (400 pmol/L).51 It remains to be established whether this group 
of 26 patients included some patients with PA. Therefore, adding this criterion might 
have contributed to our lower prevalence. 
 Fourth, in our study the screened patients were younger and had higher blood 
pressures as compared to non-screened patients. This indicates that GPs introduced 
some selection bias, as they tested mainly patients who were young and who had a 
more severely increased blood pressure. It seems that they intuitively followed the 
screening recommendations of the Endocrine Society guideline.4 This might have 
resulted in an underestimation of the proportion of patients with PA. In addition, for 
unknown reasons GPs were less likely to perform biochemical screening in patients 
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with newly diagnosed hypertension who had suffered a stroke in the past. Possibly, 
GPs might have had the misconception that testing patients who already had a 
stroke was not useful anymore. Alternatively, it might be that GPs considered stroke 
as ‘severe comorbidity’, which was an exclusion criterion for participation in our 
study. It is conceivable that all this selective screening has contributed to an 
underestimation of the real prevalence of PA. Our experience in the current study 
raises the question whether similar potential selection bias might have confounded 
previously published primary care studies on the prevalence of PA.
 Although previously thought to be a prerequisite for a diagnosis of PA, current 
literature shows that in general 9% to 37% of all patients with PA have hypokalemia.52 
In line with previous studies our results show that hypokalemia is not a reliable clinical 
clue for PA, as in our study none of the patients with PA had hypokalemia. This 
implies that normokalemia does not exclude PA and therefore, the current strategy in 
Dutch primary care to consider PA in hypertensive patients with hypokalemia, is no 
longer valid.
carDiovascular Damage stuDy
Since the nineties it became increasingly clear that cardiovascular damage in 
patients with PA is more extensive than in patient with essential hypertension with 
similar blood pressure levels. Milliez et al. matched patients with essential 
hypertension and patients with PA for gender, age and systolic blood pressure, and 
found that cardiovascular damage was more prevalent in patients with PA.53 It was 
hypothesized that this damage was causally related to the high level of aldosterone. 
Our study suggests that cardiac hypertrophy might be present at an early stage of 
PA, when hypertension is diagnosed for the first time, and that this is unrelated to the 
blood pressure level (Chapter 4). A recently published paper by Monticone et al. 
claims that there are alternative pathogenetic mechanisms to blood pressure or the 
mineralocorticoid receptor-mediated effects of aldosterone that enhance 
cardiovascular damage in patients with PA.54 The variety of pathogenetic 
mechanisms for cardiovascular damage in patients with PA explains why regular 
antihypertensive therapy is ineffective, and mineralocorticoid receptor antagonist 
treatment is less effective than adrenalectomy.55-58 Previous studies have also 
shown that young age and a short duration of hypertension are the most important 
predictors of successful outcome of treatment. 59-62 This all implies not only that 
there is a strong rationale for detecting PA as early as possible, but also that it is 
worthwhile to identify those patients with PA who benefit most from adrenalectomy.63
stuDy of alDosterone-to-renin ratio for guiDing antihypertensive treatment 
In our study with 304 patients we did not find an association between the level of the 
ARR and the response in blood pressure within one year of antihypertensive 
treatment, and this applied to all studied classes of antihypertensive agents (Chapter 
5). It should be noted that in our study not a single patient was treated with a 
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mineralocorticoid antagonist, as in the Netherlands mineralocorticoid receptor 
antagonists are not used in primary care as monotherapy in essential hypertension.64 
As we provided no instructions to the participating practices about the use of specific 
antihypertensive agents, our study reflects daily clinical practice. 
 Although it has been suggested that hypertensive patients with a high ARR 
respond favourably to spironolactone,65,66 several studies in hypertensive patients 
could not confirm this. Parthasarathy et al. studied the antihypertensive response of 
spirono lactone compared to bendroflumethiazide in two groups of antihypertensive 
patients, one with high and one with low ARR, and the level of the ARR did not predict 
the anthypertensive effects of both drugs. However, patients with high ARR were not 
tested for PA, and participants were not newly diagnosed hypertensive patients.67 
Prisant et al. performed a placebo-controlled trial to assess whether baseline ARR 
levels could predict the antihypertensive response of add-on eplerenone to the use 
of ACE-I or ARB, but did not find one of the arms to be superior.68 We did not find 
studies that assessed the association of the ARR and blood pressure response in 
newly diagnosed hypertensive patients, and in particular examining the effect of the 
blood pressure response to the classes of hypertensive agents that are used in 
primary care (ACE-I, ARB, BB, CCB, thiazide diuretic).
 An additional and disturbing finding in our study was that the proportion of 
treated patients that had reached target blood pressure within one year after the 
diagnosis of hypertension was low (31%). This result is in agreement with other 
European studies, in which the proportions of patients reaching target blood pressure 
varied from 22% to 50%.69,70 The low proportion of patients who had reached target 
blood pressure limits our conclusion regarding the predictive value of the ARR for 
the antihypertensive effect. 
 Although lifestyle advice is recommended for each patient with hypertension by 
the Dutch Guideline for Cardiovascular Risk Management (Dutch CVRM guideline), 
we were not able to extract these data from the EHRs. It remains possible that the 
decline in blood pressure in the group who received no medication at all, was the 
result of adherence to advised lifestyle changes.71,72
CLINICAL IMPLICATIONS
In our study described in Chapter 3, we found a prevalence of PA of 2.6% (95% CI 
1.4% to 4.9%) in patients with newly diagnosed hypertension, in whom a few had 
already left ventricular hypertrophy (Chapter 4). Based on these data, systematic 
screening of new hypertensive patients would be expected to result in approximately 
1100 to 3700 new patients with PA per year in the Netherlands.73,74 The majority of 
these patients will not be discovered when the Dutch CVRM guideline is followed. 
This guideline recommendation for case finding of PA relies mainly on the presence 
of hypokalemia, and therapy resistant hypertension.9 However, hypokalemia cannot 
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be used for this purpose, as it is only present in 9% to 37% of all patients with PA,52 
and in none of the patients we identified in our study. Consequently, most patients 
would be missed if one would rely on the presence of hypokalemia.
 To assess whether implementing screening of all patients with newly diagnosed 
hypertension is useful, the criteria for screening as defined by Wilson and Jungner75 
should specifically be applied to PA. Although these criteria are fulfilled to some 
extent, the lack of reliable data precludes assessment of other criteria (Table 1). 
Indeed, PA confers an important health problem since it affects a large absolute number 
of new patients per year, who run an elevated risk of progressive cardiovascular 
damage, with an associated poor quality of life, when PA is not timely and properly 
treated. Initial diagnostic screening is feasible, as there is a simple blood test that 
can be easily incorporated in the current standard hypertension protocol in primary 
care. Further confirmation or exclusion of PA is already clinical practice in the referral 
centers, and there is clear evidence that the currently accepted treatment options are 
very effective, resulting in an improved long-term outcome for patients.63,76-80
 Although several arguments support early screening of all patients with newly 
diagnosed hypertension, there are also several compelling and valid arguments to 
refrain from systematic screening. One is that health care facilities will face an 
increased work load for GPs as well as for specialists due to additional confirmatory 
testing and associated subsequent treatment, while benefit is still uncertain. In 
addition, the most important argument is the lack of convincing and reliable data that 
provide insight in the cost-effectiveness of such approach. Cost-effectiveness 
studies have already shown positive results of screening for PA in specific groups 
with an increased risk of PA, such as patients with resistant hypertension,81,82 but are 
absent for the approach we explored in this study. The costs involve not only those 
of biochemical screening and confirmation testing, but also of subtype differentiation, 
including expensive procedures such as adrenal venous sampling. The costs of 
treatment (such as adrenalectomy) and proper follow-up should also be taken into 
account. The benefits for the patient of early screening for PA involves an improvement 
in quality of life, and a reduction in cardiovascular and renal complications on the 
long-term. Intuitively, this reduction in PA-related morbidity and mortality is expected 
to more than compensate for the healthcare and societal costs that are associated 
with early diagnosis and treatment of PA.
 Taking all pros and cons into consideration, and applying the criteria of Wilson 
and Jungner,75 we cannot advise screening for PA in primary care in all patients with 
newly diagnosed hypertension. As there are clearly defined subgroups of patients 
with an increased risk of PA, as described by the Endocrine Society guideline (Table 2), 
we do suggest to adjust the Dutch CVRM guideline by incorporating these subgroups 
that need to be screened for PA.4 If such a strategy would be implemented in primary 
care, this would lead to screening for PA in approximately 50% of all hypertensive 
patients.84
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Table 1  Arguments for early detection of primary aldosteronism in new 
hypertensive patients according to the criteria of Wilson and Jungner75
1. The condition sought should be an important health problem.
PA is an important health problem. As shown in our study, the prevalence of PA 
in newly diagnosed hypertensive patients in primary care is 1.4% to 4.9%, which 
translates in approximately 1100 to 3700 new patients with PA per year in the 
Netherlands. In addition, PA carries a high risk of cardiovascular complications, and 
untreated PA is associated with a poor quality of life.
2. There should be an accepted treatment for patients with recognized disease.
There are highly effective treatments available for patients with PA.
3. Facilities for diagnosis and treatment should be available.
In the Netherlands healthcare facilities for diagnosis and treatment of PA are widely 
available.
4. There should be a recognizable latent or early symptomatic stage.
Early symptoms consist of hypertension, and in some patients of hypokalemia. In 
addition, our study has shown that cardiovascular damage is already present in the 
initial phase of PA.
5. There should be a suitable test or examination.
A suitable test is available for screening: a venous blood sample for measurement of 
aldosterone and renin.
6. The test should be acceptable to the population.
The screening test can be performed in primary care by adding the test to the 
standard laboratory tests, which are performed when hypertension is diagnosed.
7. The natural history of the condition, including development from latent to declared 
disease, should be adequately understood.
The pathogenetic mechanism of PA, and development from latent to declared disease, 
are reasonably well understood. 
8. There should be an agreed policy on whom to treat as patients.
After screening a confirmation test will confirm or refute the diagnosis of PA, thus 
guiding which patients will benefit of PA specific treatment.
9. The cost of case finding (including diagnosis and treatment of patients diagnosed) 
should be economically balanced in relation to possible expenditure on medical care 
as a whole.
Previous studies in patients with resistant hypertension have shown that an early 
diagnosis of PA is cost-effective,81,83 but it is unknown if this is valid for patients with 
newly diagnosed hypertension.
10. Case-finding should be a continuing process and not a “once and for all” project.
Screening for PA can be easily incorporated in standard hypertension care.
In italic, the original criterion as formulated by Wilson and Jungner.
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FUTURE RESEARCH
From all considerations described above we propose to perform further studies to 
determine the utility and benefits of screening for PA in all newly diagnosed hyper- 
tensive patients in primary care. To this end GPs and medical specialists should join 
efforts. Such collaboration of primary care and referral centres is necessary, as GPs 
have access to the target population of hypertensive patients, and medical specialists 
have the expertise for the diagnostic work-up and initiation of treatment. Such studies 
should adopt a similar design as the study described in Chapter 3, and should be 
carried out in patients with newly diagnosed untreated hypertension. A major and 
essential component is to incorporate the collection of data on costs and effectiveness. 
The latter should also include the assessment of quality of life. Therefore, active 
participation of patients or patients’ advocacy groups in the design of such a study 
should be sought. Given the suboptimal recruitment rate and the biased inclusion of 
patients in the present study, exploration of reasons for that by focus groups with 
GPs is mandatory and the design and the execution of such studies should be 
adapted to prevent lagging and biased recruitment as much as possible. 
CONCLUSION
Indiscriminate screening for PA of all patients who are diagnosed with new hyper- 
tension in primary care cannot be recommended based on the results of this thesis, 
as not all criteria of Wilson and Jungner for screening are fullfilled. The prevalence of 
PA is reasonably well established, and PA seems associated with left ventricular 
Table 2  Recommendation for screening for primary aldosteronism according to  
the Endocrine Society guideline4
Patients with a high prevalence of PA include those with:
• sustained BP above 150/100 mmHg* 
• resistant hypertension (BP >140/90 mmHg)#
• controlled BP (<140/90 mmHg) on four or more antihypertensive drugs
• hypertension and spontaneous or diuretic-induced hypokalemia
• hypertension and an adrenal incidentaloma
• hypertension and sleep apnea
• hypertension and a family history of early onset hypertension or cerebrovascular accident at 
a young age (<40 years)
• all first-degree relatives of patients with PA
*on different days. #resistant to three conventional antihypertensive drugs (including a diuretic). BP, blood 
pressure. PA, primary aldosteronism. 
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hypertrophy at the time of the diagnosis of new hypertension. A cost-effectiveness 
analysis including all costs and long term benefits is required to determine whether 
screening for PA of all (new) hypertensive patients should be implemented in primary 
care. For the time being, focused screening of selected hypertensive patients with an 
increased risk of PA should be encouraged as recommended by the Endocrine 
Society guideline. To improve the detection rate, early treatment, and final outcome 
of patients with PA, the Dutch CVRM guideline should consider to adopt the 
recommendations of the Endocrine Society guideline.
key messages
1) Primary aldosteronism is present in 1.4% to 4.9% of patients with newly diagnosed 
hypertension in primary care.
2) Focussing on only hypokalemia will miss most patients with primary aldosteronism, 
and therefore lack of hypokalemia cannot be used to exclude PA.
3) In newly diagnosed hypertensive patients with PA, left ventricular hypertrophy 
seems more prevalent than in a comparable group of patients with essential 
hypertension, suggesting more rapid development of cardiovascular damage 
than in essential hypertension.
4) At this moment, screening for PA in primary care should be preserved for specific 
subgroups as recommended by the Endocrine Society guideline. We suggest to 
adopt these recommendations for screening by the Dutch CVRM guideline.
5) The ARR is not a useful biomarker to guide antihypertensive treatment.
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 157
157
General discussion and summary
REFERENCES
1. Maiolino G, Calo LA, Rossi GP. The Time has Come for Systematic Screening for Primary Aldosteronism 
in All Hypertensives. J Am Coll Cardiol 2017;69:1821-3.
2. Gordon RD, Stowasser M. Primary aldosteronism: the case for screening. Nat Clin Pract Nephrol 
2007;3:582-3.
3. Nishikawa T, Saito J, Omura M. Prevalence of primary aldosteronism: should we screen for primary 
aldosteronism before treating hypertensive patients with medication? Endocr J 2007;54:487-95.
4. Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, 
Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 
2016;101:1889-916.
5. Williams TA, Reincke M. MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and Management of 
Primary Aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol 2018.
6. Monticone S, Viola A, Tizzani D, et al. Primary aldosteronism: who should be screened? Horm Metab 
Res 2012;44:163-9.
7. van Dis I, Kromhout D, Geleijnse JM, Boer JM, Verschuren WM. Evaluation of cardiovascular risk 
predicted by different SCORE equations: the Netherlands as an example. Eur J Cardiovasc Prev Rehabil 
2010;17:244-9.
8. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. 
CG127. London: NICE, 2016. https://www.nice.org.uk/guidance/cg127 (accessed 15 April 2018)
9. Collaboration group Cardiovascular Risk Management. Dutch Guideline Cardiovascular Risk 
Management. (Second review). Huisarts en Wetenschap 2012;55:14-28.
10. Börgel J, Springer S, Ghafoor J, et al. Unrecognized secondary causes of hypertension in patients with 
hypertensive urgency/emergency: prevalence and co-prevalence. Clin Res Cardiol 2010;99:499-506.
11. Nilsson G, Mooe T, Soderstrom L, Samuelsson E. Use of exercise tests in primary care: importance for 
referral decisions and possible bias in the decision process; a prospective observational study. BMC 
Fam Pract 2014;15:182.
12. Lebeau JP, Cadwallader JS, Vaillant-Roussel H, et al. General practitioners’ justifications for therapeutic 
inertia in cardiovascular prevention: an empirically grounded typology. BMJ Open 2016;6:e010639.
13. Ng KP, Jain P, Gill PS, et al. Results and lessons from the Spironolactone To Prevent Cardiovascular 
Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial. BMJ Open 
2016;6:e010519.
14. Biermans MC, Spreeuwenberg P, Verheij RA, de Bakker DH, de Vries Robbe PF, Zielhuis GA. Striking 
trends in the incidence of health problems in The Netherlands (2002-05). Findings from a new strategy 
for surveillance in general practice. Eur J Public Health 2009;19:290-6.
15. Poggenburg S, Reinisch M, Hofler R, Stigler F, Avian A, Siebenhofer A. General practitioners in Styria - 
who is willing to take part in research projects and why? : A survey by the Institute of General Practice 
and Health Services Research. Wien Klin Wochenschr 2017;129:823-34.
16. Tiu SC, Choi CH, Shek CC, et al. The use of aldosterone-renin ratio as a diagnostic test for primary 
hyperaldosteronism and its test characteristics under different conditions of blood sampling. Journal of 
Clinical Endocrinology & Metabolism 2005;90:72-8.
17. Jansen PM, van den Born BJ, Frenkel WJ, et al. Test characteristics of the aldosterone-to-renin ratio as 
a screening test for primary aldosteronism. J Hypertens 2014;32:115-26.
18. Hripcsak G, Knirsch C, Zhou L, Wilcox A, Melton G. Bias associated with mining electronic health 
records. J Biomed Discov Collab 2011;6:48-52.
19. Jordan K, Jinks C, Croft P. Health care utilization: measurement using primary care records and patient 
recall both showed bias. J Clin Epidemiol 2006;59:791-7.
20. van der Linden MW WG, de Bakker DH, Schellevis FG. Tweede Nationale Studie naar ziekten en 
verrichtingen in de huisartspraktijk. Klachten en aandoeningen in de bevolking en in de huisartspraktijk. 
Utrecht/Bilthoven: NIVEL/RIVM, 2004.
21. Käyser SC, Deinum J, de Grauw WJ, et al. Prevalence of primary aldosteronism in primary care: a cross-
sectional study. Br J Gen Pract 2018;68:e114-e22.
22. Rossi GP, Cesari M, Cuspidi C, et al. Long-term control of arterial hypertension and regression of left 
ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013;62:62-9.
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 158
158
Chapter 6
23. Cesari M, Cicala MV, Seccia MT, Mantero F, Pessina AC, Rossi GP. LONG-term changes of left ventricular 
diastolic function after adrenalectomy or medical treatment for primary aldosteronism. J Hypertens 
2010;28:e302.
24. Jansen PM, Boomsma F, van den Meiracker AH. Aldosterone-to-renin ratio as a screening test for 
primary aldosteronism--the Dutch ARRAT Study. Neth J Med 2008;66:220-8.
25. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in 
population-based studies--a review of the current literature. Horm Metab Res 2012;44:157-62.
26. Plouin PF, Amar L, Chatellier G. Trends in the prevalence of primary aldosteronism, aldosterone-
producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial 
Transplant 2004;19:774-7.
27. Raizman JE, Diamandis EP, Holmes D, Stowasser M, Auchus R, Cavalier E. A renin-ssance in primary 
aldosteronism testing: obstacles and opportunities for screening, diagnosis, and management. Clin 
Chem 2015;61:1022-7.
28. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may 
not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol 
Physiol 1993;20:296-8.
29. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism 
in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994;21:315-8.
30. Kaplan NM. Is there an unrecognized epidemic of primary aldosteronism? Con. Hypertension 
2007;50:454-8; discussion -8.
31. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS 
Med 2008;5:e67.
32. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on 
aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary 
aldosteronism. Clin Endocrinol (Oxf) 2002;57:457-65.
33. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary 
aldosteronism. Hypertension 2002;40:897-902.
34. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF, Jr. Prevalence of primary aldosteronism among 
Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000;85:2854-9.
35. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension 
2003;42:161-5.
36. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of 
secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. 
Hypertens Res 2004;27:193-202.
37. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic 
accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 
2005;51:386-94.
38. Westerdahl C, Bergenfelz A, Isaksson A, Wihl A, Nerbrand C, Valdemarsson S. High frequency of primary 
hyperaldosteronism among hypertensive patients from a primary care area in Sweden. Scand J Prim 
Health Care 2006;24:154-9.
39. Williams JS, Williams GH, Raji A, et al. Prevalence of primary hyperaldosteronism in mild to moderate 
hypertension without hypokalaemia. J Hum Hypertens 2006;20:129-36.
40. Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, Mugellini A. Prevalence of primary aldosteronism among 
unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio 
above 25 as a screening test. Hypertens Res 2007;30:111-7.
41. Westerdahl C, Bergenfelz A, Isaksson A, Nerbrand C, Valdemarsson S. Primary aldosteronism among 
newly diagnosed and untreated hypertensive patients in a Swedish primary care area. Scand J Prim 
Health Care 2011;29:57-62.
42. Monticone S, Burrello J, Tizzani D, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism 
Encountered in Primary Care Practice. J Am Coll Cardiol 2017;69:1811-20.
43. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial 
hypertension: the Task Force for the management of arterial hypertension of the European Society of 
Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357.
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 159
159
General discussion and summary
44. Rossi GP, Belfiore A, Bernini G, et al. Prospective evaluation of the saline infusion test for excluding 
primary aldosteronism due to aldosterone-producing adenoma. J Hypertens 2007;25:1433-42.
45. Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests 
in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006;24:737-45.
46. Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: 
implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002;48:1919-23.
47. Letavernier E, Peyrard S, Amar L, Zinzindohoue F, Fiquet B, Plouin PF. Blood pressure outcome of 
adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J 
Hypertens 2008;26:1816-23.
48. Perschel FH, Schemer R, Seiler L, et al. Rapid screening test for primary hyperaldosteronism: Ratio of 
plasma aldosterone to renin concentration determined by fully automated chemiluminescence 
immunoassays. Clin Chem 2004;50:1650-5.
49. Manolopoulou J, Fischer E, Dietz A, et al. Clinical validation for the aldosterone-to-renin ratio and 
aldosterone suppression testing using simultaneous fully automated chemiluminescence 
immunoassays. J Hypertens 2015;33:2500-11.
50. Seiler L, Rump LC, Schulte-Monting J, et al. Diagnosis of primary aldosteronism: value of different 
screening parameters and influence of antihypertensive medication. European Journal of Endocrinology 
2004;150:329-37.
51. Stowasser M, Gordon RD. Primary Aldosteronism: Changing Definitions and New Concepts of 
Physiology and Pathophysiology Both Inside and Outside the Kidney. Physiol Rev 2016;96:1327-84.
52. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including 
surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004;89:1045-50.
53. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of 
cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-8.
54. Monticone S, D’Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary 
aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet 
Diabetes Endocrinol 2018;6:41-50.
55. Velema M, Dekkers T, Hermus A, et al. Quality of Life in Primary Aldosteronism: A Comparative 
Effectiveness Study of Adrenalectomy and Medical Treatment. J Clin Endocrinol Metab 2018;103:16-24.
56. Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary 
aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison 
with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol 
Metab 2011;96:2904-11.
57. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in 
medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 
2018;6:51-9.
58. Rossi GP, Maiolino G, Flego A, et al. Adrenalectomy Lowers Incident Atrial Fibrillation in Primary 
Aldosteronism Patients at Long Term. Hypertension 2018;71:585-91.
59. Streeten DH, Anderson GH, Jr., Wagner S. Effect of age on response of secondary hypertension to 
specific treatment. Am J Hypertens 1990;3:360-5.
60. Celen O, O’Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary 
aldosteronism. Arch Surg 1996;131:646-50.
61. Lumachi F, Ermani M, Basso SM, Armanini D, Iacobone M, Favia G. Long-term results of adrenalectomy 
in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved 
hypertension and review of the literature. Am Surg 2005;71:864-9.
62. Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary 
aldosteronism: an international consensus on outcome measures and analysis of remission rates in an 
international cohort. Lancet Diabetes Endocrinol 2017;5:689-99.
63. Reincke M. Anxiety, Depression, and Impaired Quality of Life in Primary Aldosteronism: Why We 
Shouldn’t Ignore It! J Clin Endocrinol Metab 2018;103:1-4.
64. Bazoukis G, Thomopoulos C, Tsioufis C. Effect of mineralocorticoid antagonists on blood pressure 
lowering: overview and meta-analysis of randomized controlled trials in hypertension. J Hypertens 
2018;36:987-94.
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 160
160
Chapter 6
65. Lim PO, Jung RT, MacDonald TM. Is aldosterone the missing link in refractory hypertension?: aldosterone-
to- renin ratio as a marker of inappropriate aldosterone activity. J Hum Hypertens 2002;16:153-8.
66. Brown MJ. Matching the right drug to the right patient in essential hypertension. Heart 2001;86:113-20.
67. Parthasarathy HK, Alhashmi K, McMahon AD, et al. Does the ratio of serum aldosterone to plasma renin 
activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypertens 2010;28:170-7.
68. Prisant LM, Krum H, Roniker B, Krause SL, Fakouhi K, He W. Can renin status predict the antihypertensive 
efficacy of eplerenone add-on therapy? J Clin Pharmacol 2003;43:1203-10.
69. Torma E, Carlberg B, Eriksson M, Jansson JH, Eliasson M. Long term trends in control of hypertension in 
the Northern Sweden MONICA study 1986-2009. BMC Public Health 2015;15:957.
70. Hedblad B, Nerbrand C, Ekesbo R, et al. High blood pressure despite treatment: results from a cross-
sectional primary healthcare-based study in southern Sweden. Scand J Prim Health Care 2006;24:224-30.
71. Aronow WS. Lifestyle measures for treating hypertension. Arch Med Sci 2017;13:1241-3.
72. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood 
pressure control: main results of the PREMIER clinical trial. JAMA 2003;289:2083-93.
73. Centraal Bureau voor de Statistiek. Kerncijfers bevolking 2016. http://statline.cbs.nl/StatWeb/publication
/?VW=T&DM=SLNL&PA=37296ned&D1=a&D2=0,10,20,30,40,50,60,( l -1),l&HD=130605-
0924&HDR=G1&STB=T (accessed 28 May 2018).
74. Nivel zorgregistraties eerste lijn, incidenties en prevalenties 2016. https://www.nivel.nl/nl/nzr/incidenties-
en-prevalenties (accessed 28 May 2018).
75. Wilson JM, Jungner G. Principles and practice of screening for disease. World Health Organization 
1968;Public Health Papers No. 34:p 26-7.
76. Byrd JB. Primary Aldosteronism in the Primary Care Clinic: Rife or Rare? Endocr Pract 2016;22:1350-2.
77. Brown MJ. Primary Aldosteronism: the spectre of cure. Clin Endocrinol (Oxf) 2015;82:785-8.
78. Funder JW. Primary Aldosteronism: Seismic Shifts. J Clin Endocrinol Metab 2015;100:2853-5.
79. Velema MS, de Nooijer AH, Burgers VWG, et al. Health-Related Quality of Life and Mental Health in 
Primary Aldosteronism: A Systematic Review. Horm Metab Res 2017;49:943-50.
80. Sukor N, Kogovsek C, Gordon RD, Robson D, Stowasser M. Improved quality of life, blood pressure, and 
biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin 
Endocrinol Metab 2010;95:1360-4.
81. Lubitz CC, Economopoulos KP, Sy S, et al. Cost-Effectiveness of Screening for Primary Aldosteronism 
and Subtype Diagnosis in the Resistant Hypertensive Patients. Circ Cardiovasc Qual Outcomes 
2015;8:621-30.
82. Sato M, Morimoto R, Seiji K, et al. Cost-Effectiveness Analysis of the Diagnosis and Treatment of Primary 
Aldosteronism in Japan. Horm Metab Res 2015;47:826-32.
83. Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary 
hyperaldosteronism. Br J Surg 2002;89:1587-93.
84. Mulatero P, Monticone S, Burrello J, Veglio F, Williams TA, Funder J. Guidelines for primary aldosteronism: 
uptake by primary care physicians in Europe. J Hypertens 2016;34:2253-7.
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 161
161
General discussion and summary
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 162
524305-L-bw-Kayser




Processed on: 24-9-2018 PDF page: 164
524305-L-bw-Kayser




Dit proefschrift gaat over de vraag of het zinvol is om in de huisartspraktijk patiënten 
met een nieuw ontdekte verhoogde bloeddruk te screenen op primair hyperaldostero-
nisme (PHA). PHA is een aandoening die wordt veroorzaakt door een afwijking in één 
of beide bijnieren. Verhoogde bloeddruk, ook wel hypertensie genoemd, is vaak het 
enige symptoom van PHA. Deze Nederlandstalige samenvatting start met informatie 
over hypertensie. Daarna wordt beschreven wat PHA is en waarom het belangrijk is dat 
deze diagnose tijdig wordt gesteld. Aansluitend volgt de inhoud van dit proefschrift.
hypertensie
Hypertensie is de grootste risicofactor voor ziektelast bij zowel mannen als vrouwen 
en is medeverantwoordelijk voor 9,4 miljoen doden per jaar wereldwijd. De prevalentie 
(=hoe vaak het voorkomt) van hypertensie in Nederland is ongeveer 30%. Dit betekent 
dat 30 van de 100 mensen een te hoge bloeddruk hebben. Met het stijgen van de 
leeftijd neemt de prevalentie toe tot ongeveer 45%. Van de mensen met hypertensie 
heeft 85% tot 90% een verhoogde bloeddruk waarbij geen specifieke oorzaak te 
vinden is. Dit heet essentiële hypertensie. Echter, in 10% tot 15% van de gevallen is er 
wel een oorzaak te vinden. Dit wordt secundaire hypertensie genoemd. PHA is één 
van die specifieke oorzaken van verhoogde bloeddruk.
 De huisartsenrichtlijn in Nederland (=NHG-standaard ‘Cardiovasculair risico-
management’) stelt dat hypertensie gediagnosticeerd wordt op basis van het 
gemiddelde van tenminste twee verschillende bloeddrukmetingen op twee ver schillende 
momenten. Bij zo’n bloeddrukmeting wordt de meetwaarde weergegeven in twee 
getallen: de bovendruk (systolische bloeddruk) en de onderdruk (diastolische 
bloeddruk), waarbij de bovendruk altijd als eerste wordt genoemd. In de huisarts praktijk 
is de afkapwaarde voor een verhoogde bloeddruk een bovendruk >140 mmHg 
(150-160 mmHg bij patiënten vanaf 80 jaar). 
 Chronische hypertensie leidt tot atherosclerose (=(slag)aderverkalking)), verdikking 
van de hartspier en nierschade. Hierdoor stijgt de kans op het krijgen van hart- en 
vaatziekten (bijvoorbeeld een beroerte, of hartinfarct). De meeste mensen merken 
niet dat ze hypertensie hebben, omdat een verhoogde bloeddruk meestal geen 
klachten geeft. Het wordt opgemerkt tijdens een bloeddrukmeting op de huisarts-
praktijk, een keuring, of als langer bestaande hypertensie tot complicaties heeft 
geleid (bijvoorbeeld een hartinfarct). 
 De behandeling van hypertensie is gericht op preventie van hart- en vaatziekten. 
Omdat hart- en vaatziekten meestal het gevolg zijn van meer factoren dan alleen 
hypertensie, worden door de huisarts ook andere risicofactoren in kaart gebracht 
(bijvoorbeeld overgewicht, roken enz.). Op basis van dit ‘cardiovasculaire risicoprofiel’ 
wordt een behandeling ingezet. Hierbij behoren alle patiënten leefstijladviezen te 
krijgen die passen bij hun persoonlijke situatie. Het naleven en het effect van deze 
adviezen moeten geëvalueerd -en zo nodig bijgesteld- worden. Afhankelijk van het 
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resultaat van de leefstijladviezen en de hoogte van de bloeddruk, kan met bloeddruk-
verlagende medicatie worden gestart. 
 Om recht te doen aan het veelal internationale karakter van wetenschappelijk 
onderzoek, waarin gebruik wordt gemaakt van een internationaal geaccepteerde afkap - 
waarde voor hypertensie, wordt in dit proefschrift de definitie van hypertensie volgens 
de European Society of Hypertension gebruikt: bij een meting in de huisartsenpraktijk 
is sprake van hypertensie bij meerdere metingen met een systolische bloeddruk ≥140 
en/of een diastolische bloeddruk ≥90 mmHg. 
primair hyperalDosteronisme
Bij PHA is sprake van autonome productie van aldosteron door één of beide bijnieren. 
De belangrijkste factoren die verantwoordelijk zijn voor de aldosteronproductie in de 
normale situatie zijn het renine-angiotensine-aldosteron systeem (RAAS), het kalium 
(=een mineraal dat we binnen krijgen met onze voeding) en ACTH (= een hormoon 
van de hypofyse (=hersenklier)). 
 De aanmaak van aldosteron begint met de omzetting van angiotensinogeen 
naar angiotensine I door het enzym renine (Figuur 1, linker kolom). De aanmaak van 
renine wordt met name gestimuleerd door een lage bloeddoorstroming van de nier. 
Angiotensine I wordt door het angiotensine-converterend enzym omgezet in 
angiotensine II. Dit angiotensine II zorgt voor het samentrekken van bloedvaten 
(=vasoconstrictie) en werkt daardoor bloeddrukverhogend. Daarnaast zorgt 
angiotensine II voor het vrijkomen van aldosteron in de bijnieren. Aldosteron werkt 
onder andere in de nieren waar het verantwoordelijk is voor het vasthouden van 
natrium (=bestanddeel van ‘keukenzout’) en daardoor ook van water, waardoor de 
bloeddruk stijgt. Bij patiënten met PHA reageert aldosteron niet langer op fysiologische 
signalen zoals renine en kalium (Figuur 1, rechter kolom). De ongereguleerde 
productie van aldosteron resulteert in een overmaat aan aldosteron met als gevolg 
een toename van het vasthouden van zout en water door de nieren. Dit leidt tot een 
blijvend verhoogde bloeddruk en een remming van de renineproductie.
 Voorheen werd gedacht dat PHA zeldzaam was. Inmiddels is bekend dat PHA 
vaker voorkomt, namelijk bij ongeveer 5% tot 10% van alle mensen met hypertensie. De 
diagnose is niet makkelijk te stellen omdat, net als bij essentiële hypertensie, specifieke 
klachten ontbreken. Ook het klassieke concept dat patiënten met PHA altijd een 
verlaagd kalium hebben (=hypokaliëmie) blijkt achterhaald: een hypokaliëmie komt 
slechts voor bij ongeveer 30% van de patiënten met PHA.
 PHA kent twee subgroepen: éénzijdig PHA, wat meestal wordt veroorzaakt door 
een adenoom (=zwelling) in één bijnier (ook wel ‘ziekte van Conn’ genoemd), en 
dubbelzijdige bijnierhyperplasie (=zwellingen in beide bijnieren) waarbij beide bijnieren 
teveel aldo steron produceren. Dit verschil is van groot belang voor de behandeling: 
bij éénzijdig PHA heeft operatief verwijderen van de bijnier de voorkeur, omdat hiermee 
in de meerderheid van de gevallen de overmatige aldosteronproductie genormaliseerd 
wordt. Wanneer beide bijnieren teveel aldosteron produceren is behandeling met 
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specifieke bloeddrukverlagende medicatie (mineralocorticoïd receptor antagonisten) 
nodig, waardoor de effecten van het teveel aan aldosteron geblokkeerd worden. 
Dit resulteert in een daling van de bloeddruk en een normalisering van een eventueel 
verlaagd kalium.
 De tijd tussen het stellen van de diagnose hypertensie en de diagnose PHA is vaak 
lang (gemiddeld acht jaar). Een tijdige en juiste diagnose van PHA is belangrijk om vier 
redenen:
1) De kans op hart- en vaatziekten bij hypertensie door PHA is hoger vergeleken 
met de kans op hart- en vaatziekten bij essentiële hypertensie.
2) PHA behoort anders behandeld te worden, namelijk met een operatie of met 
specifieke bloeddrukverlagers (mineralocorticoïd receptor antagonisten). Hierdoor 
worden ook de schadelijke effecten van de overmaat aan aldosteron op bijvoorbeeld 
hart en bloedvaten tegengegaan.
3) Behandelresultaten zijn beter als patiënten jong zijn en de hypertensie nog niet 
lang bestaat, dit geldt met name voor patiënten die geopereerd worden.
4) De kwaliteit van leven van onbehandelde patiënten met PHA is slechter dan die 
van patiënten met onbehandelde essentiële hypertensie, maar deze verbetert of 
normaliseert na specifieke behandeling.
Diagnostiek van primair hyperalDosteronisme
De diagnostiek van PHA bevat drie stappen: 1) screening, 2) bevestigen (of uitsluiten) 
van de diagnose, en 3) onderzoek naar het aantal aangedane bijnieren (enkelzijdig, 
of dubbelzijdig). Screening op PHA gebeurt door meting van aldosteron en renine in 
een bloedmonster, waarna de ratio van beide berekend kan worden. Een verhoogde 
aldosteron-renine ratio is verdacht voor PHA en reden tot vervolgonderzoek. Zo’n 
vervolg onderzoek kan niet bij de huisarts plaatsvinden, hiervoor is een verwijzing 
naar een internist nodig. In het ziekenhuis krijgt de patiënt een zogenaamde 
‘confirmatietest’, meestal een ‘zoutbelastingstest’, waarbij wordt gekeken of het 
aldosteron hoog blijft na toediening van zout. Hierna volgt vaak vervolgonderzoek 
naar het aantal aangedane bijnieren, tenzij bij voorbaat duidelijk is dat de patiënt niet 
geopereerd kan/wil worden: dan volgt direct behandeling met een mineralocorticoïd 
receptor antagonist. 
screening op primair hyperalDosteronisme
In Nederland behoort de diagnostiek en behandeling van hypertensie grotendeels tot 
het domein van de huisarts. De huidige richtlijn voor huisartsen formuleert twee 
redenen om aan PHA te denken: hypokaliëmie (=verlaagd kalium) en/of therapie- 
resistente hypertensie (=hypertensie waarbij de bloeddruk hoog blijft ondanks het 
gebruik van meer dan drie verschillende soorten bloeddrukverlagers) en adviseert in 
dat geval een verwijzing naar het ziekenhuis. Echter, aangezien zo’n 70% van de 
patiënten met PHA géén hypokaliëmie heeft, is het aannemelijk dat veel patiënten 
met PHA worden gemist. Dit leidt tot een vertraging van de diagnose, en een hogere 
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kans op cardiovasculaire complicaties. Het is derhalve de vraag of het wellicht zinvol 
zou zijn om alle patiënten met nieuwe hypertensie te screenen op PHA. De huisartsen-
praktijk lijkt hiervoor de ideale setting, immers:
1) De diagnose hypertensie wordt meestal in de huisartsenpraktijk gesteld.
2) Screening op PHA moet bij voorkeur plaatsvinden zonder dat een patiënt al 
bloed drukverlagende medicatie gebruikt, want deze medicatie beïnvloedt de 
meetresultaten van aldosteron en renine. 
3) Ook bij een lage prevalentie is het absolute aantal patiënten met PHA hoog 
(2000 tot 5000 mensen per jaar).
4) Door PHA veroorzaakte schade aan hart en bloedvaten is deels omkeerbaar bij 
PHA-specifieke behandeling.
Alvorens te overwegen te screenen op een bepaalde aandoening, is het van belang 
naar een aantal criteria te kijken zoals geformuleerd door Wilson en Jungner (WHO, 
1968). Om aan deze criteria te kunnen voldoen, is wetenschappelijke kennis nodig, 
waaraan dit proefschrift een bijdrage hoopt te leveren. In Tabel 1 zijn de criteria van 
Wilson en Jungner toegespitst voor screening op PHA.
stuDies in Dit proefschrift
Hoofdstuk 2 beschrijft de opzet en resultaten van een ‘systematic review’ en ‘meta-
analysis’ naar de prevalentie van PHA. Toen uit verschillende studies bleek dat de 
prevalentie voor PHA zeer verschillend was, namelijk variërend van 1% tot 29%, 
zochten wij verklarende factoren voor deze discrepantie in prevalenties. Hiervoor 
verrichtten wij eerst een geprotocolleerd literatuuronderzoek. Vervolgens formuleerden 
wij mogelijke oorzaken voor de diversiteit in prevalenties. Op basis van de literatuur 
namen wij aan dat de prevalentie van PHA in de 1e lijn (=huisartspraktijk) verschilt 
van die in de 2e lijn (=ziekenhuis), daarom hebben wij deze apart geanalyseerd. 
Voor het literatuuronderzoek verzamelden wij alle prevalentiestudies over PHA die 
gepubliceerd zijn vanaf 1-1-1990 t/m 31-1-2015 uit verschillende medische databanken, 
namelijk PubMed, EMBASE, Web of Science, en Cochrane Library. Artikelen werden 
geïncludeerd (=insluiten voor onderzoek) als zij de prevalentie van PHA in volwassen 
patiënten (≥18 jaar) met hypertensie beschreven, mits de diagnose PHA was bevestigd 
door een confirmatietest in tenminste 50% van de patiënten met een positieve screening 
test. Negenendertig studies met in totaal 42510 patiënten werden geïncludeerd, 
waarvan negen studies met in totaal 5896 patiënten afkomstig waren uit de 1e lijn.
 Prevalenties varieerden van 3,2% tot 12,7% in de 1e lijn, en van 1% tot 29% in de 
2e lijn. Omdat de opzet van de studies te veel van elkaar verschilde, was het niet 
mogelijk om een gemiddelde prevalentie uit te rekenen. De meta-analyse toonde dat 
studies uit de 2e lijn met één of meer van de volgende factoren meer kans hebben op 
een hoge prevalentie: 1) gepubliceerd na 2000, 2) uit Australië, 3) doel van de studie was 
het onderzoeken van de prevalentie van secundaire hypertensie, 4) retrospectieve 
studies, 5) studies die hun patiënten opeenvolgend includeerden, en 6) studies die 
geen gebruik maakten van een screening test. Helaas bleek het niet mogelijk om de 
524305-L-bw-Kayser
Processed on: 24-9-2018 PDF page: 170
170
Chapter 7
Tabel 1  De criteria van Wilson en Jungner voor primair hyperaldosteronisme
1. De op te sporen ziekte moet een belangrijk gezondheidsprobleem zijn.
PHA is een belangrijk gezondheidsprobleem in een aanzienlijk aantal patiënten. 
 Aangenomen dat de prevalentie 5% is, zijn er ongeveer 5000 nieuwe patiënten in 
 Nederland met PHA. Daarnaast verhoogt PHA het risico op hart- en vaatziekten,  
en ervaren patiënten met onbehandelde PHA een lagere kwaliteit van leven.
2. Er moet een algemeen aanvaarde behandelingsmethode voor de ziekte zijn.
De behandeling voor PHA is afhankelijk van het subtype: bij een adenoom is het verwij-
deren van de aangedane bijnier de beste keuze, bij dubbelzijdige bijnierhyperplasie is 
behandeling met een mineralocorticoïd receptor antagonist de beste keuze.  
Beide behandelingen zijn effectief.
3. Er moeten voldoende voorzieningen voorhanden zijn voor diagnose en behandeling. 
In Nederland zijn de gezondheidsvoorzieningen voor de diagnose en behandeling van 
PHA goed bereikbaar.
4. Er moet een herkenbaar latent of vroeg symptomatisch stadium van de ziekte zijn.
Vroege symptomen van PHA zijn hypertensie, en in sommige gevallen een verlaagd 
kalium.
5. Er moet een betrouwbare opsporingsmethode bestaan.
Screening op PHA bestaat uit een bloedtest waarbij de aldosteron-renine ratio wordt 
gemeten.
6. De opsporingsmethode moet aanvaardbaar zijn voor de bevolking.
De screeningstest kan worden toegevoegd aan het standaard bloedonderzoek dat de 
huisarts verricht als de diagnose hypertensie is gesteld.
7. Het natuurlijke verloop van de op te sporen ziekte moet bekend zijn.
Het verloop van PHA van latente tot manifeste ziekte is redelijk goed bekend. 
8. Er moet overeenstemming bestaan over de vraag wie behandeld moet worden.
Bij een positieve screening vindt een confirmatietest plaats, waarna de diagnose wordt 
gesteld of verworpen. 
9. De kosten van opsporing, diagnostiek en behandeling moeten in een acceptabele ver-
houding staan tot de kosten van de gezondheidszorg als geheel. 
De kosten van screening blijken in meerdere onderzoeken op te wegen tegen de kosten 
van niet-screenen, maar deze studies zijn uitgevoerd bij specifieke groepen patiënten en 
daarom zijn de resultaten mogelijk niet geldig voor de patiënten met hypertensie in de 
huisartspraktijk.
10. Het proces van opsporing moet een continu proces zijn en niet een eenmalig project.
Screening op PHA kan vrij makkelijk worden geïmplementeerd in de standaard 
 hypertensiezorg.
In cursief: het criterium zoals geformuleerd door Wilson en Jungner.
PHA, primair hyperaldosteronisme.
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verklarende factoren voor studies met een hoge prevalentie ook voor de 1e lijn te 
berekenen, omdat het aantal geïncludeerde studies hiervoor te laag was. 
 De prevalentie van PHA in de Nederlandse huisartsenpraktijk wordt beschreven 
in Hoofdstuk 3. Het doel van deze studie was de prevalentie van PHA vast te stellen 
in mensen met nieuw ontdekte hypertensie. Hiervoor werd een aantal huisartsen uit 
de regio Nijmegen gevraagd om bij alle opeenvolgende patiënten met nieuwe 
hypertensie de aldosteron-renine ratio te bepalen. Bij een verhoogde ratio volgde 
een zoutbelastingstest, die de diagnose PHA bevestigde of juist verwierp. Van de 
totaal 3748 patiënten met nieuwe hypertensie werd bij 343 patiënten de aldosteron- 
renine ratio bepaald. In 9 van de 74 patiënten met een verhoogde aldosteron-renine 
ratio werd de diagnose PHA bevestigd door een positieve zoutbelastingstest. 
Dit resulteerde in een prevalentie van PHA in patiënten met nieuw ontdekte 
hypertensie van 2,6% (95% betrouwbaarheidsinterval 1,4 - 4,9). Alle patiënten met 
PHA hadden een normaal kalium. Bij 8 van de 9 patiënten was de bloeddruk bij 
herhaling >150/100mmHg. Deze bevindingen sluiten aan bij het advies van de 
richtlijn over PHA van de Endocrine Society (2016) welke patiënten te screenen op 
PHA. Hoewel de expliciete vraag aan de deelnemende huisartsen was om bij álle 
patiënten met nieuwe hypertensie de aldosteron-renine ratio te bepalen, viel het 
aantal gescreende patiënten met nieuwe hypertensie veel lager uit dan verwacht. Dit 
lage aantal gescreende patiënten (9,2%) weerspiegelt hoe lastig het kan zijn om 
prevalentie- onderzoek te doen in de 1e lijn. Daarnaast bleek op basis van de 
gegevens uit de huisartsendossiers, dat er sprake was van ‘selectiebias’. Dit betekent 
dat de gevonden resultaten voornamelijk betrekking hebben op een deel (=selectie) 
van de patiënten. Uit onze studie bleek dat patiënten die jonger waren, of die een 
hogere bloeddruk hadden, een hogere kans hadden op een meting van de aldosteron- 
renine ratio. Het lijkt alsof huisartsen er intuïtief vanuit gingen dat de kans op het 
vinden van PHA bij deze patiënten het grootst is. Dit is in overeenstemming met het 
gegeven dat jongere mensen met hypertensie en mensen met een heel hoge bloed- 
druk daadwerkelijk een verhoogde kans hebben op een onderliggende oorzaak van 
die verhoogde bloeddruk. In eerder gepubliceerde studies werd de kans op selectiebias 
meestal genegeerd of niet onderzocht. Dit betekent dat de eerder gerapporteerde 
prevalenties kritischer bekeken moeten worden.
 In Hoofdstuk 4 onderzochten we in hoeverre het hart en de bloedvaten bij 
patiënten met nieuwe hypertensie en PHA zijn aangedaan in vergelijking met 
eenzelfde groep patiënten zonder PHA. Het was reeds bekend dat patiënten met 
hypertensie bij wie de diagnose PHA wordt gesteld meer schade aan het hart en de 
vaten hebben dan te verwachten op basis van de hoogte van de bloeddruk, maar we 
wisten nog niet of deze extra schade al zichtbaar is op het moment van het stellen 
van de diagnose hypertensie. Dit is zinvolle informatie, omdat de ernst van een 
aandoening meeweegt in een uiteindelijke beslissing om screening in te voeren. We 
hebben zes patiënten met nieuwe hypertensie en PHA vergeleken met 24 patiënten 
met nieuwe essentiële hypertensie. Deze twee groepen waren vergelijkbaar met 
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betrekking tot geslacht, leeftijd, en de hoogte van de bloeddruk. Zij kregen allen 
uitgebreide onderzoeken van het hart, de nieren en de vaten. Twee van de zes patiënten 
met PHA bleken reeds een verdikte hartspier te hebben, terwijl geen van de patiënten 
in de groep met essentiële hypertensie dit had. Er werden geen verschillen gezien bij 
de overige onderzoeken. Omdat het maar om kleine aantallen gaat, kan deze 
bevinding slechts als richtinggevend beschouwd worden. Er zijn grotere studies 
nodig om onze resultaten te bevestigen.
 Ondanks vele studies naar zogenaamde ‘biomarkers’ als hulpmiddel voor de 
keuze van een bepaald soort bloeddrukverlager bij de behandeling van hypertensie, 
worden tot op heden alleen grove maten als leeftijd en ras als onderscheidend 
beschouwd. Hoofdstuk 5 beschrijft onze studie naar het gebruik van de aldosteron- 
renine ratio als mogelijke leidraad bij het starten van bloeddrukverlagende medicatie 
bij patiënten met essentiële hypertensie. Vóór de start van de behandeling werd de 
aldosteron-renine ratio bepaald, om na één jaar behandeling de bloeddrukverandering 
te evalueren. Er was geen protocol voor de keuze van de bloeddrukverlager anders 
dan de huisartsenrichtlijn. Van 304 patiënten hadden we 947 bloeddrukmetingen, 
waarvan 220 metingen behorend bij patiënten die bloeddrukverlagers gebruikten. 
Er werd geen verband gezien tussen de waarde van de aldosteron- renine ratio vóór de 
start van de behandeling en de bloeddrukverandering door de medicatie. Als belangrijke 
nevenbevinding vonden we dat slechts bij 31% van de patiënten met hypertensie na 
één jaar behandeling de streefwaarde van de bloeddruk was bereikt. Er was geen 
verband tussen de aldosteron-renine ratio en het (niet) bereiken van die streefwaarde.
implicaties voor De Dagelijkse praktijk
In dit proefschrift vonden wij een prevalentie van PHA van 2,6% (95% betrouwbaar-
heidsinterval 1,4-4,9) bij patiënten met nieuw ontdekte hypertensie. Gebaseerd op 
deze data, zouden we bij het invoeren van screening bij patiënten met nieuwe 
hypertensie in de Nederlandse huisartspraktijk per jaar tussen de 1100 en 3700 
nieuwe patiënten met PHA vinden. Bij het grootste deel van hen wordt de diagnose 
op dit moment gemist, omdat de huidige huisartsenrichtlijn niet gericht is op het 
opsporen van PHA. Daarnaast is het waarschijnlijk dat reeds in de vroege fase van 
PHA hartschade bestaat bij een aantal patiënten. 
 Hoewel er verscheidene argumenten zijn om screening op PHA in te voeren, 
wordt op dit moment niet voldaan aan alle screeningscriteria van Wilson en Jungner. 
Het grootste probleem is het gebrek aan kosten-effectiviteitsstudies, waarin wordt 
aangetoond dat screenen op PHA effectief is als je kijkt naar wat het kost aan 
gezondheidzorg en wat het uitspaart aan kosten voor de gezondheidszorg wanneer 
PHA niet (eerder) was gediagnosticeerd. Op dit moment bestaan deze studies alleen 
voor patiënten met therapie-resistente hypertensie: screenen op PHA in deze groep 
is kosten-effectief. Naast kosten-effectiviteit op medisch gebied (invoeren screening, 
aanvullende diagnostiek en behandeling), zou ook gekeken moeten worden naar de 
maatschappelijke en financiële gevolgen van (onbehandelde) PHA, zoals werkverzuim 
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of arbeidsongeschiktheid. Tot meer duidelijkheid bestaat over dit kostenaspect, 
adviseren wij dat in de huidige huisartsenrichtlijn de aanbevelingen met betrekking 
tot screening op PHA worden overgenomen zoals geformuleerd in de richtlijn van de 
Endocrine Society. Als deze screeningsstrategie zou worden geïmplementeerd, zou 
ongeveer 50% van de patiënten met hypertensie in aanmerking komen voor 
screening op PHA.
Tabel 2  Aanbevelingen voor screening op primair hyperaldosteronisme volgens  
de richtlijn van de Endocrine Society 
Patiënten met een verhoogd risico op onderliggend primair hyperaldosteronisme zijn zij met:
• aanhoudende bloeddruk >150/100 mmHg
• therapie-resistente hypertensie (bloeddruk >140/90 mmHg)
• gereguleerde bloeddruk (bloeddruk <140/90 mmHg) bij vier of meer soorten bloeddruk-
verlagers
• hypertensie en spontane of diuretica-geïnduceerde hypokaliëmie
• hypertensie en een incidentaloom in de bijnier
• hypertensie en obstructief slaap apneu syndroom
• hypertensie en een familie-anamnese met hypertensie op jonge leeftijd of een beroerte  
op jonge leeftijd (<40 jaar)
• alle eerstegraads familieleden van patiënten met primair hyperaldosteronisme
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Graag wil ik allen die hebben bijgedragen aan het tot stand komen van dit proefschrift 
hartelijk danken. Een aantal mensen wil ik expliciet noemen.
Farid, m’n lieve Liefste, wat bof ik ontzettend met jou! En wat houd ik geweldig veel 
van jou en onze lieve Simon en Hugo! Ik bewonder jouw passie om de dingen te 
doen waarin je gelooft, en de wijze waarop je met verschillende mensen en hun 
belangen rekening houdt. Met een beetje wikken hier en een vleugje plannen daar, 
heb ik mede dankzij jou in mijn (onze!) eigen tijd dit traject kunnen afronden. 
Dankjewel dat je altijd naast en achter mij staat, en er voor mij en anderen bent: 
jij maakt het leven mooier. 
Lieve Mama, ik heb groot respect voor de wijze waarop jij Papa hebt verzorgd. 
Jij leerde mij de werkelijke betekenis van trouw en toewijding, waarbij het prima is 
om jezelf weg te cijferen als dit even nodig is. Dat heb je ook voor mij gedaan: ik heb 
dit proefschrift kunnen voltooien dankzij al die keren dat jij op Simon en Hugo paste, 
zodat ik kon werken als huisarts of aan mijn onderzoek. Farid en ik zijn je intens 
dankbaar voor alles wat je voor ons doet. Wat een zegen dat onze kinderen opgroeien 
met ‘Nana’ die hen zoveel warmte schenkt! Lieve Mama: een diepe buiging voor jou, 
ik dank je uit de grond van mijn hart. 
Mijn welgemeende dank aan alle patiënten die hebben deelgenomen aan dit onder - 
zoek. Daarnaast veel dank aan alle huisartspraktijken die moeite hebben gedaan 
om deze patiënten te includeren. Dit proefschrift heeft bestaansrecht dankzij jullie. 
Dr. Bakx, beste Carel, wat was het een voorrecht om dit project te starten onder jouw 
behoedzame vleugels. Die eerste maanden ging mijn leercurve bijna loodrecht 
omhoog! Eén van mijn dierbare herinneringen is jouw gezichtsuitdrukking toen ik vol 
enthousiasme ons protocol in 12-voud kwam laten zien: je vroeg je af of de medisch- 
ethische commissie ooit eerder zo’n kleurrijk protocol had beoordeeld, maar was 
snel overtuigd van het nut van mijn efficiënte (inderdaad wat fleurige) indeling. 
En toen stierf je. Weet je dat mensen nog steeds een glimlach op hun gezicht krijgen 
als het over jou gaat? Ook ik voel mij een gezegend mens met jou in mijn herinnering. 
Heel veel dank voor jouw vertrouwen en inspiratie, waarmee ik uiteindelijk ook zonder 
directe begeleiding van een huisarts mijn weg heb weten te vinden in de wereld van 
huisartsgeneeskundig onderzoek.
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Professor dr. Lenders, beste Jacques, na het overlijden van Carel en het afscheid 
van Mark was dit project een chaos. Jij kwam, je zag, en je nam het over: het is jouw 
verdienste dat de neuzen weer dezelfde kant op gingen staan. Jouw kritische blik en 
tomeloze inzet lijken onuitputtelijk, en ik kan de betrokkenheid die hieruit spreekt 
enorm waarderen. Je blijft continu in contact met het gezamenlijke doel, ongeacht de 
soms tegenstrijdige belangen binnen het team. Je stimuleert, doceert, inspireert en 
begrenst. Ik heb het als een zeer leerzame en prettige samenwerking ervaren. Het 
ziet er allemaal zo makkelijk uit als jij het doet! Mijn hartelijke dank voor de waardevolle 
adviezen op zowel medisch-inhoudelijk als persoonlijk vlak, je nauwgezette correcties 
en je standvastigheid.
Dr. Deinum, beste Jaap, jij bent het anker van dit project. Ik ontmoette je voor het 
eerst toen ik als student geneeskunde mocht deelnemen aan de masterclass interne 
geneeskunde en was zo onder de indruk dat ik bijna mijn nek verrekte met opkijken 
naar jou. En terecht: je bent een warm en integer persoon, een geduldig en kritisch 
clinicus, en een inspirerend en gedreven onderzoeker. Veel dank voor het vertrouwen 
dat jij mij vanaf het begin hebt gegeven. Bovenal veel dank voor jouw onvermoeibare 
en secure ‘stofkam’: daar werd ik altijd blij van! 
Dr. Biermans, beste Marion, epidemiologie is duidelijk jouw expertise. Dankzij jouw 
opmerkzaamheid hebben wij de prevalentie van primair hyperaldosteronisme op de 
meest zuivere wijze berekend. Veel dank voor het overnemen van het copromotor-
schap, het leiden van het uitermate gecompliceerde proces van de data-extracties, 
jouw aanwezigheid bij de gezamenlijke overleggen en het kritisch commentaar bij de 
artikelen. 
 
Dr. Schermer, beste Tjard, jouw jarenlange ervaring op het gebied van huisarts-
geneeskundig onderzoek maakte je bijdrage aan dit project waardevol. Jouw 
uitgebreide Engelse woordenschat hebben menige zin verduidelijkt en je daagde me 
uit de tekst dusdanig helder te formuleren dat deze voor een ieder te volgen was. Veel 
dank voor jouw inzet en oplossingsgerichte adviezen.
Dr. van der Wel, beste Mark, het spijt me hoe het tussen ons is gelopen na het 
overlijden van Carel. We waren allebei erg verdrietig. Ik waardeer het ontzettend dat 
jij, ondanks onze meningsverschillen, bleef herhalen dat je dacht dat ik dit kon, dat dit 
‘mijn’ project was. De herinnering aan jouw vertrouwen in mij heeft mij de afgelopen 
jaren gesteund, samen met de vastberadenheid deze ‘tweede’ kans zorgvuldig te 
benutten. En daarbij, het grootste deel van het werk (protocol, inclusie huisarts-
praktijken en samenwerking met SHO) hadden wij reeds samen gerealiseerd: hoe 
moeilijk kon het nog worden? Veel dank voor ons traject samen: ik kijk er met genegen - 
heid op terug.
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Dr. de Grauw, beste Wim, jouw bijdrage als huisarts-onderzoeker is zeer waardevol 
geweest. In 2014 werd het studieprotocol dusdanig aangepast, dat er ruimte kwam 
voor een nieuwe onderzoeksvraag vanuit de eerste lijn: Hoofdstuk 5 is het resultaat 
van jouw explorerende geest. Veel dank voor dit zorgvuldig meedenken, als ook voor 
jouw inzet als huisarts én onderzoeker tijdens de gezamenlijke overleggen. 
Veel dank aan het SHO, met name aan Dick, Eric, Carolien en Holger: ik heb onze 
samenwerking als zeer prettig ervaren. Dankzij jullie is de werkinstructie voor de 
afname van aldosteron en renine uitstekend geïmplementeerd. Gezien de resultaten 
van dit proefschrift, hoop ik van harte dat deze bepalingen in de toekomst regelmatig 
zullen worden aangevraagd. Evaluatie over een jaar?
Beste professor van der Wilt, veel dank voor uw begeleiding en kritische noten bij de 
uitvoering en het opschrijven van onze meta-analyse.
Beste Hans (Groenewoud), heel veel dank voor jouw hulp bij de meta-analyse. Ik heb 
altijd uitgekeken naar de overleggen met jou, waarin je me naast de biostatistiek ook 
onderwees in jouw passie. Sindsdien kijk ik toch anders naar nachtvlinders.
Beste Hans (Peters) en Waling, veel dank voor het extraheren van de HIS-data en 
het maken van de PAGODE-bestanden. Beste Waling, rust zacht.
Beste Hans (Bor) en Reinier, veel dank voor jullie hulp met de statistiek in de huisarts-
praktijk. Jullie enthousiasme en expertise waren voor mij als twee boeien in de 
verraderlijke zee vol parametrische stormen en non-parametrische zeeslangen 
(ik word er poëtisch van). Gelukkig zijn er mensen zoals jullie die gewapend met 
logisch redeneren, en wellicht een specifiek gen dat ik mis, deze wateren wel 
kunnen bevaren.
Lieve Bianca, rots in de statistische branding. Ik blijf me verbazen over de eenvoudige 
wijze waarop jij de meest ingewikkelde berekeningen kan uitvoeren en uitleggen. 
Heel veel dank voor het maken van de koppelingen tussen vier (!) databases, het 
maken en toelichten van ingewikkelde analyses (dat gen zit dus niet alleen op de ‘Y’), 
het nakijken en corrigeren van mijn eigen analyses, en het oplossen van (statistische) 
complicaties. Ik zal onze overleggen in de Hemelkamer missen! 
Graag wil ik alle co-auteurs danken voor de vruchtbare samenwerking. Twee van hen 
wil ik in het bijzonder noemen. 
Lieve Tanja, wat hebben we hard gewerkt in ons streven naar volledigheid en -vergeef 
mij mijn onbescheidenheid- wat is het een prachtig artikel geworden! Hartelijk dank 
voor een zeer prettige samenwerking. Veel succes met het afronden van jouw boekje!
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Beste Daniëlle, ere wie ere toekomt: als internist met het aandachtsgebied vasculaire 
aandoeningen heb jij alle uitgebreide onderzoeken voor onze studie naar vaatschade 
verricht. Veel dank voor de fijne samenwerking. Jouw boekje is nu bijna af: succes 
met de laatste loodjes!
Beste collegae en medewerkers van de ELG, na een gastvrije start op de eerste 
etage (dankzij Annelies, Hilde, Wouter, Anne vd B, Riet, Joke, Lisette, Debby en 
Franca) ben ik via de tweede (Loes, Tilly, Twanny, Henk, Sietske, Marianne, Floris, 
Chris, Pim) geëindigd op de derde (Breg, Erik, Elza, Karin, Annette, Anouk, Kees). 
Graag wil ik jullie allen danken voor jullie steun, leuke anekdotes en praktische hulp 
(zoals een nieuw plafond toen het mijne tijdens een regenbui naar beneden kwam, 
dankjewel Marike!). Speciale dank aan Lea voor het maken van de Access database 
voor de PAGODE-praktijken.
Veel dank aan de studenten Jenneke, Tessa en Jasper voor het bijhouden van de 
PAGODE-data toen ik in de huispraktijk mijn opleiding afrondde. 
Tot slot enkele woorden van dank gericht tot mensen uit mijn persoonlijke omgeving, 
die mij direct dan wel indirect hebben gesteund bij dit traject. 
Lieve Max, wat een geluk dat ik het eerste jaar van mijn huisartsenopleiding bij jou 
kwam! Je liet mij zien hoe te relativeren en leerde mij wijze lessen over geneeskunst, 
waarin bekwaamheid en aardig zijn voor de patiënt hand in hand gaan. Veel dank 
voor jouw vertrouwen en het verbeteren van verschillende hoofdstukken in dit 
proefschrift. Ik ben trots één van jouw aios te zijn geweest.
Lieve Renske, ik vind je een fantastische opleider en bewonder je authenticiteit. Veel 
dank voor de manier waarop je meedacht toen ik tijdens mijn zwangerschap van 
Hugo iets rustiger aan moest doen. Je had voor mij de ideale oplossing: ik ging mijn 
patiënten met een rollende bureaustoel uit de wachtkamer halen.
Lieve Lidy, wat was je een inspirerende opleider en wat heb ik een goede tijd in jouw 
praktijk gehad. 
Lieve Liesbeth, het door jou geïnitieerde gesprek tussen Lidy, jou en mij heeft groot 
verschil gemaakt. 
Ik wil jullie beiden hartelijk danken voor jullie uitgesproken vertrouwen in mij en de 
tastbare betrokkenheid bij mijn onderzoek in mijn laatste jaar als aios huisartsgenees-
kunde.
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Mijn lieve vriendinnen Sabina, Carlijn, Rasha, Anne K, Vera, Neeria, Kerensa en 
Maaike, ik ben dankbaar voor jullie vriendschap, zorgzame adviezen, grappige 
anekdotes en bovenal jullie begrip voor het feit dat ik telefonisch contact vaak 
prefereer boven een bezoek met reistijd. Veel dank dat jullie deze ietwat heuvelige 
weg met mij bewandeld hebben. To be continued.
Lieve Raquel, hoe heet de grond onder mijn voeten ook werd, jij zag geen reden voor 
mij om te stoppen. Jij weet hoe het is om offers te brengen, en ik bewonder de wijze 
waarop jij dat doet: zorgvuldig, beheerst en vol bezieling. Wat fijn dat jij nu mijn 
paranimf bent! Veel dank voor jouw innige vriendschap en de bemoedigende 
kaarten (met chocola!).
Lieve Marloes, mijn supersociale vriendin en planwonder (zowel in tijd als in ideeën): 
ik ben heel blij dat jij mijn paranimf wilt zijn! Wat is het fijn om na een drukke dag 
samen uit te waaien tijdens een rondje fietsen. Onze mini-intervisie en recidiverende 
icc. Veel dank voor jouw warmte en wijsheid.
Lieve Lotje en Phuocie, van ons heb ik waardevolle herinneringen van samen een 
zolder delen in onze studententijd en gezondheidsadvies bij de McDonald’s, tot 
speechen op mijn bruiloft en opvoedingstips. Wat koester ik onze vriendschap! Veel 
dank voor de zorgvuldige beoordeling van de Nederlandse samenvatting, zodat 
deze ook voor niet-medici te volgen is.
Lieve Marian, mijn lieve ‘grote zus’, wat bewonder ik jou als persoon en als moeder. 
Hoewel het lastig is om in woorden uit te drukken hoe belangrijk jij voor mij bent en 
hoe eindeloos mijn dankbaarheid en waardering jegens jou is, denk ik dat de 
songtekst van Celine Dions ‘Because you loved me’ toch redelijk in de buurt komt. 
Dankjewel, lievie.
Mijn lieve schoonzusjes Chamiram, Hanan, Salua en Feryal, het is een genot om 
naar jullie te kijken als jullie samen zijn, de liefde voor elkaar straalt er vanaf! Dank 
jullie wel voor jullie temperament (waarbij ik verbleek tot de rust zelve) en jullie on-
voorwaardelijke liefde voor jullie familie.
Lieve Ninos en Dani, ik bof ontzettend met zwagers die altijd (letterlijk!) voor ons 
klaar staan. Dank voor wie jullie zijn en wat jullie uitdragen.
Mijn lieve zwager Nabil, je bent altijd bereid om mee te denken en er is maar weinig 
wat je niet kan. Heel veel dank voor jouw geweldige hulp met de PAGODE-website 
en het inkleuren van het PAGODE-logo.
Mijn broertje Stan, veel dank voor jouw hulp met het opzetten van de PAGODE-website 
en het optimaliseren van het PAGODE-logo.
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Mijn lieve bijzondere zeer gedisciplineerde Papa, ik had je zo graag beter leren 
kennen. Tegelijkertijd voel ik mij enorm bevoorrecht dat ik, in tegenstelling tot velen, 
een fijne vader heb gekend. Wat hadden Mama en jij een lol samen, en wat hebben 
jullie hard gewerkt om mijn broertje en mij een zo goed mogelijke start te geven. Heel 
veel dank voor de wijze lessen en waardevolle herinneringen. 
Lieve Simon en lieve Hugo, jullie zijn het grootste geluk van mij en jullie Papa. Wat ik 
jullie wil zeggen:
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Sabine Christina Käyser werd in 1979 geboren te Nijmegen. Zij behaalde haar middel - 
bare schooldiploma aan het Stedelijk Gymnasium, waarna zij vier keer werd uitgeloot 
voor de studie Geneeskunde. In 1996 volgde zij opleidingen tot aerobics- en steps - 
docent (European Fitness and Aerobics Association), waarna zij werkzaam bleef als 
sportdocent. Na het intermitterend volgen van de studie Medische biologie (Universiteit 
van Amsterdam), werd zij in 2002 ingeloot voor de studie Geneeskunde (Radboud 
Universiteit). Naast de studie Geneeskunde volgde zij enkele modules in de Sociale 
psychologie (Radboud Universiteit). Na het behalen van het artsexamen werkte zij op 
de afdeling chirurgie van het ziekenhuis Gelderse Vallei (Ede). In 2011 startte zij met de 
opleiding tot huisarts. Gezien haar bijzondere belangstelling voor onderzoek op het 
gebied van hart- en vaatziekten, startte zij in 2012 haar promotietraject bij Carel 
Bakx† en Jaap Deinum met als resultaat dit proefschrift. Aanvankelijk combineerde zij 
opleiding en onderzoek met het geven van onderwijs, voornamelijk op het gebied 
van cardiovasculair risicomanagement. In 2013 ontving zij een posterprijs van de 
European Society of Hypertension. In 2015 rondde zij de huisartsenopleiding af en 
sindsdien werkt zij als waarnemend huisarts in regio Nijmegen. Van 2015 tot 2017 
was zij als secretaris actief bij de WAGRO Nijmegen e.o. (WAarnemers GROep). 
Sabine is getrouwd met Farid Abdo en samen hebben zij twee zoontjes.
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Name PhD candidate:  
SC Käyser-Abdo 
Departments:  
Primary and Community care & Internal medicine
Graduate School:  
Radboud Institute for Health Sciences
PhD period:  
01-03-2012 till 06-11-2018  
(combined programme with GP residency)
Promotor:  
Prof. dr. JWM Lenders
Co-promotors:  




a) Courses & workshops
- PubMed introduction course
- PubMed advanced course
- Workshop Endnote
- Workshop Medical legislation
- NCEBP introduction course
- Workshop Statistics and meta-analysis





- Introduction to data-analysis



























b) Seminars & lectures
- AIOTHO (arts in opleiding tot huisarts-onderzoeker) seminar
- NHG (Nederlands Huisartsen Genootschap) scientific seminar
- HartVaatHAG (HuisartsenGroep) seminar (oral presentation)
- Radboud Adrenal Centre (RAC) seminar (oral presentation)











c) Symposia & congresses
- European Society of Hypertension (poster and oral presentation)
- NHG congress
- National hypertension congress
- National hypertension congress
- HartVaatHAG congress (poster and oral presentation)
- National hypertension congress
















- Journal club (monthly), department of Primary and Community care  
(oral presentations)
- RAC meeting (every two weeks), department of Internal medicine









- Evidence Based Medicine (EBM) for medical students Radboudumc
- Cardiovascular risk management (CVRM) for medical students Radboudumc







f) Supervision of internships / other
- Supervision of medical students 2014-2015 0.5
TOTAL 23.9
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Organ Damage, Epidemiology, 
and treatment
op dinsdag 6 november 2018
om 14.30 uur precies
in de Aula van de
Radboud Universiteit Nijmegen,
Comeniuslaan 2 te Nijmegen.
U bent van harte welkom bij  
deze plechtigheid met aansluitend  




















Primary Aldosteronism in General practice:
Organ Damage, Epidemiology, and treatment
- PAGODE study -
